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Abstract 
One of the major problems in biology is to identify genes that are involved in 
specific processes. Classical genetics and biochemistry, although powerful and 
informative, can be very labour intensive and do not necessarily characterise 
networked genes in processes that may overarch numerous biochemical pathways. 
Here we utilised genomic tools that are capable of defining networks to identify 
genes involved the complex target mode-of-action of a novel antifungal compound, 
neothyonidioside and in regulating specific stress processes and the PDR 
phenotype.   
The first part of this study investigated the mode-of-action of the antifungal 
compound, neothyonidioside (neo). We developed a neo resistant mutant strain 
then utilising a modification of SGAM, a genetic mapping tool, and application of 
genome-wide chemical-genetic profiling, we identified the neo resistant locus 
NCP1. This gene acts at a late step in ergosterol biosynthesis but is not the target 
of neo. The finding that many of the component genes in the ESCRT complex 
were necessary for neo resistance allowed us to predict and verify by high-content 
fluorescence microcopy that interruptions in the endosome-multivesicular body 
pathway were involved. From the known function of the ESCRT proteins and that 
neo binds ergosterol only above threshold concentrations of ergosterol (explaining 
the mutant phenotype) we concluded that neo disruption of membrane curvature 
and fusion capability in the endosome-vacuole pathway is its target.  
In the second part of this study we identified genes in a genome-wide fashion that 
modulate the pleiotropic drug resistance (PDR) phenotype and oxidative stress 
response. Many PDR targets are well studied ABC transporters (e.g. PDR5 , 
YOR1), but the modulating events between xenobiotic sensing and transcription 
factor activation, and possible crosstalk between PDR and other stress responses 
such as oxidative stress are not well characterised. 
To identify specific genes involved in the PDR and oxidative stress processes, we 
developed a fluorescent reporter screen for effects on the PDR-target ABC-
transporters, Pdr5p and Yor1p tagged with GFP.  For the oxidative stress 
response, the oxidative stress (OS) transcription factor Yap1p tagged with GFP 
was used. Each reporter was placed in the yeast non-essential gene deletion 
 
 
background of ~4800 strains which were then subjected to either xenobiotic 
treatments (PDR –GFP reporters) or oxidant treatments (Yap1p-GFP). We then 
screened for gene deletions which prevented the normal upregulation of PDR 
reporters in the presence of xenobiotics.  Controls were included in the screens 
that assured we were assessing genes that must contribute to or act before the 
transcription of the ABC-transporters.  A similar screening strategy was pursued 
for identifying gene deletions that prevent the normal nuclear re-localisation of 
Yap1p in the presence of oxidants.   
A major finding in this study was identification of genes contributing to the PDR 
phenotype that involved signalling (Rho-GTPase, MAPK), that were involved in 
RNA polymerase II mediator complexes and chromatin modification (subunits of 
ADA and SAGA histone acetyltransferase complexes), and that were involved in 
sphingo/phosphorlipids biosynthesis. Secondary screens comprising spot dilution 
growth assays and Western blots of Pdr5p abundance confirmed key genes of the 
primary screen and showed that these were specific and not global transcriptional 
effects.For some of the gene-dependencies, our results can only be construed to 
indicate the existence of alternative pathways underpinning the PDR phenotype in 
a Pdr1p/Pdr3p independent manner.   
We then supposed that if in fact PDR phenotypes are the result of genetic 
networks, then genes known to interact with the most highly connected hubs from 
our PDR screen results should also to some extent contribute to the PDR 
phenotype (spot dilution growth assays, Western blot abundance). A selection of 
18 such genes that also appeared in our primary screen but were deemed to be 
below the cut-off point were phenotype tested and in 60% of the cases showed 
similar phenotypes to the genes already identified. This result not only proved the 
validity of the screening methods but validated the original supposition, i.e. that 
PDR phenotypes can be affected, through gene networks.   
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Important genes in this study 
PDR1: Zinc finger transcription factor that regulates the pleiotropic drug response. 
PDR3: Transcriptional activator of the pleiotropic drug resistance network. Pdr3p 
forms heterodimers with Pdr1p. 
PDR5:  A major plasma membrane ABC multidrug transporter actively regulated 
by Pdr1p. Used here as a reporter for Pdr1p and Pdr3p activation.  
SNQ2: Plasma membrane ABC multidrug transporter involved in multidrug 
resistance and resistance to singlet oxygen species 
YOR1: Plasma membrane ABC multidrug transporter. Used here as a reporter for 
Pdr1p and Pdr3p activation.  
YAP1: Basic leucine zipper (bZIP) transcription factor; required for oxidative stress 
tolerance. Overexpression confers resistance to many compounds, 
including cycloheximide and fluconazole. Thought to played part in 
multidrug resistance. 
 
Abbreviations  
ABC transporter: ATP-binding cassette (ABC) transporter 
EMS: Ethyl methanesulfonate (act a mutagen) 
GSH: Glutathione 
ORF: Open reading frame 
PKC: Protein kinase C 
MAPK: Mitogen-activated protein (MAP) kinases 
NLS: Nuclear localising signal 
ROS: Reactive oxygen species 
SAGA:  Histone acetyltransferase complex that contains Spt8p 
 
 
SWI/SNF: (SWItch/Sucrose NonFermentable), a nucleosome remodeling complex 
TF: Transcription factor 
 
Glossary 
Xenobiotics: toxic or inhibitory small molecules   
PDR: Pleiotropic drug resistance, here referred to as mechanisms that cells use  
to compensate for compound toxicity (such as alternative pathways to the 
one that has been affected by xenobiotics), as well as classic efflux pumps 
controlled by Pdr1p/Pdr3p, and other stress responses which can lead to 
resistance to a variety of compounds 
Genetic interaction: ―Two genes A and B "genetically interact" when the 
phenotype generated as the result of mutations in both genes (double mutant ab) 
is unexpectedly not just an additive phenotype of the two single mutants a and b‖. 
(Eddy S. R., 2006 Genetics) 
Different forms of genetic interaction are listed below. 
Dosage lethality: Form of genetic interaction, overexpression or increased 
dosage of one gene causes lethality in a strain that is mutated or deleted for 
another gene. 
Dosage rescue: Form of genetic interaction.  Dosage-rescue-genetic interaction 
is inferred when overexpression or increased dosage of one gene rescues the 
lethality or growth defect of a strain that is mutated or deleted for another gene. 
Negative genetic:  Form of genetic interaction. This occurs when 
mutations/deletions in separate genes, each of which alone causes a minimal 
phenotype, result in a more severe fitness defect or lethality under a given 
condition when combined in the same cell. 
Phenotypic enhancement: In this type of interaction, a genetic interaction is 
inferred when mutation or overexpression of one gene results in enhancement of 
 
 
any phenotype* (other than lethality/growth defect) associated with mutation or 
overexpression of another gene. 
(* phenotype: observable traits of strains that carry a mutation at that locus) 
Phenotypic suppression: In this process, a genetic interaction is inferred when 
mutation or overexpression of one gene results in suppression of any phenotype 
(other than lethality/growth defect) associated with mutation or overexpression of 
another gene. 
Positive genetic: Form of genetic interaction. In this type of interaction, 
mutations/deletions in separate genes, each of which alone cause a minimal 
phenotype, result in a less severe fitness defect than expected under a given 
condition when combined in the same cell. 
Synthetic genetic interaction: A genetic interaction in which a combination of 
mutations in two or more genes of a single strain results in a phenotype that is 
different in degree or nature from the phenotypes conferred by the individual 
mutations. The most common type of synthetic interaction is synthetic lethality, in 
which two mutations, neither of which causes inviability when present individually, 
cause inviability when present together in the same strain. Synthetic interactions 
may result in other phenotypes, e.g., slow growth or respiratory growth defects. 
Synthetic interaction can be an indication that the genes involved participate in the 
same pathway or process; synthetic interaction between two point mutant alleles 
may be an indication that the gene products physically interact. 
Synthetic growth defect: a genetic interaction is inferred when mutations in 
separate genes, each of which alone cause  a minimal phenotype, result in a 
significant growth defect under a given condition when combined in the same cell. 
Synthetic lethality: Form of genetic interaction when mutations or deletions in 
separate genes, each of which alone cause a minimal phenotype, result in lethality 
when combined in the same cell under a given condition. 
Synthetic rescue:  Form of genetic interaction when mutation/deletion of one 
gene rescues the lethality or growth defect of a mutation in another gene. 
Epistasis: a general term for synthetic genetic interactions
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Chapter 1. Introduction  
Section I: Genomics as a tool for studying biological processes 
Much of our understanding of biological processes comes from studying the 
effects of gene mutation/disruption on the phenotypes of interests. Forward classic 
genetics utilises mutagens such as ethyl methane sulfonate (EMS), UV, viruses to 
introduce mutations, then screens for the phenotypes. This method normally 
produces clearly defined and easy to score phenotypes,  and an example of 
successful application of this approach is the discovery of  the major components 
of the Ras signalling pathways (Boutros and Ahringer 2008). Nevertheless, the 
identity of the mutations needs to be established, usually through cloning which is 
labour intensive and time consuming. An alternative is presented by genomic tools, 
such as the complete sequence and gene deletion sets in model organisms such 
as the yeast Saccharomyces cerevisiae, the nematode Caenorhabditis elegans, 
and the fruit fly Drosophila melanogaster. These provide geneticists with powerful 
means to study gene function in a systematic and genome-wide manner. These 
collections of genome-wide screening tools, particularly in yeast, have many 
advantages over the classic genetic approach.  Firstly, every gene in the deletion 
collections has been sequenced and identified, and therefore the resultant 
phenotype can be recorded for every gene. Secondly, the function of some genes 
may not be probed in classical genetics, an approach which screens random 
mutations. In genome-wide screens, the mutations and screen is systematic, and 
furthermore, all of the genes in the genome are tested simultaneously.  In such a 
systematic process, therefore, ―there is no place to hide‖, and the result is a more 
complete picture of the genetic contribution to the biological phenotypes and or 
processes of interest (Carpenter and Sabatini 2004). It has long been known in 
classical genetics that most phenotypes are the result of complex gene expression 
(Lobo 2008)—for example, drug resistance (Perlstein, Ruderfer et al. 2007). Yet, 
classical genetics has not cracked the molecular basis of complex gene 
expression beyond quantitative trait loci approaches, which are powerful, but 
limited in their resolution for determining all the underlying genetic contribution.  
This situation has become a key driver in specific literature of the last decade to 
utilise genomic tools in a different approach to genetic complexity.  
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Biological processes that have been studied using genome-wide screens included, 
for example, RNA interference (RNAi) screens in order to identify enzymes 
involved in a development defect in C. elegans, and eye development in D. 
melanogaster. Employing various reporter genes in combination with an RNAi 
(gene knockdown) collection has been used to study the Hedgehog signalling 
pathway (Carpenter and Sabatini 2004). The reporter genes have allowed 
examination of intracellular phenotypes, which cannot be seen in gross cellular 
morphology, growth or in changes in gene expression.  
Gene deletion collections (S. cerevisiae) or knockdown collections (C. elegans) 
have been used for exploring all the genes involved in a growth  phenotype in 
response to drug (Simon and Bedalov 2004; Artal-Sanz, de Jong et al. 2006; Kwok, 
Ricker et al. 2006), and more recently, phenotypic assays that involve the  
morphology of cells utilising high-throughput screening microscopes have been 
developed (Zemanová, Schenk et al. 2003; Pepperkok and Ellenberg 2006; Paran, 
Ilan et al. 2007). This has allowed for observation of developmental morphology, 
and intracellular localization in C. elegans (Chung, Crane et al. 2008) and 
intracellular localization in S. cerevisiae (Vizeacoumar, van Dyk et al. 2010), as 
well as for investigation of complexes that are  involved in protein folding in ER in 
S. cerevisiae (Carpenter and Sabatini 2004; Boutros and Ahringer 2008) 
A DNA microarray is a collection of gene-specific oligonucleotides that are 
attached to a solid surface such as a glass slide. Genomic DNA, or 
complementary DNA from cells subjected to different treatments, or from different 
tissue types, are hybridised to the slide, and the expression profile on the arrays is 
analysed. This method is widely used to study processes such as the dynamics of 
gene expression during development and differentiation, differential expression 
between normal cells and cancer cells, or gene expression and transcription 
activity in different stress environments (Causton, Ren et al. 2001; Kurimoto and 
Saitou 2010). 
Although genome-wide based ―reagents‖ (that is deletion strains) are available in a 
number of genetic model organisms (there is a complete set for Saccharomyces 
cerevisiae, Saccharomyces  pombe, a partial set for C. elegans, and 
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approximately 8000 mouse strains as cell lines), the most widely used collection is 
the yeast deletion array in S. cerevisiae. 
Saccharomyces cerevisiae as model organism 
Yeast, especially S. cerevisiae or baker‘s yeast, is a popular model organism,   
owing to a variety of attributes. These include a high homology to mammalian 
genes (31% of protein coding gene/ORF in yeast have homologues in mammals 
(Botstein, Chervitz et al. 1997)), their small size, a sequenced compact genome, 
high rates of homologous recombination, which allows for precise allele-specific 
genetic manipulation, and existence of both haploid and diploid life cycles. The 
haploid life cycle allows for easy recovery of recessive mutations and attenuates  
the necessity of considering epistatic interaction between alleles (Forsburg 2001) 
by removing dominant epistasis. 
S. cerevisiae was the first eukaryote for which precise gene deletion collections 
were compiled. In yeast, there are approximately 6300 genes that have been 
identified, and approximately 4800 genes can be deleted without showing growth 
phenotypic defects when grown in rich medium. This set of non-essential gene 
―knockouts‖ has proved to be a valuable tool for studies of many biological 
processes. The first example was the study of a complex genetic interaction 
network using synthetic genetic array (SGA) methodology (Tong, Evangelista et al. 
2001). Genetic interactions are identified when deletion of two genes results in 
enhancement or reduction in phenotype that is greater than the expected single 
additive effect of each deletion. The most extreme type of genetic interaction, 
synthetic lethality, occurs when combination of deletions of two viable gene 
deletions results in death. Such studies of genome-wide genetic interactions have 
identified genes that function in the same pathways, in buffering pathways, in 
related processes, as well as in prediction of function of novel genes based on the 
fact that genes which contribute to the same processes usually show genetic 
interaction to one another (Forsburg 2001).   
Because of its importance to this dissertation, synthetic genetic array (SGA) 
analysis is described here in more detail, as a method utilised to study genetic 
interactions in a genome-wide manner. In brief, a gene of interest is chosen based 
on the cell biology one wishes to study. In the deletion strain of this gene, the gene 
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is replaced with an antibiotic selection marker cassette, thus generating a ―query 
strain‖. This query strain is then mated against the non-essential genome-wide 
deletion mutant array (DMA) in which each gene has been systematically deleted 
and replaced with a different antibiotic selection marker. The diploid from this 
mating is sporulated to produce haploid cells, which are subjected to a 
sophisticated screen that selects for haploids of a specific mating type with the 
result of haploid strains each containing a query gene deletion and non-essential 
gene deletion genome-wide. A specific mating type must be selected to prevent 
opposite mating type haploids mating to form diploid cells. For genetic interaction, 
the growth phenotype of each deletion is scored and DMA deletions that show 
synthetic lethality in combination with the query gene deletion are scored as genes 
which genetically interact with the query gene. SGA has been used to study global 
genetic interaction in yeast (Tong, Lesage et al. 2004; Costanzo, Baryshnikova et 
al. 2010) as well as has many other specific  biological processes such as protein 
folding  and the secretory pathways (Schuldiner, Collins et al. 2005; Jonikas, 
Collins et al. 2009; Bircham, Maass et al. 2011), the cellular chaperone network 
(Zhao, Davey et al. 2005), and the yeast histone modification network (Lin, Qi et al. 
2008). Experimentation with haploid cells allows us to reduce the allelic effects of 
the same genes found in diploid cells which can complicate the interpretation of 
the genetic –interactions between two genes. 
The SGA-based method of creating double mutants in high-throughput can also be 
modified, and combined with fluorescent reporters to investigate the subcellular 
morphological effects of different stimuli such as chemicals or mutations. Bircham 
et al 2011 investigated genes which play roles in the secretory pathway by 
observing  the subcellular localisation of plasma membrane proteins tagged with 
the green fluorescent protein (GFP) in the different genetic background provided 
by the DMA (Bircham, Maass et al. 2011).  Because resistance mutations to 
certain chemicals can act in lieu of antibiotic selection markers, and because the 
yeast genome deletion array is arrayed according to the chromosome position of 
genes, it is possible to use the DMA as a high-density genetic map. Thus the SGA 
method can be modified and used as a way to identify both mutations  and 
multigenic traits without the necessity of cloning with plasmids (Jorgensen, Nelson 
et al. 2002). Jorgensen et al utilised this method to identify SSD1 as the 
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suppressor of the lethality associated with defects in the Cbk1 signalling pathway, 
and named this method ―synthetic genetic array mapping‖ (SGAM). 
It was the purpose of the foregoing to show that systematic genome-wide 
screening is a powerful genetic tool that can be used to investigate the molecular 
basis of genetic complexity, including drug resistance. It is a major aim of this 
dissertation to further develop these methodologies that may help identify 
components of many important biological processes in a way that is faster and 
less labour intensive than classical genetics and biochemistry.   
 
Section II:  Genomics and drug target identification 
Genomic methodologies have proved to be useful for bioactive target identification 
and mode-of-action characterization. Both allow us to understand the side effects 
of the compound, as well as help to increase efficacy and potency of future drug 
design. Target identification is eventually required for drug approval, but can be 
quite difficult when using biochemical methods. There are a number of genomic 
methodologies, which have been developed for the identification of drug targets. 
These include affinity capture, in which the ―target is purified from cellular extract 
using an immobilized or radio-labeled version of the chemical‖ (Baetz, McHardy et 
al. 2004; Bradner, McPherson et al. 2006). 
 Another technique, based on a similar idea to affinity capture, is a protein array in 
which purified protein molecules are arrayed on a glass slide, and thus can be 
used to study protein-protein, or ligand-protein interaction (Huang, Zhu et al. 2004).   
DNA microarray-based methods are another form of genomic approach. The yeast 
deletion mutant array (DMA), has unique DNA barcodes flanking each ORF 
deletion (Winzeler, Shoemaker et al. 1999), thus enabling identification of 
individual strains within a pooled population (Giaever, Shoemaker et al. 1999; Lum, 
Armour et al. 2004). Using the DMA, pooled (multiplexed) genome-wide screens of 
deletion mutants that display drug hypersensitivity allows the identification of 
pathways that compensate or ―buffer‖ genes affected by drug toxicity in a process 
known as chemical-genetic interaction profiling (Parsons, Brost et al. 2004; 
Parsons, Lopez et al. 2006). This multiplexed approach is extremely efficient in 
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terms of using scarce test-drug resources. The assumption behind the chemical 
genetic approach is that small molecules may bind to and inhibit specific proteins, 
thus acting in lieu of a mutation in that gene to elucidate the biological processes 
that gene is involved in (Figure 1-1). Chemical-genetic interactions, which may 
occur between an inhibitory drug and a deletion mutant, can appear as synthetic 
lethal (SL) interactions, giving us insight into the mode-of-action of the inhibitor, 
and the protein/gene involved. Similarly, to genetic interaction profiles, where 
genes that interact with one another tend to have similar functions, small molecule 
inhibitors may show a synthetic lethal profile with genes that are related to the 
drug target.  A comparison of interaction profiles that have a gene deletion as a 
―query‖ with those that have a small molecule inhibitor as a ―query‖ provides 
revealing information about the drug target. This information is very useful in 
studying novel compounds with unknown mode-of-action (Parsons, Brost et al. 
2004; Parsons, Lopez et al. 2006). Nevertheless, chemical genetic profiling does 
not necessarily reveal the direct drug target. Information that we can obtain from 
chemical-genetic profiling is that small molecules that affect the same/similar 
pathway tend to have similar profiles (Figure 1-2). By comparing the chemical-
genetic profile of known compounds to novel ones, profile similarity information 
can be used to predict pathways that are affected by novel compounds. 
Another recent genomic application of DNA genome-wide deletion mutant arrays 
is ―haploinsufficiency profiling‖ (HIP). This technique, developed by Giaever et al. 
(1999), is based on  the assumption that reducing  the number of gene copies 
encoding the drug target will result in an increased sensitivity to the drug 
compared to diploid wild-type cells. Haploinsufficiency profiling has many 
advantages, such as identifying potential drug targets directly (Lum, Armour et al. 
2004). However, HIP also has limitations, since in practice it can only be used to 
study essential genes, because non-essential genes tend to have back-up 
pathways. Other limitations include the fact that the ―noise‖ of  false positives or 
false negatives is high (Lum, Armour et al. 2004), and that protein production is 
not necessarily correlated with the gene dosage effect of haploinsufficiency. 
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Figure 1-1: Chemical genetic interaction. 
 (a) Right panel: the drug target interacts with the product of gene X, and the two buffer 
each other effect, so that deletion of either the drug target gene or gene X is non-lethal, but 
the deletion of both genes leads to lethality. (a) Left panel: a small molecule (drug) inhibits 
its target and act in lieu to the deletion of the drug target gene. Cells that contain a deletion 
in gene X in the presence of the drug will show the same phenotype as cells that contain 
both deletions in the drug target gene and gene X—lethality (red block). (b) Comparing the 
chemical-genetic profile of  the compound of interest with the genetic-genetic interaction 
profiles of genes across the genome can lead us to identify the drug target, or genes in the 
pathway which is affected by the drug (their profiles should be similar).  Figure from 
Parsons, A. B., R. L. Brost, et al. (2004). 
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For example, cyclosporin A and FK506 are both immunosuppressive drugs and show 
similar chemical-genetic profiles (similar sets of genes involved in buffering drugs toxicity). 
A similar match is observed with camptothecin and hydroxyurea, both of which affect DNA 
integrity. Camptothecin inhibits DNA enzyme topoisomerase I, while hydroxyurea inhibits 
enzyme ribonucleotide reductase. Diagram modified from Parsons, A. B., R. L. Brost, et al. 
(2004). 
 
A commonly used method to identify targets is through the generation of drug-
resistant mutants. Complementation cloning relies on finding a condition where the 
drug resistant mutant does not grow, e.g. minimal media, temperature sensitivity, 
various carbon sources, formamide etc. A plasmid–based genomic library can 
then be used to complement the growth defect, i.e. a gene that can rescue the 
growth defect should be the one that gives rise to drug-resistance when mutated 
(Parsons, Lopez et al. 2006). Another way of identifying the drug-resistance gene 
is to transform wild-type strains with a plasmid-based genomic library derived from 
a resistant mutant.  A mutant gene which can rescue a wild-type growth defect in 
the presence of drug should be the target of the drug (Miyamoto, Machida et al. 
2002). The first method has the disadvantage that we must identify a condition 
where the resistant mutant will not grow, while the second method is extremely 
time consuming, labor intensive, and must be repeated for every mutant. In 
addition, both methods are plasmid–based method, which can be time consuming; 
  
Figure 1-2: Drugs with similar mode-of-action show similar chemical-genetic profiles.  
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there are difficulties around the construction of plasmid libraries and getting full 
coverage of the genome.  
An emerging field to identify the mechanism of drug action and resistance is 
mRNA sequencing (RNAseq). In this technique drug resistant clones are selected, 
mRNA from the resistant clones and parental clones are then massively parallel 
sequenced. Bioinfomatics analysis is used to identify the high frequency mutated 
genes as potentials drug resistant loci (Figue1-21) (Wacker, Houghtaling et al. 
2012). This method, although very fast and allows chemical modifications of the 
drug of interest, relies on powerful bioinformatics to distinguish between natural 
occurring single nucleotide variations, and the nucleotide changes that cause drug 
resistant.  
 
 
Image from Wacker, Houghtaling, et al. (2012). 
In seeking drug targets of novel compounds, especially natural products, small 
quantities of the novel material is a major limitation; thus, finding a condition that 
mimics a drug to determine the resistance locus by complementation is a viable 
stratagem, but can be a vast wasted effort if a condition is not found.  We therefore 
employed an alternative genome-wide strategy to identify the resistance locus of a 
drug (neothyonidioside) by using the linkage disequilibrium group that 
characteristically surrounds the query gene interactions in SGAs. This technique, 
known as ―SGAM‖ (Jorgensen, Nelson et al. 2002), reasons that if a drug is 
potently cytotoxic, then resistant mutants are equivalent to antibiotic markers and 
the drug can be used in lieu of an antibiotic for selection. The drug resistant strain 
Figure 1-3: Schematic presentation of RNAseq as technique to identify drug resistant loci 
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is therefore used as a query strain and is crossed into the DMA background by 
mass mating, creating a comprehensive set of haploid double mutants (Tong, 
Evangelista et al. 2001). This technique relies on the fact that in haploids, the drug 
target locus can only be occupied by the mutated drug target that confers drug 
resistance, or the antibiotic marker from the DMA, but not both. Therefore, growing 
the DMA mutant that corresponds to the drug target on both the antibiotic and an 
inhibitory concentration of the drug will result in no growth. Gene deletions closely 
linked to the query gene form double mutants that, though they are not the target, 
still show reduced growth, owing to linkage disequilibrium with the target gene, in 
media containing the combined antibiotic and toxic drug. Because the strains in 
the DMA are ordered according to chromosome position, this ―linkage group‖ is 
clearly visible on SGA plates and can be used for mapping of the mutant gene 
(―SGAM‖) at a single gene resolution (Jorgensen, Nelson et al. 2002). In this way, 
SGAM may be utilized to map the locus that confers resistance to 
neothyonidioside to just a few possible gene candidates i.e. middle of the linkage 
group in just a few assay steps. We can then sequence relatively few candidate 
genes for point mutations instead of sequencing the entire genome or 
transcriptomes (RNAseq).   
 
Section III: Genomics and multidrug resistance 
Organisms require a very particular internal cellular environment in order to 
function, grow and reproduce. However, cells can encounter various 
environmental conditions which lead to stress, such as oxidative stress, heat 
shock, hyper-and hypo-osmotic stress, and toxin challenge (either from cellular 
metabolism or from external sources). To maintain the optimal internal 
environment, cells develop various mechanisms to protect from, cope with, or 
adapt to stress. These protective mechanisms involve many types of proteins and 
transcription factors, which can be activated in response to stress, and then go on 
to rapidly  activate many more target genes (Gasch, Spellman et al. 2000). Many 
of these pathways involve signaling, which, on sensing the stress, then relay the 
information to the nucleus (Hanlon, Rizzo et al. 2011). For example, the 
osmosensor for sensing osmotic stress, known as MAPK signal transduction, 
activates a range of general stress-response transcription factors. Other pathways, 
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such as the oxidative stress response pathway, make use of enzymes that convert 
toxic metabolites to non-toxic products (Jamieson 1998; Ikner and Shiozaki 2005), 
and some of pathways utilise certain membrane protein transporters in cellular 
detoxification by effluxing toxic compounds/metabolites. An example of one of 
these pathways is the multidrug resistant stress response (Kuchler and Schüller 
2007). 
Multidrug resistance (MDR) is usually defined as the ability of a living cell to show 
resistance to a wide variety of structurally and functionally unrelated compounds. 
This phenomenon is conserved in bacteria to humans and allows organisms to be 
able to survive or defend themselves against a variety of cytotoxic compounds in 
the environment. MDR is also one of the main mechanisms by which pathogenic 
fungi or cancer cells develop drug resistance.  
The MDR response can be mediated in many ways such as mutation in drug 
targets, inactivation of drugs, reduced cellular uptake of drugs by reduction of 
membrane permeability (Kuchler and Schüller 2007), Figure 1-4.  However, the 
most commonly observed MDR response is mediated through overexpression of 
membrane-spanning efflux pumps. Two major classes of transporters that play 
important roles in MDR are the ABC (ATP binding cassette) family of transporters 
that are ATP-dependent, and Major Facilitator Superfamily (MFS) transporters. In 
many organisms the master regulator of MDR pump expression are transcription 
factors belonging to the Zinc Cluster protein class, which are further detailed below 
(Gottesman, Fojo et al. 2002; Sipo and Kuchler 2006; Gulshan and Moye-Rowley 
2007). 
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Multidrug resistance has been widely studied in budding yeast and   S.cerevisiae 
shows a great range of small molecule resistance (Gulshan and Moye-Rowley 
2007). In yeast, MDR is referred to as pleiotropic drug resistance (PDR).    
Although, the transcription factors (Pdr1p/Pdr3p,discussed below) and ABC-
transporters (Pdr5p, Snq2p, and Yor1p discussed below) involved in PDR have 
been widely studied, the way in which cells sense the presence of the drugs, relay 
this information to the transcription factor and how the transcription factors 
themselves are controlled are still unclear. As discussed below there are many 
transcription factors from other stress response pathways that seem to contribute 
to the PDR phenotypes and might act in either Pdr1p/Pdr3p-dependent or 
Figure 1-4: Mechanisms of multidrug resistance.  
Cells can achieve the MDR phenotype in many ways such as reducing cellular uptake, 
changing membrane permeability, using of molecular scavengers, intracellular inactivation 
of drugs, sequestering drugs to specific compartments where they can be destroyed or 
effluxed out of the cells, changes in transcription or mutation in the target genes, and 
increased expression of efflux pumps.  Diagram modified from (Kuchler and Schüller 2007) 
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Pdr1p/Pdr3p-independent manners; how they actually contribute to the phenotype 
is also unclear. 
In this project, we probed how cells sense the presence of xenobiotic drugs (toxic 
or inhibitory small molecules in the environment), by investigating possible new 
regulators/modulators of Pdr1p/Pdr3p (Chapter 4).  Another concept that we 
investigated (Chapter 5) was the relationship between PDR and Yap1p, an 
oxidative stress transcription factor which has been shown to confer resistance to 
many drugs when overexpressed (Wendler, Bergler et al. 1997). Recognition 
sequences for Yap1p are also found on main PDR ABC-transporter genes PDR5 
and SNQ2, which suggests that it controls many major facilitators of the PDR 
pathway (Kolaczkowska and Goffeau 1999) (discussed below). We investigated if 
there are any common regulators between Yap1p and Pdr1p/Pdr3p, which could 
in turn lead to cross talk between oxidative stress response and the PDR response. 
The possible crosstalk between these two processes has been suggested in 
numerous papers and reviews (Miyahara, Hirata et al. 1996; Wendler, Bergler et al. 
1997; Zhang, Cui et al. 2001; Moye-Rowley 2003).  We then investigated another 
mechanism of drug resistance that does not require Pdr1p/Pdr3p or activation of 
ABC-transporters (Chapter5), but involves the sterol composition of the plasma 
membrane, and how a drug-like compound may exert its cellular toxicity via 
endocytosis and vacuole formation pathway.   
  
PDR1 and PDR3; the main transcription factors in PDR 
PDR gene expression is rapidly induced in the presence of xenobiotics ( toxic or 
inhibitory small molecules  under the control of two transcription factors, Pdr1p and 
Pdr3p that are members of the Zn2Cys6 family of transcription factors (Balzi, Chen 
et al. 1987; Balzi and Goffeau 1995; DeRisi, van den Hazel et al. 2000; Gulshan 
and Moye-Rowley 2007).  PDR1 was first identified in 1987 by Balzi et al. as a 
gene which regulates the resistance to various small molecules such as 
cycloheximide and oligomycin in S. cerevisiae (DeRisi, van den Hazel et al. 2000). 
In 1986 Subik et al. mapped the locus of PDR3  which encodes another zinc finger 
transcription factor controlling the PDR response in budding yeast (Šubik, 
Ulaszewski et al. 1986). Co-immunoprecipitation and chromatin 
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immunoprecipitation experiments showed that Pdr1p and Pdr3p can form both 
homo and heterodimers and Pdr1p constitutively binds to its target promoters in 
vivo (Mamnun, Pandjaitan et al. 2002; Fardeau, Lelandais et al. 2007). These two 
zinc cluster proteins are 36% identical to each other and contain six highly 
conserved cysteines that bind zinc, a C-terminal acid activation domain and a DNA 
binding domain (Delaveau, Delahodde et al. 1994). This domain recognizes a 
DNA sequence known as the pleiotropic drug resistance element (PDRE) that 
contains the consensus sequence TCCGCGGA (MacPherson, Larochelle et al. 
2006). One or several PDREs are found within the 5‘ UTR of their target genes, 
mostly ABC pumps, such as PDR5, SNQ2, YOR1, PDR10, and PDR15, each of 
which is described more fully below and is known to be involved in the PDR 
response (MacPherson, Larochelle et al. 2006). Other major targets of Pdr1p and 
Pdr3p are MFS genes such as RTA1, HXT2, HXT9, HXT11, TPO1, RSB1, and 
some genes involved in lipid homeostasis such as PDR16 and IPT1 
(Kolaczkowska and Goffeau 1999). These targets of Pdr1p and Pdr3p overlap but 
are not identical. For example, Pdr15p which is a close homologue to Pdr5p is 
more responsive to Pdr3p, and while deletion of PDR1 causes reduction of mRNA 
level of PDR5, the mRNA level of PDR15 is shown to increase in this background  
(Wolfger, Mahe' et al. 1997). Pdr1p is also active under normal growth condition 
because one of its targets, Pdr5p, is a highly expressed protein, suggesting that 
Pdr1p has a partially constitutive role (Mamnun, Schuller et al. 2004). The 
difference in transcriptional regulation between Pdr1p and Pdr3p might be due to 
post-translational modifications. Pdr1p is possibly post-translationally regulated by 
Ssz1p (Pdr13p), a member of Hsp70 family in yeast (Hallstrom, Katzmann et al. 
1998; Eisenman and Craig 2004) while Pdr3p is shown to be controlled by signals 
from mitochondria as well (Hallstrom and Moye-Rowley 2000; Devaux, Carvajal et 
al. 2002). 
Although a single PDRE is sufficient to respond to Pdr1p/Pdr3p transcriptional 
activation (YOR1 contains only a single PDRE in its promoter), it has been shown 
that multiple PDREs are required for full promoter activity, at least in PDR5 
(Katzmann, Hallstrom et al. 1996). Interestingly, PDR3 also contains two PDREs 
in its promoter as does YRR1, another Zn2Cys6 zinc-finger transcription factor 
involved in multidrug resistance response which will be discussed later (Sipo and 
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Kuchler 2006). These PDREs act in auto-regulation as well as in response to 
Pdr1p regulation (Delahodde, Delaveau et al. 1995; Moye-Rowley 2003). 
Experiments have shown that the mRNA level of PDR3 increased in the 
hyperactive form of PDR1 (the PDR1-12 mutation confers hyper-resistance to 
diazaborine) and that the autoregulation process is relevant for cycloheximide 
response (Delahodde, Delaveau et al. 1995; Wehrschütz-Sigl, Jungwirth et al. 
2004). Wehrschütz-Sigl et al. also showed by Northern Blot that the mRNA level of 
PDR1-12 was increased in this strain compared to wild-type; however they did not 
detect an increase in expression of a lacZ reporter linked to the PDR1 promoter in 
the PDR1-12 strain as expected. They suggested that the higher PDR1-mRNA 
level in this mutant strain might be due to higher mRNA stability and other 
transcriptional stimulation at the PDR1 promoter. 
Figure 1-2 shows the possible way that Pdr1p might regulate the expression of 
other PDR transcription factors such as PDR3, and YRR1It is possible PDR1 
expression may be subjected to other modifications such as ubiquitination or 
activation by mediator complexes. Pdr1p then regulates the transcriptional 
expression of PDR3 and YRR1 as well as other PDR genes (ABC transporters, 
MFS etc.), all containing PDRE in their promoter regions. Pdr3p is autoregulated 
as well as regulating YRR1 and other PDR genes that might overlap with Pdr1p. 
Yrr1p is activated by both Pdr1p and Pdr3p and transcriptionally activates other 
PDR genes, and therefore, amplify the signal input. 
There are about 200 genes which contain PDRE in their promoter regions, but 
only 10% of these genes respond to a hyperactive form of PDR1 and/or PDR3 
(discussed below) (Fardeau, Lelandais et al. 2007), which is unexpected if 
Pdr1p/Pdr3p are the sole controllers of the PDR response. This fact suggests that 
there may be other modulators that are required, in addition to the presence of 
PDRE, that are necessary for transcriptional activation by Pdr1p/Pdr3p.   
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Multidrug resistance in fungi is often achieved via change in activity of transcription 
factors, mainly, Pdr1p and Pdr3p. Loss of either PDR1 or PDR3 results in 
differential drug tolerance, and loss of both PDR1 and PDR3 results in severe drug 
hypersensitivity(Kolaczkowska and Goffeau 1999). Gain-of-function pdr1 and pdr3 
mutant alleles produce hyperactive Pdr1p and Pdr3p, which in turn overproduce 
their target efflux pumps, and therefore confer a multidrug resistance phenotype 
(Kolaczkowska and Goffeau 1999; Gulshan and Moye-Rowley 2007). Many single 
point mutations in both PDR1 and PDR3 have been identified that cause 
hyperactive transcriptional activity, such as pdr1-2, pdr1-3, pdr1-6, pdr1-7, pdr1-8, 
pdr3-2 to pdr3-10. Of these, pdr1-3 mediates the highest increase in resistance to 
many compounds, such as cycloheximide, oligomycin, 4-nitroquinoline-N-oxide 
and ketoconazole ((Carvajal, van den Hazel et al. 1997). Polymorphic forms of 
PDR1, pdr1-11, and pdr3-11 also disrupt the inner bilayer leaflet steady-state and 
cause translocation of  phosphatidylethanolamine, across the plasma membrane, 
leading to the notion that control of phospholipid composition is also regulated in 
multidrug resistance. Indeed, it has been shown by many experiments that normal 
multidrug resistance in fungi depends on the lipid homeostasis (Kolaczkowska and 
Goffeau 1999; Schüller, Mamnun et al. 2007; Shahi and Moye-Rowley 2009). This 
will be discussed in later chapters. 
Figure 1-5: Possible regulation PDR transcription factors PDR1, PDR3 and YRR1. ―Ub‖ 
equals sensory input. Adapted from Bolouri & Davidson, 2002. 
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Membrane transporters in pleiotropic drug resistance 
In yeast, the main targets of Pdr1p and Pdr3p that cause the majority of PDR 
phenotypes are ATP-binding cassette (ABC) drug transporters (Sipo and Kuchler 
2006). This family of proteins is conserved from bacteria to humans. ABC 
transporters are present in all cellular compartments except the endoplasmic 
reticulum (ER) and nuclear membrane (Figure 1-6) (Wolfger, Mamnun et al. 2001) 
 
 All ABC proteins share similar hallmark domain organization, shown in Figure 1-7 
which includes at least one conserved ATP-binding cassette (ABC) , also known 
as nucleotide binding domain (NBD), and several α-helical membrane-spanning 
segments (transmembrane segment, TMS) (Wolfger, Mamnun et al. 2001).  S. 
cerevisiae ABC-proteins are often used as a model to study the clinical problem of 
drug resistance in infectious disease and cancer as well as in pharmaceutical 
screens for novel drugs (Gottesman, Fojo et al. 2002; Golin, Ambudkar et al. 2003; 
Simon and Bedalov 2004; Jungwirth and Kuchler 2006; Kuchler and Schüller 2007; 
Xia, Yang et al. 2010). The most prominent and well-characterized ABC 
transporters in yeast that are targets of Pdr1p/Pdr3p are Pdr5p, Snq2p, and Yor1p. 
These plasma membrane proteins have broad specificity to structurally and 
 Figure 1-6: Membrane ABC transporters in yeast and their locations. 
 Figure from (Kuchler and Schüller 2007) with permission. 
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functionally unrelated compounds, which they ―pump‖ out of the cell in an ATP-
dependent manner. 
 
PDR5 
Pdr5p has a six membrane-spanning domains and a repeated putative ATP-
binding domain. It is the functional homologue of mammalian ATP transporters, P-
glycoproteins (P-gps), which are upregulated in many cancer cell lines (Balzi and 
Goffeau 1995; Wolfger, Mamnun et al. 2001; Gottesman, Fojo et al. 2002). The 
structure of Pdr5p is shown in Figure 1-8 (Rutledge, Esser et al.2001). Pdr5p was 
purified and characterized from the overexpression of pdr1 mutants (Decottignies, 
Kolaczkowski et al. 1994). Pdr5p function involves PDR phenotype, as well as 
cation resistance (Miyahara, Hirata et al. 1996) and lipid translocation (Kihara and 
Igarashi 2004). 
 
Figure 1-7:  multidrug ABC transporter structure of Staphylococcus aureus (Sav1866).  
TMD: transmembrane domain. NBD: Nucleotide binding domain. ICL: intracellular loops 
(between transmembrane helices). Image from (Dawson RJ and Locher KP 2006) 
http://www.rcsb.org/pdb. 
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Disruption of PDR5 is non-lethal, but causes sensitivity towards many compounds, 
such as cycloheximide, chloramphenicol, ketoconazole, and sulfometuron methyl. 
A strain lacking PDR5 also exhibits a metal salt hypersentive phenotype (Balzi and 
Goffeau 1995; Miyahara, Hirata et al. 1996). Pdr5p is observed in the highest 
abundance during exponential growth phase and is thought to be involved in 
detoxification of toxic metabolites, in a similar manner to its closest homologue, 
Pdr15p. However, unlike Pdr15p, Pdr5p abundance is strongly repressed in 
stationary phase and Pdr15p seemed to be more dependent on Pdr3p and less 
dependent on Pdr1p than Pdr5p is (Mamnun, Schuller et al. 2004). Another close 
homologue of Pdr5p is Pdr10p, sharing 66% identical residues (Wolfger, Mamnun 
et al. 2001). Pdr10p was shown  to play a role in maintaining the distribution and 
function of a subset of other plasma membrane proteins (Rockwell, Wolfger et al. 
 
Figure 1-8: Pdr5p structure.  
Top: Predicted topology of Pdr5p. Bottom: Stereoscopic view of the Pdr5p model showing 
two trans-membrane domains: TMDs. Underneath the TMDs are the nucleotide binding 
domains, NBDs (in blue and red). The NBDs are connected by loops L1–L3 in yellow and 
orange. Images from (Rutledge, Esser et al. 2011) 
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2009). Cells lacking PDR10 show a defect in maintaining plasma membrane 
asymmetry, a defect in endocytosis of phosphatidylethanolamine (PE), and chitin 
synthase Chs3p function (Rockwell, Wolfger et al. 2009). 
PDR5 contains at least three known PDREs in its promoter and its expression is 
positively regulated by Pdr1p and Pdr3p (Balzi and Goffeau 1995; Katzmann, 
Hallstrom et al. 1996), and negatively regulated by Rdr1p (Hellauer, Akache et al. 
2002). Experiments have shown that PDR5 can also be heat-shock induced via 
the transcription factors Yap1p and Cad1p (Miyahara, Hirata et al. 1996). 
SNQ2 
As with PDR5, SNQ2 encodes an ABC transporter that may confer PDR in yeast 
when overexpressed. It is a functional homologue to the mammalian P-
glycoprotein. The Snq2p transporter confers multidrug resistance particularly to 
mutagens such as methyl-nitro-nitrosoguanidine (MNNG) and 4-nitroquinoline-N-
oxide (4-NQO) (Servos, Haase et al. 1993; Bauer, Wolfger et al. 1999). Like PDR5, 
the null mutant of SNQ2 is non-lethal but causes hypersensitivity toward many 
drugs and metal salts (Balzi and Goffeau 1995; Miyahara, Hirata et al. 1996). 
However; the null mutation of SNQ2 does not  increase in sensitivity toward 
cycloheximide, a well-known xenobiotic that is removed from cells by Pdr5p, or 
oligomycin (Decottignies, Kolaczkowski et al. 1994; Gulshan and Moye-Rowley 
2007) . It has been shown that besides functioning in the PDR response Snq2p 
also is involved in cation resistance and can be upregulated by the transcription 
factors Yap1p and Cad1p via binding site in its promoter(Miyahara, Hirata et al. 
1996).  
The closest homologue of Snq2p is Pdr12p which shares 60% primary sequence 
identity (Bauer, Wolfger et al. 1999). However, they have differential expression 
since PDR12 is highly induced in response to weak organic acids such as sorbate 
and benzoate rather than to hydrophobic drugs like SNQ2 (Piper, Mahe et al. 1998; 
Wolfger, Mamnun et al. 2001). Some other stressors such as high osmolarity or 
ethanol level can also induce PDR12 but the increase in expression is not as 
pronounced as with sorbate. PDR12 expression induction by cellular stress is also 
independent from Pdr1p/Pdr3p and does not require other well-known stress- 
response transcription factors such as Yap1p or Msn2p. The fact that SNQ2 and 
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PDR12 require different inducers despite high similarity in primary sequence 
suggest that there might be other novel transcription factors control yet to be found. 
YOR1 
YOR1 encodes a multidrug-resistance –associated protein (MRP) in a subfamily of 
plasma membrane ATP-binding cassette (ABC) proteins. The YOR1 null mutation 
is viable but confers sensitivity to many drugs and metals. It shows significant 
homology to mammalian MRP and to some extent to the cystic fibrosis 
conductance transmembrane regulator (CFTR) (Wolfger, Mamnun et al. 2001). 
YOR1 was identified in the genetic screens for oligomycin and reveromycin A 
resistance (Katzmann, Hallstrom et al. 1996). Besides multidrug resistance, Yor1p 
also plays a role in metal detoxification, for example, that of cadmium, mercury, 
and arsenite (Katzmann, Hallstrom et al. 1995; Cui, Hirata et al. 1996; 
Decottignies, Grant et al. 1998; Liu 2011), and also in transportation of toxic 
compounds such as unconjugated bilirubin, selenodigluthione, and oxidized 
glutathione (Lazard, Ha-Duong et al. 2011). 
Yor1p shares many substrates with Pdr5p and Snq2p but also has distinct 
substrates preferences (Rogers , Decottignies et al. 2001). Like PDR5 and SNQ2, 
YOR1 expression is positively regulated by Pdr1p/Pdr3p through the presence of 
PDREs in its promoter. While expression of PDR5 is severely affected in the 
Δpdr1/Δpdr3 background, the expression of SNQ2 and YOR1 is decreased  but 
can still maintain a Pdr1p/Pdr3p-independent expression (Kolaczkowska and 
Goffeau 1999). PDR5 and SNQ2 both contain binding sites for an AP-1-like basic 
leucine zipper (bZIP) transcriptional activator such as Yap1p (Yap1p response 
element, YREs) which are involved in the oxidative stress response, and Cad1p 
which is involved in stress responses and iron metabolism(Kolaczkowska and 
Goffeau 1999). These binding sites are not found in the YOR1 promoter region. 
Yor1p however, can confer oligomycin resistance via activation by Yrr1p, another 
Zn(II)2Cy6 transcription factor involved in PDR which binds to the Yrr1p response 
element ,similar to PDRE ,in the promoter region. Interestingly the Yrr1p binding 
site is absent in the promoter regions of PDR5 and SNQ2 (Kolaczkowska and 
Goffeau 1999; Gulshan and Moye-Rowley 2007). 
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The closest homologues of Yor1p are Ycf1p and Mrp1p, where both act as 
glutathione conjugate transporters. Ycf1p plays a role in cadmium resistance and, 
to some extent, lies under the control of  Yap1p (Bauer, Wolfger et al. 1999). 
Ycf1p also has function in unconjugated bilirubin, selenodigluthatione, and 
oxidized glutathione transport (Lazard, Ha-Duong et al. 2011).  
Interestingly, deletion of the SNQ2 and/or YOR1 open reading frame (ORF) 
increases resistance to ketoconazole and other compounds that are specific to 
Pdr5p (Kolaczkowska, Kolaczkowski et al. 2008). Similar results were observed 
when PDR5 was deleted namely resistance to Yor1p, and Snq2p specific 
substrates was increased. These data suggest some sort of ―compensatory 
activation‖ (Kolaczkowska, Kolaczkowski et al. 2008). Such activation of 
paralogous transporters is Pdr1p-dependent and occurs when one or more of the 
other transporters are deleted even in the absence of drugs. Compensatory 
activation is Pdr3p-independent; indeed, deletion of PDR3 stimulates even more 
induction of this ―compensatory activation‖ suggesting that Pdr3p is a suppressor 
of this compensatory process. Such observations in general support the idea that 
even though Pdr1p and Pdr3p share very similar sequences they regulate their 
(overlapping) downstream targets differently. Moreover, they might be subjected to 
different regulation and other unknown proteins/ modulators might involve in the 
upstream regulation of the PDR master regulator Pdr1p/Pdr3p. Figure 1-9  from 
Davidson EH 2010, shows how a gene regulatory network (GRN) provides 
―system level explanations of developmental and physiological functions‖ such as 
differentiation in different stage of development. Perhaps PDR networks in yeast 
might employ similar ―logic‖ systems to control the PDR response dependant on  
combinations of ―overall inputs‖  modifying the overall ―remain-on‖ circuitry shown 
in figure 1-6 caused by general xenobiotics (initial inputs) where particular kinases 
are  ―signal inputs‖. 
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Major facilitators 
Besides the ABC transporter, another type of transporter that contributes to the 
PDR phenotype is the major facilitator superfamily (MFS) which is proton-
motive–force -dependent. There are at least 20 different MFS proteins that have 
been shown to be involved in multidrug resistance(Gulshan and Moye-Rowley 
2007) and often share overlapping substrate specificity with ABC transporters. An 
example is Flr1p, a plasma membrane multidrug transporter that contributes to 
fluconazole and cycloheximide resistance in a similar way to Pdr5p but also 
pumps out benomyl (Alarco, Balan et al. 1997; Brôco, Tenreiro et al. 1999).  
MFS-MDR transporters are found in bacteria, Achaea and eukaryotes. They are 
classified by the number of predicted transmembrane spans into two families. First 
is the 12-spanner drug:H+-antiporter-1 (DHA1) ,and second is the 14 spanner 
drug:H+-antiporter-2 (Gbelska, Krijger et al. 2006).  
Figure 1-9: Gene regulatory network (GRN)  
The Gene Regulatory Network is shown with a master controller and downstream effectors.  
In multicellular organisms, a specific GRN receives the signal input that can then turn on a 
few master regulators. Specific downstream effectors encode for cell-type-specific proteins 
that respond to number of regulatory factors that then produce the final phenotype. There 
may be cross talk between regulators to activate downstream effectors.  It is possible that 
different ABC transporters (downstream effectors), might be regulated by Pdr1p/Pdr3p and 
other regulators which are all controlled by unknown upstream GRN. Image from (Davidson 
2010). 
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In S.cerevisiae, 12 genes comprise the DHA1 family. These are AQR1, QDR1, 
QDR2, QDR3, FLR1, DTR1, TPO1, TPO2, TPO3, TPO4, HOL1, and YHK8 
(Gbelska, Krijger et al. 2006). Aqr1p, Qdr1-3p and Flr1p are all plasma membrane 
proteins that are involved in PDR phenotypes with the first four proteins involved in 
resistance to quinidine, an anti-arrhythmic agent (Nunes, Tenreiro et al. 2001; 
Tenreiro, Vargas et al. 2005). Tpo1p and Tpo1-4p are plasma membrane proteins 
and confer resistance to polyamine toxicity by detoxifying excess spermidine and 
putrescine, produced during the breakdown of amino acids (Sá-Correia and 
Tenreiro 2002; Albertsen, Bellahn et al. 2003). Tpo1p and Tpo4p can mediate 
growth resistance to cycloheximide, a well-known Pdr5p substrate, and quinidine 
similar to Aqr1p and Odr1-3p (Sá-Correia and Tenreiro 2002). Furthermore the 
null mutant of TPO1 (Δtpo1) displays increased  sensitivity to nystatin, a well-
known antifungal drug (Sá-Correia and Tenreiro 2002). 
There are 10 DHA2 drug: H+-antiporters that have 14 predicted membrane-
spanning segments in S. cerevisiae.  This group consists of VBA1, VBA2, VBA3, 
VBA4, VBA5, ATR1, AZR1, SGE1, YML1, and YMR279C. 
Vba1-3p are vacuolar membrane proteins involved in basic amino acid 
transportation (Shimazu, Sekito et al. 2005). ATR1 (former name SNQ1) was one 
of the first characterized yeast efflux pumps and is required for resistance to 
aminotriazole and 4-nitroquinoline-N-oxide (Kanazawa, Driscoll et al. 1988; 
Gömpel-Klein and Brendel 1990). Azr1p, a plasma membrane transporter confers 
resistance to azole antifungal drugs such as ketoconazole and fluconazole which 
are also pumped out by ABC transporter Pdr5p. Azr1p also pumps acetic 
acid ,propanoic acids (weak organic acids), and crystal violet dye (Tenreiro, Rosa 
et al. 2000; Bauer, Rossington et al. 2003). 
Although most DHA1 and DHA2 transporters are involved in the PDR phenotype 
and have similar primary sequences, only TPO1 contains a PDRE in its promoter 
and is regulated by Pdr1p. ATR1 and FLR1 are both regulated by Yap1p,the 
oxidative stress transcription factor which as mentioned above also has a binding 
site in front of ABC transporters Pdr5p and Snq2p (Kolaczkowska and Goffeau 
1999). In fact the FLR1 mRNA level is hardly detectable during yeast exponential 
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growth phase, and is highly induced in the presence of benomyl; such induction is 
highly Yap1p-dependent (Sá-Correia and Tenreiro 2002).  
Other proteins in the major facilitator superfamily (MFS) transporters that might be 
involved in multidrug resistance are the hexose transporters (Nourani, 
Wesolowski-Louvel et al. 1997; Ozcan and Johnston 1999). MFS proteins can 
transport glucose down a concentration gradient (Ozcan and Johnston 1999). 
HXT9, and HXT11 encode nearly identical proteins that are not induced by 
glucose as other HXT genes (HXT1-4) are, but are under the transcription control 
of both Pdr1p and Pdr3p where Pdr3p is shown to bind directly to the promoter 
region of HXT11, probably at a PDRE (Ozcan and Johnston 1999). Interestingly, 
deletion of one or both of HXT9 or HXT11 increases sensitivity to cycloheximide, 
sulfometuron methyl, and 4-NQO (Ozcan and Johnston 1999) which is reverse of 
what normally is observed when Pdr1p/Pdr3p targets, such as PDR5, 
SNQ2,YOR1, or TPO1, are deleted. Thus, it was speculated that hexose 
transporters could negatively regulate ABC transporters or are involved in drug 
uptake itself (Nourani, Wesolowski-Louvel et al. 1997). 
Other transcription factor regulators for PDR 
Even though Pdr1p and Pdr3p are the main transcription factors for multidrug 
resistance in yeast, there are other transcription factors as well as other 
modulators that play important roles in the PDR phenotype.  
For example, Thakur et al. 2008 showed that Pdr1p and Pdr3p directly bind to 
ketoconazole in the carboxy(C)-terminal of DNA binding domain (Thakur, Arthanari 
et al. 2008), and that a Gal11p/Med15p, a subunit of the RNA polymerase II 
mediator complex, is required for the xenobiotic response and multidrug resistance.  
Furthermore, not all ABC transporters involved in PDR are entirely dependent on 
Pdr1p / Pdr3p. This observation is supported by experiments showing that deletion 
of both PDR1 and PDR3 greatly reduces the basal level of their main target, Pdr5p 
but do not eliminate PDR5 induction upon cycloheximide or diazaborine treatment. 
This is similar to SNQ2 expression in 4-nitroquinoline 1-oxide (4-NQO) which can 
be Pdr1p/Pdr3p independent (Cui, Shiraki et al. 1998; Wehrschütz-Sigl, Jungwirth 
et al. 2004).  
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Both ABC and MFS genes together with many other genes involved in the control 
of lipid biosynthesis, contain sites for multiple transcription factors for various 
stress responses leading to cross pathway regulation events. Gain-of-function of 
mutations in many transcription factor besides PDR1/PDR3 cause change in 
plasma membrane composition via their target genes (Lucau-Danila, Delaveau et 
al. 2003).  
To date, there is little known about what may regulate the regulators 
(Pdr1p/Pdr3p). This dissertation questions whether other transcription factors and 
proteins play roles in multidrug resistance in S. cerevisiae. Figure 1-10 shows 
possible PDR phenotype regulation in S. cerevisiae, and some of the proteins 
involved in PDR regulation are discussed below. 
 
 
Zinc cluster transcription factors 
YRR1 and YRM1 
Yrr1p is another Zn2Cys6 zinc-finger transcription factor identified through a 
mutation that increases resistance to the cell-cycle inhibitor revoromycin A, 4-NQO, 
and oligomycin (Cui, Shiraki et al. 1998; Zhang, Cui et al. 2001; Moye-Rowley 
Figure 1-10: PDR regulation in S. cerevisiae. 
 Besides Pdr1p and Pdr3p, many of the ABC transporters and MFS may be controlled by 
other transcription factors from other stress responses, such as the Yap1p from oxidative 
stress response and the Msn2p from general stress reponse. Pdr1p and Pdr3p can also be 
controlled by other proteins such as Pdr13p (Ssz1p) and SAGA complexes, Ngg1p, as well 
as mitochondrial status (discussed in the section ―Other regulators of PDR‖, page 28) . 
Figure from (Jungwirth and Kuchler 2006). 
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2003). Yrr1p mediates drug resistance via binding to the promoter region of the 
ABC transporter genes, SNQ2 and YOR1, and upregulating them, since loss of 
YRR1 reduced expression of these two important efflux pumps. There has been 
defined a Yrr1p response element (YRRE) that is found in front of the coding 
region of  these genes with the consensus sequence of  
T/ACCGC/TG/TG/TA/TA/T (Le Crom, Devaux et al. 2002), similar to PDRE (5'-
TCCGCGGA-3'). Other genes with promoters that interact with Yrr1p are SNG1, 
which encodes a plasma membrane protein, AZR1, and FLR1. The latter two 
encode MFS transporters, and FLR1 is also controlled by the Yap1p transcription 
factor. The promoters of YLL056C and YLR346C also contain the YRRE. Both of 
these genes encode putative proteins of unknown function, and the latter is found 
in mitochondria and also lies under the control of Pdr1p, implying crosstalk 
between Pdr1p and Yrr1p (Le Crom, Devaux et al. 2002). Similarly to PDR3, 
YRR1 also has a PDRE in its promoter region and YRR1 expression is 
autoregulated, as well as being regulated by Pdr1p, and possibly Pdr3p (Zhang, 
Cui et al. 2001). They showed that although Yrr1p contributes to oligomycin 
resistance via Yor1p, it does so in a Pdr1p/Pdr3p-dependent manner. 
Nevertheless, the YRR1 gain of function mutant (YRR1-1) which exhibits drug 
resistance and increased target expression was found to contain short duplication 
of residues in the C-terminus that can activate YOR1 gene expression in 
Pdr1p/Pdr3p-independent manner (Zhang, Cui et al. 2001). The authors speculate 
that it is possible that the signal from Pdr1p and or Pdr3p was amplified by another 
transcription factor, like Yrr1p, which shares overlapping target genes with Pdr1p 
and Pdr3p. Figure 1-10 shows the PDR target genes that are controlled by Pdr1p, 
Pdr3p, Yrr1p and Yrm1p. Some of the targets are controlled by more than one 
transcription factor. 
The closest YRR1 closest homologue is YRM1 (Lucau-Danila, Delaveau et al. 
2003), another Zn2Cys6 zinc-finger transcription factor. Lucau-Danila et al. have 
shown using genome-wide expression analysis and chromatin 
immunoprecipitation that Yrm1p upregulated 23 genes, 14 of which are also 
regulated by Yrr1p.  These include ABC and MFS transporter genes such as 
AZR1, YOR1, SNG1, and SNQ2. FLR1 is the only Yrr1p target in which its 
promoter does not interact with Yrm1p. Furthermore, Yrm1p only interacts with 
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targets in the absence of Yrr1p, and that gene expression in the 14 common 
targets as well as gain-of-function mutant of YRR1 activity are repressed when 
YRM1 is overexpressed. To make the multidrug resistance phenotype yet even 
more complex, deletion of YRM1 does not affect expression of YRR1. However, a 
Yrm1p mutant that has lost its central regulatory region will not recognize the 
presence of Yrr1p. This suggests that post-transcriptional processes might also 
play role in transcription factor regulation. Furthermore, Lucau-Danila et al. also 
suggested that the central middle homology region (MHR) region of C6 zinc 
cluster transcription factors might play roles in DNA target discrimination 
(Schjerling and Holmberg 1996). As mentioned previously, most targets of these 
two transcription factors are plasma membrane ABC and MFS transporters, as 
well as genes involved in lipid metabolism that can affect the plasma membrane 
composition and change sensitivity to different drugs.  
 
Figure 1-11: Overlapping targets between different PDR transcription factors.  
Target genes involved in the PDR phenotype mostly encode plasma membrane proteins. 
Genes that are controlled by Pdr1p/Pdr3p and Yrr1p/Yrm1p are shown as black squares. 
Genes that are regulated by Pdr8p and Yrr1p/Yrm1p are indicated by black triangles. Figure 
from (Lucau-Danila, Delaveau et al. 2003). 
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STB5 and RDS1, 2, 3 
Stb5p was found to play roles in multidrug resistance by forming a heterodimer 
with Pdr1p and binding to PDRE in front of target genes such as PDR5  and SNQ2 
(Akache, MacPherson et al. 2004). STB5 encodes for a Zn2Cys6 zinc finger 
transcription factor. As well as multidrug resistance regulation, STB5 regulates 
oxidative stress response via genes in the pentose phosphate pathway, and genes 
involved in the production of NADPH, which is a metabolite required for oxidative 
stress resistance (Larochelle, Drouin et al. 2006). Deletion of STB5 causes 
hypersensitivity toward cycloheximide, even in the presence of Pdr1p and Pdr3p, 
as well as reduced PDR5 and SNQ2 expression (Akache, MacPherson et al. 
2004). 
Similarly to STB5, RDS1, 2, 3 are zinc cluster proteins, and strains lacking RDS1 
and/or RDS3 are sensitive to cycloheximide, while deletion of RDS2. which 
involves in regulating gluconeogenesis and the glyoxylate cycle, confers sensitivity 
toward ketoconazole. PDR5 expression was decreased upon deletion of  the RDS 
genes, and deletion of RDS2 caused a decrease in the PDR16 RNA level (Akache, 
MacPherson et al. 2004). As discussed above, these transcription factors generate 
another level of multidrug resistance regulation and interplay between different 
regulators. However, much is still unknown about the function of these genes. 
RDR1 
Rdr1p is a member of the Gal4p family of zinc cluster proteins, which are 
proposed to act as transcriptional repressors. Deletion of RDR1 results in an 
inability for cells to grow in non-fermentable carbon sources and causes up-
regulation of many membrane protein-encoding genes, including ABC transporters, 
PDR5, PDR15, and PDR16. It also confers  increased resistance to cycloheximide 
(Hellauer, Akache et al. 2002). Nevertheless, deletion of RDR1 does not increase 
resistance to cycloheximide in cells lacking Pdr5p nor does it cause a change in 
expression of SNQ2. These results suggest that Rdr1p is a PDR5 suppressor and 
might act via the Pdr1p/Pdr3p binding site in front of the PDR5 promoter since 
insertion of a PDRE in front of a minimal CYC1 promoter increases PDRE-CYC1 
reporter expression by 8 fold in Δrdr1 cells compared to wild-type. Another 
explanation for rdr1Δ-induced PDR5 expression is that deletion of RDR1 causes 
damage in mitochondria which results in a phenotype similar to the one observed 
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in ρ0 cells, which then activate Pdr3p and therefore increases PDR5 expression 
indirectly (Moye-Rowley 2003). This explanation is supported by the fact that Δrdr1 
phenotype includes the inability of cells to grow on non-fermentable carbon 
sources as mentioned above. More studies are needed to understand how RDR1 
regulates the ABC efflux pump Pdr5p. 
MSN2 and MSN4 
Both Msn2p and Msn4p are C2H2 zinc finger transcription activators that are 
involved in general stress responses, such as heat shock, osmotic shock, 
oxidative stress, low pH, glucose starvation, sorbic acid and high ethanol 
concentrations. Upon induction, they move from the cytoplasm to the nucleus and 
bind to stress response elements (STREs), 5'-CCCCT-3', located in the promoters 
of their target genes (Schmitt and McEntee 1996; Görner, Durchschlag et al. 1998). 
MSN4 gene expression is autoregulated, as well as being Msn2p-dependent, and 
is induced by stress, while MSN2 expression is constitutive (Görner, Durchschlag 
et al. 1998; Gasch, Spellman et al. 2000).  
Fardeau et al 2006 had showed the contributions of Msn2p and Msn4p to PDR 
phenotype. Fardeau‘s group investigated early cellular responses that lead to the 
PDR phenotype finding six transcriptional regulatory motifs that significantly 
contribute the cellular response to fluphenazine, a PDR inducer. In fluphenazine 
induction, 15 induced genes contain Msn2p/Msn4p binding sites, including SNQ2. 
This suggested roles of Msn2p, and Msn4p in PDR response. 
Consistent with this finding, Schuller et al 2007 found that perturbation of the 
plasma membrane with 2, 4-dichlorophenol (DCP), and polyoxyethylene-9-
laurylether (POELE) induced many changes in gene expression and a significant 
number of those genes contained binding sites for Pdr1p/ Pdr3p, as well as 
Msn2/Msn4p. Further investigation showed that double mutation Δmsn2Δmsn4 
confers sensitivity in high concentrations of DCP, and that both DCP and POELE 
cause re-localisation of Msn2p-GFP from the cytoplasm to the nucleus. They 
suggested that Msn2p and Msn4p contribute to DCP resistance in a Pdr1p/Pdr3p 
dependent manner. 
PDR15 encodes an ABC transporter involved in effluxing chloramphenicol, and is 
the closest homologue to Pdr5p. It contains Msn2p/ Msn4p binding sites and is 
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regulated by both proteins, as well as by Pdr1p/Pdr3p. Although Pdr1p and Pdr3p 
modulate basal level of pPdr15p, under many stress conditions, such as osmotic 
stress and weak acid stress, PDR15 expression is induced by Msn2p but not 
Msn4p, and does not require Pdr1p/Pdr3p, nor the high osmolarity glycerol (HOG) 
MAPK signalling pathway, which normally tightly regulates  Msn2p and Msn4p 
(Wolfger, Mamnun et al. 2004). These results show extensive complex cross-
reactions between the general stress response and PDR response.  
Basic Region-Leucine Zipper Transcriptional regulators (bZIP), Yap1p 
Another class of transcription factors that has been associated with the regulation 
of PDR is the basic region-leucine zipper (bZIP) family (Figure 1-12). The most 
studied bZIP transcription factor that associates with PDR phenotype is YAP1. The 
Yap1p transcription factor is required for oxidative stress tolerance (Moye-Rowley, 
Harshman et al. 1989). The Yap1p protein was purified based on the its 
biochemical similarity to mammalian AP1 which is also involved in regulation of 
oxidative stress  (Harshman, Moye-Rowley et al. 1988). Yap1p binds to the yeast 
AP-1(yAP-1) recognition element (YRE) with the consensus sequence of 
TTACTAA differing only in the second base pair from the mammalian AP-1 site 
(Fernandes, Rodrigues-Pousada et al. 1997). 
 
Figure 1-12: Structure of Basic Leucine Zipper and Zinc Cluster Transcription Factors. 
The basic leucine zipper transcription factor (left). The leucine residues which comprise the 
zipper, are represented in red (image from http://en.wikipedia.org), and the Zinc Cluster 
Transcription Factor, Zn(II)2Cys6 (Right), is represented by yellow zinc atoms (image from 
MacPherson, S., M. Larochelle, et al. (2006)) 
32 
 
YAP1 is activated by a change in cellular redox state caused by oxidants such as 
H2O2 and diamide through formation of disulfide bonds. The altered state causes 
re-localisation of Yap1p from the cytoplasm to the nucleus where it activates 
downstream target genes. Most of these genes encode radical scavengers such 
as glutathione (Gsh1p, Glr1p) or thioredoxin (Trx2p)(Jamieson 1998). It also 
mediates cadmium tolerance. More details about the Yap1p transcriptional activity 
mechanism will be discussed in later section ―YAP1 and oxidative stress response‖ 
page 45. 
Interestingly, the first known biological phenotype associated with Yap1p was not 
in the oxidative stress response but it‘s ability to confer resistance to 
cycloheximide, sulfometuron, and 4-NQO when overexpressed (Moye-Rowley 
2003). However, deletion of YAP1 does not cause hypersensitivity toward 
cycloheximide as does the  deletion of PDR1/ PDR3 or ABC-transporter gene 
PDR5 (Wu, Wemmie et al. 1993). Wendler et al. showed that overexpression of 
YAP1 results in diazaborine resistance in a PDR1- and PDR3-dependent manner, 
thus linking the oxidative stress response with PDR. In contrast, overexpression of 
YAP1 can still confer resistance to cycloheximide in the  Δpdr1Δpdr3 background 
independently of PDR5 (Wendler, Bergler et al. 1997). As discussed above, many 
of the ABC transporter genes (PDR5, SNQ2) and major facilitators (ATR1, FLR1) 
contain YRE in their promoters and lie under the control of Yap1p. It is thought that 
cycloheximide tolerance might be achieved via regulation of FLR1, and therefore 
bypasses the requirement for Pdr5p (Moye-Rowley 2003). Yap1p also activates 
Ycf1p, another ABC transporter that has the closest homology to Yor1p. Ycf1p has 
a role in detoxifying cells of  metals such as cadmium, lead, and mercury, as well 
as oxidizing agents such as diamide (Li, Lu et al. 1997; Gueldry, Lazard et al. 
2003). Ycf1p also involved in sequestering endogenous cellular toxins from 
metabolic processes (Paumi, Chuk et al. 2009), and act as one of the systems for 
exporting electrophiles that are conjugated to glutathione (Li, Szczypka et al. 
1996).Therefore, activation of YCF1 by Yap1p could lead to drug resistance. The 
ability of Yap1p to activate MFS and other transporters, besides the ones activated 
by Pdr1p/Pdr3p, suggests that Yap1p acts on a parallel pathway to Pdr1p/ Pdr3p 
and functions to strengthen the PDR phenotype. Figure 1-13  shows some targets 
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of Yap1p which contribute to the PDR phenotypes, including some that overlap 
with known PDR transcription factors, such as Pdr1p and Pdr3p. 
Other bZIP regulators 
Many close homologs of Yap1p in S. cerevisiae such as Cad1p and Cin5p show 
the ability to elevate tolerance to cadmium (Moye-Rowley 2003) and the 
chemotherapy drug cisplatin tolerance respectively (Furuchi, Ishikawa et al. 2001). 
As mentioned above PDR5 and SNQ2 expression can also be heat-shock 
activated by Yap1p as well as Cad2p (Miyahara, Hirata et al. 1996). Although 
Yap1p and Cad2p have been shown to be 88% identical in their DNA binding 
domain, Cad2p target genes are often involved in protein folding and degradation, 
while Yap1p target genes often show involvement in detoxification (Cohen, Pilpel 
et al. 2002). This property might allow cells to tolerate a larger variety of xenobiotic 
compounds. 
Another class of bZIP regulators, called the activating transcription factor /cAMP 
response element binding protein (ATF/CREB) family, Aca1p and Aca2p, are 
involved in utilization of non-optimal carbon sources and chromosome stability. 
They have been shown to increase sensitivity toward many drugs including 
hygromycin B and cycloheximide when deleted (Garcia-Gimeno and Struhl 2000). 
 
Figure 1-13: Yap1p target genes that are involved in PDR phenotypes. 
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Other regulators of PDR 
Mitochondrial status  
Screens aimed at identifying negative regulators of PDR5 show that cells carrying 
a deletion of FZO1 and/or OXA1 (genes involved in mitochondrial integrity) exhibit 
resistance to cycloheximide via a large increase in PDR5 expression. This occurs 
in a PDR3-,  but not a PDR1-dependent manner (Hallstrom and Moye-Rowley 
2000). FZO1 encodes an integral membrane protein involved in mitochondrial 
outer membrane tethering (by SNARES) and fusion, as well as having a role in 
mitochondrial genome maintenance (Rapaport, Brunner et al. 1998). Loss of FZO1 
causes rapid loss of the mitochondrial genome (ρ0 cell)  (Rapaport, Brunner et al. 
1998). OXA1, on the other hand, encodes a mitochondrial inner membrane protein 
that interacts with mitochondrial ribosomes (Jia, Dienhart et al. 2003). Both ρ0 and 
Δoxa1 cells are defective in electron transport and oxidative phosphorylation and 
display an increased expression of PDR5 (Hallstrom and Moye-Rowley 2000). 
Hallstrom and Moye-Rowley (2000) suggested that PDR3-dependent up-
regulation of PDR5 and PDR3 expression in ρ0 cells occurs because PDR1 is 
constitutively expressed while PDR3 is autoregulated. It follows that; PDR3 may 
be regulated by Pdr1p via two PDREs in its promoter region. Cells that have lost 
their mitochondria genome (ρ0) have a 15-fold increase in PDR3 expression with 
no increase in PDR1 expression (Zhang, Cui et al. 2001). The same authors 
showed that PDREs in the PDR3 promoter, and thus autoregulation property of 
PDR3, are required for up-regulation of PDR5 in the ρ0 cells. The signal from the 
F0 subunit of the mitochondrial ATPase leads to PDR5 activation. Interestingly 
expression of SNQ2 and YOR1, two other targets of PDR3, do not increase as 
much in ρ0 cells as PDR5 does (Zhang, Cui et al. 2001). 
Later experiments that screened for mutants, in which cycloheximide resistance in 
ρ0 cells was abolished, identified a mutation in LGE1. Deletion of LGE1 causes a 
strong reduction of PDR3-dependent PDR5 expression in ρ0 cells (Moye-Rowley 
2005; Zhang, Kolaczkowska et al. 2005). Lge1p was required with other ubiquitin 
enzymes to attach ubiquitin to lysine in histoneH2B (Hwang, 
Venkatasubrahmanyam et al. 2003). It was demonstrated that PDR3 required 
Lge1p for normal induction in ρ0 cells. Nevertheless, the actual mechanism of how 
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Lge1p regulates Pdr3p in ρ0 cells is still unknown. Lge1p has been linked with 
retrograde transport (Gulshan, Schmidt et al. 2008), and ubiquitination might play 
role in post translational modification of Pdr3p in ρ0 cells. 
Another possible link between mitochondrial status and PDR is a translocation of 
the phospholipid  phosphatidylethanolamine (PE)  from the inner leaflet of the 
plasma membrane bilayer to the outer leaflet stimulated by unknown ―flippases‖ 
(Kean, Grant et al. 1997). PE biosynthesis is catalyzed by the enzyme 
phosphatidylserine decarboxylase (Psd1p) in the mitochondrial inter-membrane 
space. Experiments demonstrated that PSD1 in a high-copy-number plasmid 
confers an increase in cycloheximide tolerance in wild type cells via an increase in 
the PDR5 and PDR15  expression in a PDR3-dependent manner (Gulshan and 
Moye-Rowley 2007). Gulshan and Moye-Rowley also showed that loss of PSD1 in 
ρ0 cells prevents normal activation of PDR5, and that the region in Psd1p required 
for this is in the non-catalytic amino-terminal of the protein (Gulshan and Moye-
Rowley 2007). Furthermore, Psd1p from other fungi, the human fungal pathogens, 
Candida albicans and Candida glabrate, also has the ability to activate 
cycloheximide resistance. This showed that Psd1p is also involved in regulation of 
multidrug resistance and is conserved throughout the fungal family.  
Altogether, these findings show that mitochondrial status and regulation of the 
retrograde membrane flow pathway from the plasma membrane involves the 
multidrug resistance phenotype in S. cerevisiae, thus demonstrating the extent of 
diversity of the pathways affected by PDREs and their transcription factors. 
Lipid homeostasis 
As previously discussed, Pdr1p and Pdr3p control many ABC and MFS 
transporters that are plasma membrane proteins. Assuming that some 
transporters are flippases, it may be suggested that one major outcome of Pdr1p 
and Pdr3p action is a change in plasma membrane composition,  including 
―flipping‖ of PE to the outer-membrane bilayer leaflet (Decottignies, Kolaczkowski 
et al. 1994; Pomorski, Holthuis et al. 2004).  
Lipid transporters establish a distinctly asymmetric lipid distribution between the 
outer membrane and inner membrane leaflet (Figure 1-14) and thus may affect the 
physiological function of the membrane. Many membrane-damaging agents can 
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strongly induce ABC pumps, demonstrating a coupling between lipid homeostasis 
and multidrug resistance (Pohl, Devaux et al. 2005; Sipo and Kuchler 2006). 
Deletion of PDR5 and YOR1 decreases the phospholipid PE in the outer 
membrane leaflet of cells. Both Pdr5p and Yor1p translocate phospholipids across 
the membrane in an ATP-dependent manner (Decottignies, Grant et al. 1998). 
However, Pdr5p ATPase activity is much higher than that of Yor1p (Decottignies, 
Grant et al. 1998). The authors speculated that these differences in ATPase 
activity between these two ABC transporters are possibly related to their 
differential activation by certain yeast phospholipids. 
 
It is also known that many eukaryotic ABC transporters, such as yeast Pdr10p are 
found in lipid rafts (Pohl, Devaux et al. 2005; Sipo and Kuchler 2006). As 
mentioned above, PDR10 is a close homologue of PDR5, and is involved in 
maintaining the proper distribution of plasma membrane proteins. Deletion of this 
gene causes resistance toward weak organic acids due to accumulation of the 
ABC transporter Pdr12p in the lipid raft. It might be expected, therefore, that 
flipping PE distribution could cause alteration in transporter function by affecting 
raft formation and retrograde membrane trafficking (Kihara and Igarashi .2004; 
Rockwell, Wolfger, et al. 2009).   
Figure 1-14: Composition of eukaryotic plasma membrane (courtesy ASM Press & Sinauer 
Associates Inc, 2000) 
The diagram shows that the plasma membrane comprises phospholipid bilayers in which 
specific phospholipids are found in one or other of the membrane leaflets. 
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Mahe et al (1996) conducted experiments showing that certain ABC transporters 
have roles in both detoxification and transport of lipids and human steroids, which 
can also be toxic in certain forms. They demonstrated that overexpression of 
either PDR5 or SNQ2 can reduce cellular estradiol concentration in yeast cells 
containing an estradiol-inducible chimeric VP-16 human estrogen receptor. 
Deletion of both genes showed high level of estradiol accumulated in cells. 
Although the mammalian steroid hormone signaling pathway is not known in yeast, 
steroid derivatives play important roles in the yeast cell membrane, especially 
ergosterol, which is the main membrane sterol in yeast (Mahé, Lemoine et al. 
1996). 
Strains lacking Pdr5p and Yor1p are resistant to phytosphingosine (PHS), a 
precursor of many sphingolipids, involved in cellular signalling. Phytosphingosine 
induces apoptosis in human T-cell lymphoma and non-small cell lung cancer cells, 
and it induces caspase-independent cytochrome C release from mitochondria.The 
PHS resistance is dependent on PDR1 and RSB1. Kihara and Igarashi suggested 
that there might be some signal transduction from Pdr1p to Rsb1p, which in turn 
alters the cell membrane sphingolipid composition (Kihara and Igarashi 2002). 
Close homologues of Rsb1p in Candida species, referred to as RTA, are also 
linked to multidrug resistance, as they are found to contribute to azole resistance 
in these pathogenic fungi (Jia, Ma et al. 2008).  
The main phospholipids in S. cerevisiae are sphingolipids. IPT1 encodes 
inositolphosphotransferase, an enzyme responsible for the synthesis of mannose-
(inositol-P)2-ceramide (M(IP)2C), the most abundant sphingolipid in the cell 
(Dickson and Lester 2002). IPT1 was found to be transcriptionally induced by 
Pdr1p and Pdr3p (Hallstrom, Lambert et al. 2001). Furthermore, mutation in IPT1 
can confer resistance to the antifungal syringomycin E (Thevissen, Cammue et al. 
2000).  
PDR16, and its closest homologue PDR17, which encodes phosphatidylinositol 
transfer protein (PITP) are found to be under the control of Pdr1p and influence 
levels of phospholipid and drug resistance (van den Hazel, Pichler et al. 1999). 
Deletion of PDR16 results in hypersensitivity to the azole antifungals miconazole 
and ketoconazole. Deletion of either gene, or both genes, causes change in sterol 
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composition in the cell membrane, especially in the levels of lanosterol and 
zymosterol, as well as phospholipid composition (van den Hazel, Pichler et al. 
1999). These results suggest that Pdr16p and Pdr17p contribute to multidrug 
resistance mainly via regulation of lipid composition rather than directly 
sequestering drugs, as do the other ABC-transporter targets of Pdr1p.   
Induction of phospholipid translocation across the membrane bilayer is also found 
in mammals. Mouse mdr1, mdr2 and human MDR1 and MDR3 act as 
phospholipid transporters or flippases (Decottignies, A., A. M. Grant, et al. (1998) 
and their references). MDR1 in the human adrenal cortex was suggested to be 
involved in transport steroid hormone and other lipids (Mahé, Lemoine et al. 1996). 
This shows that ABC-transporters, and their roles in phospholipid homeostasis, 
are conserved across species.  
The review of the literature in the last few pages demonstrates fundamental effects 
of xenobiotics and disruption of the PDR systems on membrane composition (Sipo 
and Kuchler 2006) and trafficking. These effects devolve down to the molecular 
organization of membranes, not just the expression of the pumps themselves, as 
discussed in initial parts of this Introduction. What we do not know is whether this 
co-ordination of regulation affects just PDR pumps, as a special class of 
membrane proteins, or if it affects all membrane proteins.  
Cells may also become resistant to toxic compounds by changing  in the 
membrane ergosterol composition (Yibmantasiri, Leahy et al. 2012). Work by 
Emter et al 2002 showed that Erg6p an enzyme in the ergosterol biosynthesis 
pathway, determines the rate of passive drug diffusion, without affecting Pdr5p 
efflux pump activity in effluxing drug (Emter, Heese-Peck et al. 2002). This is a 
further hint as to the complexity of the PDR phenotype.  
HSP70 
Ssz1p (Pdr13p) is a member of the Hsp70 protein family. SSZ1 was first 
designated as PDR13 based on its ability to increase expression of both PDR5 
and YOR1 when overexpressed, and therefore increase both cycloheximide and 
oligomycin tolerance (Hallstrom, Katzmann et al. 1998). Further investigation 
showed that Pdr13p acts via Pdr1p, but not Pdr3p, in inducing PDR5 and YOR1 
expression.  A dominant, gain-of-function mutation, S295F, in SSZ1 leads to 
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resistance to cycloheximide and oligomycin and seems to be a more efficient 
activator of drug resistance than overexpression of the wild type allele (Hallstrom, 
Katzmann et al. 1998). Hallstrom et al (1998) suggested that Ssz1p regulates 
Pdr1p through post-translational phosphorylation, since mutations that change 
serine to phenyalanine suggest that phosphorlylation might be involved. 
Another Hsp70 protein family member which seems to play a role in PDR 
regulation is Ssa1p as identified in a tandem TAP-tag affinity purification (Shahi, 
Gulshan et al. 2007). Ssa1p repressed PDR5 expression in a Pdr3p-dependent 
manner without having an effect on either Pdr1p-dependent gene expression or on 
other efflux pump targets of Pdr3p, i.e. Yor1p and Snq2p.  
Thus, Hsp70 protein families provide another level of regulatory control of 
multidrug resistance in yeast emphasising the complexity of the PDR network.    
RNA polymerase II mediator complex 
The ‗Mediator Complex‘ is a group of proteins that serve as ―adaptors‖ between 
transcription factors and RNA polymerase. Mediators are essential components of 
the RNA polymerase II-mediated transcription machinery, a major point in gene 
expression regulation. Mediators consist of at least 20 subunits with multiple 
activities. They are conserved from yeast to humans, and play a role in both basal 
and regulated transcription (Casamassimi and Napoli 2007). Mediators can both 
activate and repress the expression of a particular gene, depending on which 
subunits are interacting with each other in the whole complex (Figure 1-15). 
GAL11 (MED15) encodes a subunit of the RNA polymerase II mediator complex 
that is involved in multidrug resistance in yeast.  Gal11p forms a complex with 
Pdr1p, via its activator-targeted KIX domain, and is required for drug resistance 
(Thakur, Arthanari et al. 2008). Deletion of GAL11 in both hyperactive mutants of 
PDR1 and PDR3, although decreasing levels of PDR5 expression, does not 
completely abolish all the PDR5 expression from these strains. As with many of 
the strands of evidence discussed above, this literature suggests that there must 
be other mediators required for activation of multidrug resistance. 
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Shahi et al 2010 investigated other possible mediators required for PDR3 –
dependent PDR5 activation in ρ0 cells. They found that loss of the mediator-
encoding gene SRB8 (referred to as MED12 in the paper) strongly reduced PDR5 
induction and cycloheximide resistance in ρ0 cells bur not in wt (ρ+) cells. Further 
experiments by the same authors suggested that Srb8p plays an important role in 
mediating PDR3-dependent PDR5 activation, and does not interact with Pdr1p.  In 
contrary, Gal11p is important for PDR5 induction, regardless of mitochondrial 
status, and interacts with both Pdr1p and Pdr3p (Shahi, Gulshan et al. 2010). 
 
 
Figure 1-15: Yeast mediator complexes.  
(a) The ―Mediator‖ (blue) functions as a bridge between gene-specific activators (ACT; red) 
and the general pol II transcription machinery (purple) at the promoter‖. (b) ―Gene-specific 
repressors (REPR; green) interact with specific Mediator subunits (blue) and recruit the 
complex to upstream regulatory DNA sequences. Mediator that is recruited by repressors 
contains the Srb8–11 (Med12–Med13–Cdk8–CycC) module (pink), which prevents 
interactions with Pol II and the basal transcription machinery (purple)‖. This figure and 
description is from (Björklund and Gustafsson 2005). (c) Yeast mediator components, figure 
from (Shahi, Gulshan et al. 2010). 
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Interestingly, a Δpgd1 (Δmed3) strain had a reduced PDR5 expression in ρ0 cells, 
as measured using a PDR5-β-galactosidase reporter, but did not change 
cycloheximide tolerance in the ρ0 cells, while ρ+ Δpgd1 cells are hypersensitive to 
cycloheximide. This might be due to different regulation/mediator requirements for 
cycloheximide tolerance in different genetic backgrounds. Each mediator subunit 
can also affect transcription of hundreds of genes and result in global alteration of 
gene expression. This in turn can result in specific PDR phenotypes, without 
directly regulating the major transcription factors Pdr1p/Pdr3p. Furthermore, 
disruption of each subunit in the same complex can result in different phenotypes. 
For example, loss of Srb8p and but not Ssn2p (Med13p), prevents the 
cycloheximide resistance phenotype in ρ0 cells (Shahi, Gulshan et al. 2010).  
A summarising diagram of the regulators/modulators that contribute to the PDR 
network and phenotype in yeast is shown in Figure 1-16.  
Mammalian multidrug resistance (MDR) 
Similarly to yeast, there are many ways cells, such as cancer cells, can become 
resistant to drugs, such as through the development of a block in the apoptosis 
pathway, or activation of detoxification systems involving cytochrome P450. There 
is evidence that activation of detoxification systems, such as DNA repair, can also 
induce expression multidrug transporters (Gottesman, Fojo et al. 2002). However, 
the most common way in which mammalian cells achieve multidrug resistance 
involves up-regulation of ATP-dependent efflux pumps, which is the same principle 
as that observed in yeast cells. Nevertheless, the exact mechanism of how cells 
sense the presence of drugs, and the possible signaling pathways that control 
transcriptional activation of ABC-transporters, is still not clear. 
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While multidrug resistance in yeast is often achieved via changes in transcriptional 
activity of PDR1 and PDR3, most multidrug resistance in mammalian cells seems 
to emerge via amplification of expression of ABC transporter genes, which pump 
out drugs, and therefore lower cellular concentration of drugs (Gulshan and Moye-
Rowley 2007). The human ABCB1/MDR1, encoding the ABC transporter P- 
glycoprotein (Pgp), is overexpressed in certain tumour cells, leading to significant 
multidrug resistance to many chemotherapeutic drugs. Pgp is an efflux pump with 
Figure 1-16: Diagram summarising of the regulators and modulators that contribute to the 
PDR network and phenotype in yeast.  
Pdr1p and Pdr3p are the main transcription factors that activate (pointed arrow) the 
expression of ABC-transporter-encoding genes, such as PDR5 SNQ2 and YOR1, as well as 
autoregulating themselves. Other transcription factors, such as Yrr1p, Yap1p, and Msn2p, 
also contain recognition site(s) in the promoters of some of these ABC-transporter genes 
and help contribute to the PDR phenotype. Loss of mitochondrial DNA in cells (ρ
0
) activates 
Pdr3p, which in turn activates PDR5. Sphingolipids and phospholipids might also play roles 
in the PDR phenotype. Most ABC transporters are found in lipid rafts, and enhance outward 
movement of certain phospholipids. Some of the chaperone proteins (Ssz1p, Ssa2p) 
activate Pdr1p, while some inhibit its action (blunt arrowhead). There are likely to be more 
as yet unknown stress induced activators/ modulators, that could activate Pdr1p/Pdr3p, or 
activate ABC-transporter genes. Blue box: PDRE, Purple box: Yrr1p recognition site, Green: 
Yap1p recognition site (YRE), Yellow: Msn2p/Msn4p recognition site. 
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a broad spectrum of substrates. Pgp has 12 transmembrane regions, and two 
ATP-binding sites. The transmembrane regions bind to drugs/substrates, which 
then stimulates the ATPase activity of the Pgp, which in turn results in 
conformational change that releases the drugs/substrates outside the cell. ABC 
transporters are found throughout the body in normal tissues and not just in cancer 
cells. In a different role, ABC transporters in the blood-brain barrier have a major 
role in protecting the brain against many toxins generated in the blood during 
metabolism. The liver, kidney, and gastrointestinal tract also use ABC transporters 
as a way to excrete toxins (Gottesman, Fojo et al. 2002). Many ABC pumps in 
mammals are used as a way to expose specific lipids on the outer membrane 
bilayer leaflet, for example as uptake receptors or to cause retrograde membrane 
transport to specific locations. As previously mentioned, in yeast these activities 
are mediated by MDR components  acting as ―flippases‖, which allow lipids to 
rapidly equilibrate between the two-layers and alter the biological properties of 
membranes (Pohl, Devaux et al. 2005).  
Cancer cell lines, especially those from colon, kidney, adrenocortical, and 
hepatocellular cancers, were shown to highly express Pgp efflux pumps and  
exploit these transporters as mechanism to protect cancer cells from 
chemotherapeutic drugs (Gottesman, Fojo et al. 2002). Examples of drugs which 
are affected by up-regulation of efflux pumps are vinblastine, doxorubicin, 
daunorubicin, and paclitaxel (Gottesman, Fojo et al. 2002).  
Since not all cancer cells exhibit high expression levels of Pgp pumps and  
because cancer cells are normally genetically heterogeneous due to 
accumulations of mutations, it is likely that other mechanisms might also be 
involved in multidrug resistance (Gottesman, Fojo et al. 2002). These include up-
regulation of other detoxification pathways, such as DNA repair as mentioned 
above, and mutations in the drug target. For example, many mutations are found 
in tubulin subunits, which form microtubules. These mutations prevent microtubule 
binding agents, such as the chemotherapeutic drug paclitaxol, from binding or 
interacting with microtubules, therefore making the cells become resistance to the 
drugs (Kavallaris 2010). Defects in the apoptosis pathways can also lead to drug 
resistance. Some cancer cells can reduce the levels of ceramide, which normally 
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acts as signal for apoptosis, or some cancer cells are altered in their regulation of 
the cell cycle (Figure 1-17) (Gottesman, Fojo et al. 2002). 
 
 
Although cancer cells use more than a single mechanism to develop resistance to 
a variety of drugs, and though the cytotoxic effects of many compounds may be 
exerted via physiological mechanism not present in yeast, many of the 
mechanisms underlying multidrug resistance are conserved from yeast to higher 
eukaryotes. Moreover, many of the ABC transporters in yeast have functions 
analogous to Pgp pumps (e.g. Pdr5p and MDR1 Pgp), and Yor1p in yeast is 
related to the human MRP/CFTR family, as mentioned above. It is clear that a 
detailed knowledge of cellular mechanisms of multidrug resistance in yeast cells 
may contribute to a better understanding of the mechanism of multidrug resistance 
in mammalian cells. Particularly of how cells sense the presence of the drug, and 
how transcription factors that activate ABC transporters are regulated, as well as 
answering some questions of how sphingolipids interact with ABC transporters 
and contribute to the MDR response. All this information will greatly help in cancer 
Figure 1-17: Mechanisms by which cancer cells achieve multidrug resistant phenotype.  
Figure from (Gottesman, Fojo et al. 2002). 
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treatment and might lead to the discovery of a new potential combination of drug 
targets—for example, one drug might help reduce the up-regulation of ABC 
transporters, so that chemotherapeutic drugs will not get pumped  out and remain 
at a concentration toxic to the cell. 
Questions concerning PDR and genomic tools 
Due to the complexity of the PDR network, many questions remain to be answered. 
For example, how do cells sense the presence of the xenobiotics? Pdr1p is found 
inside the nucleus and binds to the promoter of targets independent of the 
presence of drugs (Fardeau, Lelandais et al. 2007). Most of the PDR pumps (both 
ABC, and MFS) are kept at a low level during normal growth but are rapidly and 
highly induced in the presence of xenobiotics. How can exogenous compounds 
activate Pdr1p, which is found inside the nucleus in a rapid manner? Thaker et al 
2008 suggested that Pdr1p/Pdr3p act as receptors and directly bind to xenobiotics 
(Thakur, Arthanari et al. 2008). This suggests that drugs must rapidly get through 
the plasma membrane to the nucleus to be able to bind directly to Pdr1p/Pdr3p to 
induce the rapid PDR response. So, how does such a wide variety of drugs get 
inside the cell? Some of the drugs are not lipophilic so they cannot diffuse across 
the lipid bilayers of the plasma membrane, and yet they trigger the PDR response. 
Are there any genes upstream of Pdr1p/Pdr3p which relay the information about 
the presence of xenobiotics to the nucleus? In addition, are there other unknown 
modulators that help regulate the transcriptional activity of Pdr1p/Pdr3p? (Figure 
1-18). 
As mentioned previously, there are many factors which can also contribute to the 
multidrug drug resistance phenotype, such as another transcription factor,Yap1p , 
a transcription factor for the oxidative stress response which, when overexpressed, 
confers resistance to many drugs and whose binding site is found in the promoter 
region of many of the ABC transporters and major facilitators. Lipid homeostasis 
has also been a major contributor to the drug resistance phenotype. Many of the 
antifungal agents, such as amphotericin and nystatin (polyenes) are not ABC 
transporter substrates and it has been shown that mutations in the ERG gene 
family, which is involved in sterol biosynthesis in S. cerevisiae, such as mutations 
in ERG2 and ERG3, confer resistance to these antifungal agents due to change in 
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lipid/sterol homeostasis (Woods, Bard et al. 1974; Morrissey and Osbourn 1999; 
Balkis, Leidich et al. 2002; Emter, Heese-Peck et al. 2002).  
Alteration in sterol composition also confers drug resistance in other fungal 
species, such as Candida albicans and Candida tropicalis  (Hsuchen and Feingold 
1974; Woods, Bard et al. 1974).  Antifungal like ketoconazole, which is a Pdr5p 
substrate, can be less potent in cells which have a defect in sterol composition 
(Balkis, Leidich et al. 2002) suggesting that Pdr1p/Pdr3p despite being 
transcription factors with a major role in the multidrug resistance phenotype are 
not the sole contributors to PDR. It is very likely that many unknown regulators, 
modulators, transcription factors and lipid alterations also contribute to this 
phenotype. Cross talk between different responses are possible, and signaling 
cascades such as PKA, a signalling pathway known to be involved in general 
stress response, might also play an important role in relaying information about the 
presence of drug at the plasma membrane to the transcription factors Pdr1p/Pdr3p 
in the nucleus. If a signaling pathway such as PKA is involved, how can the cell 
distinguish between a general stress response and the drug resistance response? 
Is it possible that cells initially activate all the stress response pathways, and then 
distinguish them later through possible feedback loop? Alternatively, do cells use 
one pathway to strengthen another pathway‘s response? All these questions are 
still waiting to be answered. The more knowledge we gain about other pathways 
that contribute to the drug resistance network, the more we are equipped to 
answer these questions and try to overcome this problem in the future. 
In the past, in order to study the regulators and modulators of Pdr1p/Pdr3p activity, 
one used classical genetics that involves screening for mutations that reverse   
certain phenotypes one by one, which is extremely arduous but may not always 
work for complex phenotypes. The traditional biochemical and genetic approaches 
can miss the pleiotropic nature of the function of many genes/proteins and can be 
affected by many factors, such as low affinity during protein-protein interaction 
purifications. The advantage of using yeast as a model organism is the availability 
of the genome-wide deletion set. This means that now we can design the screen 
in using a genome-wide approach and identify gene deletions that prevents the 
normal expression of reporter genes when cells are challenged with xenobiotics 
(the reporter genes here can be ABC transporters, which are Pdr1p/Pdr3p targets). 
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Therefore, we can identify most of the non-essential genes that are involved in the 
modulation/regulation of the transcription factors Pdr1p/Pdr3p and therefore 
contribute to the PDR/MDR phenotype. We think that some of the genes which 
regulate or modulate the function of Pdr1p/Pdr3p might be non-essential, because 
most of the transcription factors involved in stress responses, including PDR, are 
non-essential, and many pathways of the yeast are redundant in optimal growth 
media (Zheng, Benschop et al. 2010; Hahn and Young 2011). Although we cannot 
rule out one of the essential genes being the ―control switch‖ of the PDR response, 
our screen of non-essential genes is a good start for a relatively simple screening 
method using the deletion mutant array that became widely available since 2000. 
 
 
 
Figure 1-18: Proposed view of how cells sense xenobiotics 
How cells sense the presence of the xenobiotic compounds and relay the information to the 
dr1/Pdr3p in the nucleus. We propose that there is pathway (question mark in the figure) 
conducting drug information to Pdr1p and Pdr3p in the nucleus. 
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Use of a Yap1p-GFP reporter to investigate relationship between oxidative 
stress and PDR  
As mentioned above, expression of many of major drug transporter genes such as 
PDR5, SNQ2, and FLR1 can be induced by Yap1p, an oxidative stress response 
transcription factor. Much experimental evidence shows Yap1p contributes to the 
PDR phenotype (Wu, Wemmie et al. 1993; Alarco, Balan et al. 1997; Wendler, 
Bergler et al. 1997). However, numerous aspects of Yap1p regulation in oxidative 
stress are still unclear and the crosstalk if any between these two processes is 
unknown.  Better understanding of Yap1p regulation during the oxidative stress 
response induced by different oxidants might also shed light on PDR. 
YAP1 and oxidative stress response 
Reactive oxygen species (ROS), such as the superoxide anion (O2
-), the hydroxyl 
free radical (OH•) and hydrogen peroxide (H2O2), are generated during oxygen 
metabolism, which causes oxidative stress. Some heavy metals (e.g. cadmium), 
UV radiation, and genotoxic agents can also generate oxidative stress causing 
damage to various cellular macromolecules, including DNA, lipids and proteins 
(Jamieson 1998). In general, cells maintain a particular redox state by utilising 
oxidative stress response systems. Similarly to the regulation of the multidrug 
resistance response, oxidative stress response regulation involves many 
transcription factors and modulators, the most well-known of which is a basic 
leucine zipper (bZIP) transcription factor called Yap1p (Moye-Rowley, Harshman 
et al. 1989). Yap1p functional orthologs have been identified in many other 
eukaryotes species such as S. pombe (Toda, Shimanuki et al. 1991) , Arabidopsis 
thaliana (Babiychuk, Kushnir et al. 1995), C. glabrata (Chen, Miyazaki et al. 2007). 
Yap1p is one of the three conserved mechanisms involved in sensing oxidative 
stress and inducing anti-oxidant genes in S. cerevisiae, S. pombe and C. albicans 
(Ikner and Shiozaki 2005). The other two mechanisms are the stress-responsive 
MAPK (SAPK) cascade and the multistep phosphorelay system briefly discussed 
below (Figure 1-19) 
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The MAPKs are activated in response to stresses such as osmolarity, oxidative 
stress, heat shock and nutrient starvation (Ikner and Shiozaki 2005). The SAPK 
process involves a MAPK protein Hog1p, which transmits the stress signal and is 
well known in regulation of osmotic stress. Deletion of HOG1 confers sensitivity to 
both H2O2 and diamide. Upon osmotic stress, Hog1p enters the nucleus and 
phosphorylates Sko1p, which recruits the SAGA and SWI/SNF complexes. These 
complexes have roles in the chromatin remodelling and gene activation, but to 
date, there is no evidence that Hog1p MAPK regulates oxidative stress gene 
expression. 
The multistep phosphorelay to sense oxidative stress involves Skn7p, which was 
first identified as a gene involved in cell wall biosynthesis and whose deletion 
caused hypersensitivity toward H2O2 in the genetic screen (Brown, North et al. 
1993; Krems, Charizanis et al. 1996). Skn7p is a nuclear response regulator and 
transcription factor which regulates many anti-oxidant genes, such as TRX2 
(thioredoxin), TSA1 (thioredoxin peroxidase), CTT1 (cytosolic catalase T; 
degrades hydrogen peroxide), TRR1 (thioredoxin reductase), and SOD1 
(superoxide dismutase, which plays a role in oxygen radical detoxification and in 
copper ion buffering ) (Ikner and Shiozaki 2005). Some of these genes are also 
the target of Yap1p (TRX2, TRR1, SOD1). However, it is still unknown how 
oxidative stress signals are transmitted to Skn7p. 
  
 Figure 1-19: Different pathways of Oxidative stress response in yeast. 
 Figure modified from Ikner, A. and K. Shiozaki (2005) 
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Yap1p recognizes the sequence TTACTAA (Fernandes, Rodrigues-Pousada et al. 
1997) in the 5‘ promoter sequence of its target genes, which are mainly anti-
oxidant genes such as TRR1 (cytoplasmic thioredoxin reductase, which 
determines the redox state of the thioredoxin system), TRX2  (thioredoxin), GSH1 
(rate limiting enzyme in glutathione biosynthesis), GLR1 (cytosolic and 
mitochondrial  glutathione oxidoreductase, which converts oxidized glutathione to 
reduced glutathione,) and SOD1. 
The Yap1p N-terminus contains the DNA-binding domain and nuclear localization 
signal (NLS), while the C-terminus contains a nuclear export signal (NES). Yap1p 
also contains two clusters of cysteine residues, referred to as the cysteine-rich 
domain in both N-terminus (n-CRD) and C-terminus (c-CRD). The C-terminus 
contains three conserved cysteine residues Cys598 Cys620 and Cys629 
(Coleman, Epping et al. 1999). Under normal growth conditions, Yap1p is found 
primarily in the cytoplasm due to dominant activity of the NES, and thus Yap1p 
which enters the nucleus is rapidly transported out by the exportin protein Crm1p, 
which binds to the Yap1p NES (Kuge, Jones et al. 1997; Yan, Lee et al. 1998). 
Yap1p and Crm1p interact in an oxidant-sensitive manner. When cells are in a 
normal oxidative state, Yap1p is reduced, and the interaction between Yap1p and 
Crm1p is strong. In response to oxidative stress such as H2O2, which results in a 
change in cellular redox status, a disulfide bond is formed between Yap1p Cys-
598 in the C-terminus and an oxidized cysteine residue of Gpx3p, thiol peroxidase. 
The Gpx3p-Yap1p disulfide bond then isomerises to one between Cys-598 on 
Yap1p C-terminus and Cys-3032 on the N-terminus of Yap1p (Delaunary, Pflieger 
et al. 2002). This alteration of the C-terminus is thought to mask the NES from 
Crm1p, thus disrupting the interaction between the  two proteins and leading to the 
rapid re-localization of Yap1p to the nucleus, where it activates redox target genes 
(Moye-Rowley 2003; Ikner and Shiozaki 2005). The disulfide bond between the C-
terminal cysteine residue and N-terminal residues is not observed when the cell is 
challenged with a different oxidative stress inducer, diamide. It was found that 
during diamide treatment, multiple disulfide bridges were formed between cysteine 
residues in the C-terminus (Kuge, Arita et al. 2001). 
This nuclear localization mechanism involves interaction between the NLS, NES 
and nuclear pore proteins and karyopherins (proteins involved in transporting 
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molecules from the cytoplasm into the nucleus). It allows cells to rapidly recruit 
pre-existing proteins into an activated complex in the response to stress without 
having to synthesize them de novo (Moye-Rowley 2003).  
Mutation in the C-terminus and N-terminus of Yap1p disrupts Yap1p nuclear 
localisation 
Loss of the C-terminal cysteine-rich domain (c-CRD) or mutation in one of the 
conserved cysteine residues (C629A, S630A, and E631A) causes disruption in the 
NES, which results in Yap1p being constitutively localized to the nucleus. These 
mutants are resistant to diamide, but hypersensitive to H2O2, possibly because 
they fail to activate TRX2, a gene encoding the thioredoxin isoenzyme (Coleman, 
Epping et al. 1999). 
Deleting different portions of the N-terminal cysteine-rich domain result in 
constitutive Yap1p nuclear localization. Such systematic deletions pinpointed  the 
sequences that are specific for regulation of response towards H2O2 and 
uncovered the fact that the N-terminus is required for the normal function and 
regulation of Yap1p (Coleman, Epping et al. 1999). 
Other proteins involved in regulation of Yap1p  
Gpx3p also functions as a thiol peroxidase by mediating reduction of cellular H2O2 
(Delaunay, Pflieger et al. 2002). Nevertheless, Delaunay et al 2002 showed that in 
a Δgpx3 strain, 10-30% of the cells in the population showed partial GFP-Yap1p 
(N-terminus tagged) staining in nucleus after 30 min of H2O2 treatment. The partial 
Yap1p nuclear localization in the Δgpx3 background suggested that other 
unknown mediators might play a role in Yap1p regulation.   
TRX2 and TRR1 are targets of Yap1p, and are also important in recycling Yap1p 
and Gpx3p from the oxidized state to the normal reduced state once oxidative 
stress target genes are activated.  As previously mentioned, Gpx3p is required to 
oxidize, and thus activate, Yap1p in the presence of H2O2 by disulfide bond 
formation. Gpx3p is directly oxidized by H2O2 and yields H2O and a sulfenic acid, 
Cys36-SOH, which in turn oxidizes Yap1p. In order to recycle oxidized Gpx3p and 
Yap1p, thioredoxin (mainly Trx1p andTrx2p) acts as electron donor and reduces 
both proteins (Delaunay, Pflieger et al. 2002). Delaunay et al 2002 proposed that 
reduction of Gpx3p by thioredoxin (Trx1p, Trx2p), with recycling of Gpx3p and 
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Yap1p, provides cells with an efficient dual mechanism for hydroperoxide 
scavenging and regulation of Yap1p. Another protein that contributes to Yap1p 
regulations is Ybp1p. Veal et al. (2003) showed that Ybp1p acts in the same 
pathway as Gpx3p (a Δgpx3Δybp1strain was no more sensitive to H2O2 than each 
of the single mutants). Ybp1p forms a stress-induced complex with Yap1p (even 
prior to H2O2 treatment), which influences the nuclear localization of Yap1p in the 
presence of H2O2, but not diamide. Furthermore, deletion of YBP1 results in 
increased diamide resistance (Veal, Ross et al. 2003). Ybp1p helps regulate the 
H2O2-induced expression of TRX2 and TRR1 in a Yap1p-dependent manner and 
is H2O2 specific. It might be that H2O2 stimulates the formation of the complex 
between Ybp1p and Yap1p and, in turn, Ybp1p helps stimulate the formation of 
disulfide bonds required for nuclear localization of Yap1p in response to H2O2 
treatment (Veal, Ross et al. 2003). This information is summarised in Figure 1-20 
 
 
 
Figure 1-20: Model for regulation of Yap1p nuclear localisation. 
In a normal oxidizing state, Yap1p is in a reduced state and interacts with Crm1p, which 
exports Yap1p back to the cytoplasm. Upon encountering oxidative stress induced by H2O2, 
Yap1p forms a complex with Ybp1p and Crm1p. Gpx3p induces disulfide bond formation 
between n- and c-CRD. This leads to a conformational change and prevents interaction 
between Yap1p and Crm1p. As a result, Yap1p is relocalised to the nucleus, where it 
activates redox target genes such as TRX2. Although proteins involved in Yap1p disulfide 
formation upon H2O2 encounter are known, less is known about proteins involve in c-CRD 
disulfide formation during treatment with diamide and other oxidants. Diagram adapted 
from Veal, Ross et al. (2003). 
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Mediator components 
Rox3p (Med19p) is a subunit of the RNA polymerase II mediator complex and it 
has been found that loss of ROX3 results in a dramatic decrease in H2O2 tolerance 
while deletion of other mediator subunits such as GAL11 (mediator of PDR1 
PDR3) , MED2, MED1, or MED9 do not result in any change in H2O2 tolerance 
(Gulshan, Rovinsky et al. 2005). Nevertheless, loss of YAP1 has a more profound 
effect on the H2O2 tolerance than loss of ROX3, and therefore YAP1 expression, 
to a certain extent, bypasses the requirement of Rox3p. The increase in sensitivity 
toward H2O2 in Δrox3 cells was shown to be the result of a loss of Yap1p induction 
by H2O2  in this strain, which results in reduced levels of TRX2 (Gulshan, Rovinsky 
et al. 2005). Gulshan K et al. also showed that correct folding of Yap1p in an H2O2-
treated environment is required for the binding between Rox3p and Yap1p. He 
suggests that Rox3p might also be involved in receiving a redox signalling. 
Other transcription factors that regulate oxidative stress response 
Similar to the PDR response, the oxidative stress response is also thought to be 
modulated by many transcription factors, some which are also involved in the PDR 
response such as Msn2p/Msn4p. We will discuss these transcription factors in 
detail below.  
ACE1 
Copper and metals such as iron have the ability to transfer and gain electrons from 
ROS, which makes these metals potentially toxic. Therefore, activity of free copper 
and iron is tightly controlled in cells as a way to defend themselves against 
oxidative damage in addition to ROS detoxification (De Freitas, Wintz et al. 2003). 
The copper-binding transcription factor Ace1p regulates genes such as CUP1, 
which encodes the antioxidant metallothionein, and SOD1, which encodes a 
cytosolic copper-zinc superoxide, which plays a role in ROS detoxification and 
copper ion buffering. Although, the exact role of Ace1p in oxidative stress 
regulation is unclear, it is thought that Ace1p might act as an oxidant sensor 
(Jamieson 1998). 
HAP1 
The zinc-finger transcription factor Hap1p is involved in the complex regulation of 
gene expression in response to levels of oxygen and heme, as well as regulating 
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SOD1, CTT1, and CTA1 (all of which play a role in ROS detoxification). The last 
step of heme biosynthesis is the incorporation of iron into porphyrin, which occurs 
in mitochondria. This results in influx of free iron into mitochondria, and generation 
of free radicals, thus causing mitochondrial oxidative stress. Cta1p is catalase A, 
which breaks down hydrogen peroxide, found in both peroxisome and 
mitochondria matrix. Nevertheless, how much Hap1p contributes in oxidative 
stress regulation is less clear. The Hap1p recognition sequence is found in the 
YAP1 promoter  (Harbison, Gordon et al. 2004), but  strains containing a mutation 
in HAP1 still possess the ability to adapt to H2O2-induced oxidative stress 
(Jamieson 1998; De Freitas, Wintz et al. 2003).  
MSN2, and MSN4 
As mentioned previously, the Msn2p/Msn4p zinc-finger transcription factors are 
activated under stress conditions and regulate general stress response (Martínez-
Pastor, Marchler et al. 1996; Gasch, Spellman et al. 2000; Causton, Ren et al. 
2001). Msn2p/Msn4p are activated by phosphorylation by Hog1p, which is a 
protein in the SAPK-cascade thought to link to the oxidative stress response, as 
mentioned previously.  In response to oxidative stress, Msn2p and Msn4p regulate 
the expression of CTT1 (which encodes cytosolic catalase T). Similarly, to Yap1p, 
Ms2p and Msn4p localize to the nucleus in response to stress where they activate 
transcription of target genes. 
STB5 
In the presence of H2O2, Stb5p, a zinc cluster protein, binds and regulates the 
expression of many genes in the pentose phosphate pathway, as well as genes 
involved in the production of NADPH, a metabolite required for oxidative stress 
tolerance. NADPH is used in the thioredoxin pathway to convert H2O2 to O2 and 
H2O as well as acting as the eletron donor of reducing equivalents to the oxidized 
glutathione via glutathione reductase. Deletion of STB5 leads to diamide and H2O2 
sensitivity, and following the addition of diamide, Stb5p binding increases at some 
of its targets‘ promoters (Larochelle, Drouin et al. 2006). Interestingly, activation of 
Stb5p does not seem to be regulated by the MAP kinase pathway or a mechanism 
similar to Yap1p. This suggests that there might be other unknown modulators that 
provide an alternative pathway for both the oxidative stress response and the 
multidrug resistance response, both of which rely on Stb5p. 
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Many of the stress transcription factors mentioned above (Hap1p, Msn2p, Skn7p, 
Stb5p) have recognise elements in the YAP1 promoter (Lee, Rinaldi et al. 2002; 
Harbison, Gordon et al. 2004; Ni, Bruce et al. 2009). However, little is known about 
the interplay among transcription factors or about regulators other than Yap1p that 
may play a role in this stress regulation. 
Questions on Cellular Redox Regulation 
      : Do redox-sensing proteins have the ability to discriminate between 
different oxidative stresses?  
                : Do these proteins produce distinct outputs which lead to the cells 
responding to a specific stress? 
                : Do different stress-inducing agents modify the same sensing/ regulator 
proteins to give different outcomes, or do different stresses use different 
sensing/regulator proteins? 
A diagram representing the possible regulation of the oxidative stress response in 
S. cerevisiae is shown in Figure 1-21. 
 
Figure 1-21: Schematic representation of oxidative stress response regulation in yeast 
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Yap1p and regulation of the multidrug resistance response 
Overexpression of YAP1 
The role of YAP1 in the multidrug resistance phenotype was identified in a screen 
that searched for genes that gave rise to multidrug resistance when expressed 
from a high-copy plasmid (Moye-Rowley, Harshman et al. 1989; Hertle, Haase et 
al. 1991). The Yap1p binding site was found in the promoters of many of the 
transporters involved in the PDR, such as PDR5, SNQ2,YCF1, and FLR1 
(Kolaczkowska and Goffeau 1999), although PDR5 and SNQ2 expression in a 
Δyap1 background was similar to that in wild-type (Miyahara, Hirata et al. 1996). 
When the Δyap1 cells were exposed to heat shock at 37°C, however, the 
expression level of PDR5 and SNQ2 was dramatically reduced in comparison to 
that in the wild-type cells (Miyahara, Hirata et al. 1996), suggesting that PDR5 and 
SNQ2 respond to heat shock stress in a Yap1p-dependent manner. 
Overexpression of YAP1 confers resistance to cycloheximide, which is thought to 
be the result of increase in the expression of FLR1, because the resistant 
phenotype is also observed in a background strain lacking PDR5 (Moye-Rowley 
2003). Although expression of PDR5 and SNQ2, the two major ABC transporters, 
respond to Yap1p transcriptional activity, the disruption of these two genes had no 
effect on oxidative stress response. Pdr5p and Snq2p might have extra roles in 
other stress responses via activation by Yap1p.  
It is not certain if Yap1p works in the same pathway as Pdr1p/Pdr3p when it 
comes to regulation of multidrug resistance. Deletion of YAP1 does not confer 
extra sensitivity toward cycloheximide in a Δpdr1Δpdr3 background strain (Namal 
Coorey, personal communication). It is thought that Yap1p might be used as the 
―signal amplifier‖ of Pdr1p/Pdr3p. This is supported by the fact that YAP1-
mediated resistance to diazaborine and 4-NQO is PDR1 and PDR3-dependent, 
with a greater dependency on PDR3 (Wendler, Bergler et al. 1997). Nevertheless, 
the Pdr1p/Pdr3p recognition sequence (PDRE) is not found in the YAP1 promoter 
region (www.yeasttract.com). However, 1,10-phenanthroline hyper-resistance was 
observed only when YAP1 was overexpressed and the phenotype was stronger 
than the one observed in the gain-of-function mutant of PDR1-12 and PDR3-33, 
suggesting that Yap1p might also have a role which is Pdr1p/Pdr3p-independent 
(Wendler, Bergler et al. 1997).  It is interesting to note that neither overexpression 
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of Yap1p target genes, which are normally involved in the oxidative stress 
response, such as GSH1 GLR1 and TRX2, nor deletion of YAP1 (Δyap1) 
conferred resistance to diazaborine (Wendler, Bergler et al. 1997), implying that 
Yap1p might have a distinct role in drug resistance which is separate from its well-
known role in oxidative stress regulation.  Wendler et al. suggested that a possible 
explanation for the fact that deletion of YAP1 did not cause extra sensitivity to 
diazaborine in the Δpdr1Δpdr3 background might be that YAP1 acts on the same 
targets, or that YAP1 is acting on the same sequential pathway as PDR1, PDR3. 
These transcription factors might also share common regulatory proteins, which 
would normally suppress the function of their target proteins, and when YAP1 was 
overexpressed, these regulatory proteins bind mostly to Yap1p, leaving Pdr1p and 
Pdr3p free to activate target genes. As we know, Yap1p has many targets which 
overlap with Pdr1p and Pdr3p, such as Pdr5p and Snq2p, but Yap1p displays a 
different level of resistance to difference toxic compounds when YAP1 is 
overexpressed (e.g. diazaborine, cycloheximide and 1,10-phananthroline), 
suggesting that another unknown regulator might be involved. 
Although there is a large body of experimental evidence indicating that YAP1 
contributes to the multidrug resistance phenotype, the actual sensors or 
modulators that linked between Yap1p in oxidative stress response and Pdr1p 
Pdr3p in the pleiotropic drug resistant response are yet to be established. In 
addition, how Yap1p might distinguish its redox gene targets from PDR targets is 
unknown.   
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Section IV: Aim, hypothesis and experimental design 
The overall  aim of my research was to understand complex traits through genetic 
network analysis. Such traits include drug resistance and most drug mechanisms.   
There were three main questions in my project: 
• Can we determine a drug target and mechanism of action by genome-wide 
deletion array analysis assuming a drug can act in lieu of a mutation?  
• Are there upstream regulators (to the PDR TFs) that mediate the PDR 
response? 
• Are such ―sensors‖ or ―stress regulators‖ stress specific? Or are they 
pleiotropic? 
The aim of my project was to develop genomic methodologies to study drug 
mechanisms of actions and resistance mechanisms, and in the latter, specifically 
genes involved in regulation of pleiotropic drug resistance (PDR) signaling 
pathways that lie ―upstream‖ of the PDRE-activated gene expression of pumps. It 
was aimed to identify regulators of Yap1p and the possible ―link‖ between 
oxidative stress response and PDR.   
In the case of PDR/MDR it is implicit in this aim that we planned to test whether 
there is a specific pathway of events that conducts information from the cell 
surface to the nucleus where Pdr1p and Pdr3p are located quite probably 
including internal signalling receptors.  
The thesis is aimed at the question of whether an unbiased genome-wide of 
genetic interaction networks can identify previously unsuspected regulators of how 
cells deal with xenobiotics. 
Overall experimental design 
Mode-of-action of toxic compounds using a genome-wide approach for 
network analysis 
Determining the compounds/drugs mode-of-action remains a major challenge in 
drug discovery. Genetic interaction networks illustrate sets of compensating 
pathways thus understanding which genes compensate for compound toxicity 
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should give us insight as to how toxic compounds work,  the possible side effects 
as well as mechanisms of resistance. 
Many xenobiotics are neither substrates of the ABC transporters, nor MFS 
transporters, and are not pumped out of the cells in a Pdr1p/Pdr3p –dependent 
manner. The well-known antifungals, amphotericin B and nystatin fall into this 
category (Figure 1-22). Both of these antifungals bind to the ergosterol and disrupt 
the membrane integrity, presumably by forming pores and causing cellular leakage 
of internal constituents, which leads to cell death (Bossche, Engelen et al. 2003). 
Interestingly, cells that become resistant to both compounds have mutations in 
either ERG2 or ERG3, both of which play roles in ergosterol biosynthesis. The fact 
that sterol composition of the resistant strains also changed (Bossche, Engelen et 
al. 2003) strongly suggested that lipid homeostasis has a significant impact on the 
PDR phenotype. Although much of the thesis aims revolve around the modulators 
and regulators of the transcription factors Pdr1p/Pdr3p, and, to some extent, those 
of Yap1p, we will briefly explore the role of lipids as contributors to the PDR 
phenotype.   
 
Figure 1-22: Structure of known polyene antifungal drugs. 
Structures of the known polyene antifungals, nystatin, and amphotericin B, and the 
antifungal natamycin. None of these compounds are of ABC or MFS transporters. 
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In this regard, we studied the mode of action of the novel compound 
neothyonidioside, from Australostichopus mollis. Neothyonidioside (Neo) has been 
shown to bind to ergosterol and is not a substrate of ABC pumps. The gene which 
gives rise to neo resistance is NCP1, encoding NADP-cytochrome P450 reductase, 
which interacts with ERG11 and is involved in ergosterol biosynthesis. Cellular 
ergosterol levels of the neo-resistant cells are half of what is observed in normal 
wild-type cells (Yibmantasiri, Leahy et al. 2012). Neo also does not perforate the 
cell membrane and cause cellular leakage, like the classic antifungal amphotericin. 
Since Neo is not an ABC-transporter substrate, nor does it behave like classic 
polyenes, it is of interest to us to explore how neo exerts its cytotoxic effect, what 
pathway might be involved and how affecting lipid homeostasis can lead to the 
drug resistant phenotype in a Pdr1p/Pdr3p-independent pathway.   
Identification of upstream regulators of PDR transcription factors 
Pdr1p/Pdr3p 
To identify modulators of the PDR response which regulate Pdr1p/Pdr3p in a 
genome-wide (genomic) fashion, we developed a Green Fluorescent Protein 
(GFP)-based reporter fused to Pdr5p, Snq2p, and Yor1p, as a subset of important 
ABC transporters that are targets of Pdr1p/Pdr3p. The current literature does not 
have such an approach, probably because the automated microscope needed for 
these screens has only recently been feasible for academic laboratories. Such 
assays allow GFP fluorescence to serve as a sensitive, real-time indicator of 
Pdr1p/Pdr3p activation. Utilising high-throughput (genomic) mating techniques, our 
GFP-reporters were placed into the yeast gene deletion background, creating a 
~4800 GFP-strain collection for each reporter. These new strains were then 
challenged with xenobiotics that in the ―wild-type‖ would upregulate the efflux 
pumps. We then measured the efflux pump reporter fluorescence imaged by high-
throughput confocal microscopy, and analysed it by specialized scripts developed 
for the work. This approach allowed for comparison of the changes between the 
control and treated experiment for each of the deletion strains. We then looked for 
genes that are required for PDR induction. These genes, when absent, cause 
changes in GFP-pump abundance, which should imply that these genes are 
required for normal pleiotropic drug resistance involving PDR1 and PDR3 and are 
potentially  involved in PDR signaling upstream of Pdr1p/Pdr3p (Figure 1-23).  
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Identification of regulators/sensors in different stress responses 
As described above, PDR is a complex network involving interactions between 
transcriptional activators, also mediator complexes, where we might expect there 
would be overlap between particular processes and other stress responses, such 
as oxidative stress response. As previously mentioned Yap1p might link between 
these two stress responses. A better understanding of the Yap1p regulatory role 
could help us understand more about these two stress pathways. 
Under low-oxidative stress conditions, Yap1p is found in the cytoplasm. Upon 
oxidative stress induction, Yap1p re-localised to the nucleus, where it activates its 
target genes (Kuge, Jones et al. 1997). To investigate genes that have roles in 
regulating Yap1p localization in the presence of different oxidants, we constructed 
a Yap1p-GFP reporter and repeated the screen with this reporter under oxidative 
stress induced by hydrogen peroxide (H2O2) and diethyl maleate. In these screens, 
we looked for genes that prevent nuclear re-localisation upon oxidative stress 
induction. These genes again are the potential upstream mediators and regulators 
(Figure 1-24 ). In the results section, we compared the efflux pump reporter 
Figure 1-23: Schematic presentation of PDR efflux pumps GFP reporters 
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screens with the Yap1p reporter screens to see if there are any common 
regulators or modulators between these two stress response pathways. 
 
Figure 1-24: Schematic presentation of Yap1p_GFP reporter  
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Chapter 2. General Materials and Methods 
Compounds 
Unless otherwise stated, all compounds were purchased from Sigma Aldrich, and 
dissolved in DMSO. 
Neothyonidioside (neo) (Chapter3) was a gift from Dr. Peter Northcote from 
School of Chemical and Physical Science Victoria University of Wellington. The 
stock concentration is 20mM in DMSO. 
Compounds used in the spot dilution assay to validate PDR primary hits (Chapter 
4) are listed in Table 2-1 below 
Table 2-1: Compounds used in spot dilution assay   
Compound Concentration used in 
Δxxx  background 
Concentration used 
in Δxxx Δpdr1Δpdr3 
background 
cycloheximide (CHX) 
ketoconazole 
fluconazole  
oligomycin (in YPGE plate) 
benomyl (SC plate) 
atorvastatin (SC plate) 
0.15 µg /ml 
1 µM 
31 µM 
0.35 , 0.5 µg /ml 
60 µM with 25mM HEPES 
35 µM 
40 nM 
0.5 µM 
12 µM 
0.35 µg /ml 
Was not used 
5 µM 
 
Hydrogen peroxide, diamide, and diethyl maleate stocks were made up in sterile 
distilled water. The final concentrations were 1 mM, 1.5 mM, and 2 mM 
respectively (Chapter 5) 
Yeast media 
Yeast cells were grown in YPD under non-selective conditions, or in appropriate 
synthetic complete (SC) media under selective conditions at 30°C or at 30°C with 
shaking for liquid culture. 
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Yeast Peptone Dextrose (YPD) 1000 ml 
Bacto-Yeast Extract 10 g 
Bacto-peptone 20 g 
Adenine  0.12 g 
40% glucose solution (added after autoclaving) 50 ml 
Agar 20 g 
 
Yeast Peptone Glycerol Ethanol (Glycerol and/or ethanol as carbon source) 
Bacto-Yeast Extract 10 g 
Bacto-peptone 20 g 
Glycerol 30 ml 
Ethanol (added after autoclaving) 30 ml 
Distilled water 970 ml 
Agar 20 g 
 
SC Media 1000 ml 
Yeast Nitrogen Base without amino acid  1.7 g 
MSG 1 g 
40% glucose solution (add after autoclaving) 50 ml 
Amino Acid Mixture to suit 2 g 
Agar 20 g 
 
GNA (pre-sporulation media) 1000 ml 
Bacto-Yeast Extract 8 g 
Bacto-peptone 3 g 
40 % glucose solution (added after autoclaving) 250 ml 
Agar 20 g 
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Sporulation (Spo) Media   1000ml 
Potassium Acetate 10 g 
Bacto-Yeast Extract 1 g 
Complete Amino Acid Mixture  2 g 
40% glucose solution (add after autoclaving) 50 ml 
Agar 20 g 
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Strains used  
Yeast strains used in this study were derived from S288C and their genotypes are 
listed in Table 2-2. 
Table 2-2: Strains used in this study 
Strain Genotype Description 
BY4741 MATa his3Δ1 leu2Δ0 met15Δ0 
ura3Δ0 
Wild-type 
YCG204 neo 
R 
 MATα can1∆:: STE2pr-HIS5 
lypΔ1:: STE3prLEU2   [CEN-URA3]  
neo resistant strain 
YCG253* MAT α , can1Δ::STE2pr-Sp-URA; 
lyp1Δ::mCherry-NAT; his3Δ1; 
leu2Δ0; ura3Δ0::NLS-RedStar2-hph; 
LYS2+ 
SGA starting strain  
- mCherry-NAT is red fluorescent protein 
(RFP) linked with the NAT(nourseothricin) 
dominant selectable marker under a 
constitutive promoter It has a cytoplasmic 
location. 
-NLS-RedStar2-hph is RFP linked with the 
hygromycin dominant selectable marker 
and with NLS (localised to the nucleus). 
Both RFPs act as internal controls and as 
markers for automated cell recognition 
software. 
YCG255* MAT α , can1Δ::STE2pr-Sp-URA; 
lyp1Δ::mCherry-NAT; his3Δ1; 
leu2Δ0; ura3Δ0; LYS2+ 
SGA starting strain 
Please see YCG253 for description 
YCG281 MAT α , can1Δ::STE2pr-URA3; 
lyp1Δ::mCherry-NAT ; pdr5Δ::GFP-
hph; leu2Δ0 his3Δ1 met15Δ0 ura3Δ0 
Pdr5p reporter strain with PDR5 ORF is 
replaced by hygromycin dominant 
selectable marker linked with GFP 
YCG285 MAT α , can1Δ::STE2pr-URA3;  
lyp1Δ::mCherry-NAT; PDR5-GFP-
HIS; leu2Δ0 his3Δ1 met15Δ0 ura3Δ0  
Pdr5p reporter strain with  C-terminal GFP 
linked 
YCG330 MAT α , can1Δ::STE2pr-URA3;  
lyp1Δ::mCherry-NAT; SNQ2-GFP-
HIS; leu2Δ0 his3Δ1 met15Δ0 ura3Δ0 
Snq2p-GFP reporter strain  
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YCG334 MAT α , can1Δ::STE2p-URA3;  
lyp1Δ::mCherry-NAT; YOR1-GFP-
HIS; leu2Δ0 his3Δ1 met15Δ0 ura3Δ0 
Yor1p-GFP reporter strain 
YCG379 MAT α , can1Δ::STE2pr_URA3; 
lyp1Δ::mCherry-NAT; ura3Δ::NLS-
RS2-hph; YAP1-GFP-HIS; leu2Δ0 
his3Δ1 met15Δ0  
Yap1p-GFP reporter strain 
Dose response assay 
Cells at a concentration of 5×105 cells/ml were treated with various concentrations 
of cycloheximide. DMSO was used as a negative control. After 18 h incubation at 
30 °C, cell density was determined by measuring absorbance at 590nm using a 
spectrophotometer (Perkin-Elmer Wallac Envision 2012). Percent residual growth 
was calculated using the formula  
 
100
590
590
controlAb
treatedAb
 
Strain construction 
Yeast strains YCG285, YCG330 and YCG344 were generated by tetrad dissection 
of spores from crossing YCG255 × Pdr5p-GFP strains, Snq2p-GFP, or Yor1p-GFP 
respectively. Strain YCG379 was generated by tetrad dissection from crossing 
YCG253 × Yap1p-GFP. All the GFP strains were commercial strains from 
Invitrogen with C-terminal labeled green fluorescent protein (GFP). The haploid 
parental strain genotype is MAT a his3Δ1 leu2Δ0 met15Δ0 ura3Δ0.  The 
commercial GFP strains were mated against SGA starting strains so that the final 
progeny strains had the genotype suitable for SGA methodology (see below). 
The method for tetrad dissection was as follows: 
Fifty microliters of cells grown in liquid sporulation media for 7 days was spun 
down at 7000 rpm for 15 sec, and supernatant was discarded. The cell pellet was 
re-suspended in 50 μl of zymolase in sorbital (0.5 mg/ml zymolyse in 1M sorbitol) , 
and incubated for 10 min at 30 ˚C. Three hundred microliters of sterile distilled 
* : these strains were generated by Dr. David Maass, Chemical Genetics Laboratory , School 
of Biological Sciences , Victoria University of Wellington  
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water was added to the suspension and the tube was gently inverted to mix. 
Fifteen microliters of the suspension was spotted onto YPD plates to separate 
tetrads. Tetrads were dissected using Singer Dissection Microscope (Figure 2-1). 
 
 
 
The dissected spores were grown for 2-3 days at 30 ˚C, then replica-plated onto 
selection plates. 
For YCG 285, YCG 330 and YCG 344 selection plates were 
YPD+ 100 mg/L nourseothricin (clonNAT; Werner BioAgents, Germany) (select for 
mCherry) 
SC - Arg + 50mg/L canavanine    Mating type specific selection 
SC – Ura  
SC - Lys + 50mg/L Thialysine (S-Aminoethyl-L-cysteine hydrochloride) 
SC- His (selected for GFP) 
Spores of the desired genotype listed in Table 2-2 should grow in all conditions 
except SC - Arg + 50mg/L canavanine (only expressed in Mat a). 
For YCG 379 the selection plates were as listed above with extra selection of 
YPD+ 200 mg/L of hygromycin (Invitrogen, California). 
Figure 2-1: Tetrad dissection using Singer Dissection Microscope.   
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Deletion of the PDR5 ORF might increase the difference in GFP intensity changes 
between control and treated cells. This was tested using PCR and homologous 
recombination in vivo. The open reading frame of PDR5 was deleted and replaced 
with the GFP cassette from pYM25 (Janke, Magiera et al. 2004) with a hygromycin 
selectable marker, while its natural promoter region was kept intact. The forward 
and reverse primers were 
5‘AGACCCTTTTAAGTTTTCGTATCCGCTCGTTCGAAAGACTTTAGACAAAAAT
GAGTGCTTCTTCTGAAGATGTC3‘ and 
 
5‘TTAAAAAAGTCCATCTTGGTAAGTTTCTTTTCTTAACCAAATTCAAAATTATC
GATGAATTCGAGCTCG3‘ , respectively. 
PCR reaction and PCR cycle were as follows: 
PCR Reaction of 50 µl volume using Qiagen PCR kit 
×10 buffer 5 µl 
Q buffer 10 µl 
Forward Primer 0.5 µl 
Reverse Primer 0.5 µl 
Hot Star Taq 0.25 µl 
dNTP 2 µl 
pYM25 (template) 2 µl 
Sterile distilled water 29.75 µl 
 
PCR cycle 
95 ˚C 15 min 
95 ˚C 1 min 
55 ˚C 30 sec 
68 ˚C 3 min 
95 ˚C 1 min 
55 ˚C 30 sec 
68˚C 3 min 
68 ˚C 10 min 
 
 
 
Foot note: The red text represented base pairs complementary to pYM25. 
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Screening the library of Pharmacological Active Compounds (LOPAC) 
Reporter strains were grown on SC agar plates for 18 h at 30 ˚C before robotically 
(Singer RoTorTM) transferred to 384 well PekinElmer Cell Carrier plates 
(Massachussetts, USA) containing liquid SC. LOPAC compounds (Sigma Aldrich, 
Auckland, New Zealand) were added to the cell plates using the CyBIOTM and 
V&P Scientific liquid transfer floating pin system. 1µl of compounds were delivered 
to the recipient plate so that the final compound concentration was 27µM. DMSO 
was used as a control. Cells were incubated for 4 h at 30 ˚C before cell images 
were taken using automated PekinElmer‘s OperaR High content microscope 
(Massachussetts, USA). ). The images were analyzed using AcapellaTM  ―Texture 
Analysis‖ software to automatically identify cells using RFP cytoplasmic mCherry 
and RFP RedStar2-nuclear localization signal in the analysis of  subtle intra-
cellular changes of biological relevance that could be missed by looking at 
fluorescence intensity alone. The parameters measured by this software were 
―Spot‖, ―Hole‖, ―Saddle‖, ―Edge‖, ―Ridge‖, ―Valley‖, ―Bright‖, and ―Dark‖ (Figure 2-2). 
 
 
 
Cellular textures parameter ―Ridge‖, ―Bright‖, and‖ Edge‖ were selected due to the 
fact that they best represented the correct localization of GFP-reporter (Pdr5p, and 
Yor1p) and gave reproducible results across the different  screens.  
For each gene deletions, intensity change and change in texture parameters were 
calculated. For intensity, the fold change between treated and control after 
normalization against an internal RFP control was used. For texture analysis, Z 
Figure 2-2: Parameter of the Texture Analysis Software 
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score was calculated according to the equation stated (Materials and Methods p. 
71) 
Synthetic Genetic Array (SGA) and drug screening 
SGA analysis was carried out according to the method as previously described 
(Tong, Evangelista et al. 2001)using a Singer RoTorTM HAD bench-top replicator 
robot (Somerset, UK) in which the Matα query strain was crossed en masse with 
the MAT a yeast deletion mutant array in 384 colony format.  After 2 days 
incubation at 30 ˚C final selections plates were then pinned to SC plates in which 
plates were arrayed so that each gene deletion was duplicated side by side in 384 
format using Singer RoTorTM HAD bench-top replicator robot. Plates were then 
incubated at 30 ˚C overnight, before cells were transferred from colonies to liquid 
in 384 PekinElmer Cell Carrier plates containing DMSO (control) and drug 
(atorvastatin 35 µM) in alternate columns. After 4 hours of incubation, cell images 
were taken using PerkinElmer‘s OperaR High content microscope. The set up was 
as follows: 60XWater Immersion lens NA=1.2 utilising 488 and 561 lasers with 
power (µW) of 4110 and 731 respectively. Filter for camera 1 (488 laser):520/35, 
camera 2 (561 laser):600/40, Detect Dichro: 568,  Primary 
Dichro:405/488/561/640. Images were recorded utilising ―binning‖ of 2 and 
exposure time of 400 msec. Images were analysed using Texture analysis in 
Acapella software with the texture properties of ―Ridge‖, ―Bright‖ and ―Edge‖.    
Identification of possible regulators of pleiotropic drug resistance 
In each experiment in the primary screens, Z scores for each deletion were 
calculated. 
Z= 
treated
treated
control
control
treatedcontrol
n
s
n
s
XX
22
|)(|
 
Where: 
X  = the mean of texture properties (ridge, bright or edge) from texture analysis in 
Acapella software from each group (control or treated). 
s = standard deviation of the texture properties (ridge, bright or edge) ) from 
texture analysis in Acapella software from each group (control or treated). 
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n= number of cells identified by Acapella software from each group (control or 
treated). 
Gene deletions with the Z score lower than 5* in 2 out of 3 texture analysis 
(―Ridge‖, ―Bright‖ ,‖Edge‖) were counted as hits. Gene deletions that appeared as 
hits from 4 out of 5 screens were subjected to further validation.  
* 4.753 is the corrected Z value for multiple testing with equivalent significant level 
of 0.01. Correction for multiple testing was required because we compared control 
versus treated for 4500 genes=4500 multiple testing. The new corrected p-value 
was 0.01/4500 = 0.000002.  
For the YAP1 screen we also looked at ―Spot‖ property from texture analysis as 
well as compared intensity of 
FPCytoplasmG
NuclearGFP
 between treated and control. 
Spot dilution assay  
Yeast cells at a concentration of 5×108 cells/ml were serially diluted in water (1:10), 
and were 2 µl was spotted on YPD plates (unless stated differently) containing 
drugs of concentration stated in Table 2-1. Plates were incubated for 2 days at 
30 °C and growth phenotype was observed for each strain. 
Yeast cell extract and western blot 
Cell lysate and protein extraction was conducted according to (Egner, Mahe et al. 
1995). Cells from different strains were grown in YPD to the same OD600 of 2, and 
were then harvested by centrifuging at 4000 rpm for 2 min, then washed once with 
H2O. Cell extract was prepared by lysising the pellet with 150 µl of 1.85 M NaOH-
7.5%  2-mercaptoethanol for 10 min on ice, followed by addition of 150 µl of 50% 
trichloroacetic acid and 10 min incubation on ice. The pellet was collected by 
centrifugation at 13,000 g for 3 min and then re-suspended  in 10 µl of 1M Tris 
base and  50 µl sample buffer (40 mM Tris-HCl pH 6.8, 8 M urea, 5% sodium 
dodecylsulfate (SDS), 0.1M EDTA, 1% 2-mercaptoethanol, 0.01% bromphenol 
blue). Samples were then heated at 42 °C for 15 min, then 20 µl of each samples 
was loaded to 7.5% polyacrylamide-SDS gel and electrophoresed for 2 h at 200 V. 
The running buffer used was 3.3 g Tris-base, 14.4 g Glycine, 1 g SDS , and 
distilled water added up to 1000 ml. Proteins were then transferred to an 
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Immobilon™ transfer membrane (IPVH00010) pore size 0.45 µm which had been 
washed in methanol for 1-2 min, at 20V for 17 h. The transfer buffer used was 
3.3 g Tris-base, 14.4 g Glycine, 200 ml Methanol, and distilled water added up to 
1000 ml. 
After 17 h, the membrane was blocked with 5% bovine serum albumin (BSA) in 
0.1% Tween in Tris-buffered saline (TBST) for 1 h to reduce non-specific binding. 
Membrane was then washed with TBST for 10 min three times. The membrane 
was then incubated with a Pdr5p primary antibody (polyclonal Pdr5 (yN-18) 
antibody raised in goats (Santa Cruz Co., California, USA stock #SC-27253) 
diluted 1:500 in 5% TBST for 3 h at room temperature. The membrane was then 
washed with TBST  for 10 minutes three times before being incubated with the 
secondary antibody, Donkey polyclonal antigoat antibody labelled with Cy5 
obtained from abcam® ab6566 was diluted 1:4000 in 5% TBST for 1 h in the dark.  
The membrane was washed in Tris-buffered saline (TBS) for 10 min three times 
before scanning at 635 nm using Fujiflim FLA-5100 series fluorescent scaner. 
Pma1p/Pma2p, which are plasma membrane H+-ATPase were used as internal 
control. Primary antibody for Pma1p/Pma2p raised in rabbits was obtained from 
Santa Cruz, SC-33735 (diluted at 1:500).Pma1p/Pma2p primary antibody and Cy5 
anti-rabbit antibody  diluted at 1:4000 were incubated and detected after scanning 
for Pdr5p. 
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Chapter 3. Mechanism of action for a natural product anti-fungal 
compound, Neothyonidioside, that is not an ABC transporter 
substrate  
Introduction 
Target identification of bioactive compounds and mechanism-of-action 
characterization is a major component of drug discovery. Besides the mechanism 
this knowledge allows an understanding of side effects of a compound as well as 
enabling design of new compounds with increased efficacy and potency. Bioactive 
compound and target(s) interactions are usually complex traits genetically, and 
have historically   been quite difficult to unravel using biochemical methods alone.  
As mentioned in the general introduction, Chapter 1, genomic methodologies have 
been proven useful for bioactive target identification and mode-of-action 
characterization. This chapter describes further genomic approaches including 
chemical genetic profiling using microarrays, as well as synthetic genetic array 
mapping (SGAM) to explore drug mode-of-action.  
Although ABC transporters pump a broad spectrum of compounds antifungals of 
the polyene family such as nystatin and amphotericin B are not ABC transporter 
substrates. Systemic fungal infection presents a major problem in 
immunocompromised hosts such as cancer and HIV patients (Richardson 2005). 
Currently, only five classes of antifungal drugs are available in the clinic (Balkis, 
Leidich et al. 2002; Kanafani and Perfect 2008; Mathew and Nath 2009) which are  
i) Azoles,which inhibit biosynthesis of ergosterol, the main sterol in fungal 
membranes and not present in human membranes. 
ii) Polyenes, which binds to membrane sterols and permeabilize the cell, 
causing leakage of cytoplasmic materials. 
iii) Allylamines that block ergosterol biosynthesis by inhibiting squalene 
epoxidase encoded by ERG1 causing accumulation of squalene which 
is toxic to the cells. 
iv) Echinocandins, which inhibit synthesis of β 1, 3-glucan, the major 
structural polymer of the cell wall. 
v) Flucytosine, which inhibits RNA and DNA synthesis. 
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The relative dearth of clinical agents coupled with increasing multidrug resistance 
highlights the need for new antifungals, as well as an improved understanding of 
antifungal mode-of-action and possible side effects. Natural products have 
historically provided a wide variety of selective compounds that are highly potent 
(Gullo, McAlpine et al. 2006).  A saponin fraction isolated from the sea cucumber, 
Australostichopus mollis, is a mixture of triterpene glycoside isomers with a 2.2:1-
fold excess of neothyonidioside (Avilov, Kalinovskii et al. 1990) and its closely 
related saponin mollisoside A (Moraes, Norhcote et al. 2004). Unlike 
neothyonidioside, mollisoside A was shown to have little activity against 
mammalian cells and is probably an inactive constituent (G.W.Moraes, PhD thesis 
2003) and for brevity we will refer to the mixture as ―neothyonidioside‖ (neo). Neo 
has potency similar to the polyene antibiotics, nystatin that binds ergosterol, but it 
has a different mode of toxicity. Unlike nystatin, neothyonidioside does not 
permeabilize membranes nor does it produce a prodrug  (Yibmantasiri, Leahy et al. 
2012). 
Drug resistant mutants often provide valuable insight into the pharmacodynamics 
and pharmacokinetics of small molecules. We generated a neo resistant strain 
using EMS, and applied SGAM methodology to identify the resistance locus. 
SGAM exploits the fact that mutants in the Yeast Genome Deletion Set (YGDS) 
are arrayed according to their chromosome position, thus providing a high-
resolution genetic map. Tightly linked genes exhibit a distinctive pattern of growth 
inhibition during synthetic genetic array (SGA) analysis (Tong et al. 2001) due to 
linkage disequilibrium. Theoretically, this growth defect pattern could be used to 
identify unknown genetic loci. Using SGAM, we identified NCP1, NADP-
cytochrome P450 reductase, involved in ergosterol biosynthesis as the resistant 
locus (Yibmantasiri, Leahy et al. 2012). 
Although neo binds to ergosterol, the resistant strain has lower cellular ergosterol 
than wild-type cells. This is unexpected since in most circumstances mutant cells 
overexpress the compound target(s) to display resistance. We performed 
chemical-genetic profiling to explore genes involved in this complex trait, in order 
to understand the interaction between neo and its target and its mode of action,  
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Gene Ontology (GO) analysis of neo chemical-genetic profile had shown that 
genes compensating for neo toxicity are specifically enriched in ESCRT 
(endosomal sorting) complex genes (Figure 3-1). Nine ESCRT gene deletions, 
comprising members of all the ESCRT complexes (0, I, II and III), and VPS4, an 
endosome ATPase providing motive force for ESCRT-III complex action caused 
neo hypersensitivity. Since multivesicular body (MVB) and autophagic vacuole 
formation require all the ESCRT complexes, we thus reasoned that endocytosis 
and multivesicular body (MVB) vesicle formation might be blocked by neo. Neo in 
this way resembles the polyene antibiotic natamycin that also binds to ergosterol 
but does not permeabilize the cell membrane rather acting on endocytosis which is 
known to be dependent on sterol (Munn 2001; Wachtler and Balasubramanian 
2006). To test the hypothesis that neo blocked vacuole formation, we used the 
vacuole-membrane vital dye FM-4-64 FX (Vida and Emr 1995) and observed the 
phenotype of cells by confocal fluorescence microscopy. We also compared the 
phenotype of neo treated cells with those that have mutations in vacuolar protein 
sorting (vps) genes.  
There are six morphological classes (A-F) of vacuolar protein sorting (vps) 
mutants (Raymond, Roberts et al. 1992). Class A mutants show wild-type 
morphology with a spherical shape of one to three vacuoles as observed in vps35. 
Fragmented vacuoles were observed in class B, for example vps17. Class C, for 
example, vps18, shows very small cytoplasmically dispersed fragments of 
fluorescence. A single enlarge vacuole is characteristic of class D mutant, for 
example vps15. In Class E mutants, for example vps27, vacuoles are not strongly 
stained with FM-4-64 dye (Vida and Emr 1995). However, a membrane-enclosed 
structure observed next to normally single vacuoles was intensely stained in this 
mutant class. This organelle is thought to be a vacuolar intermediate blocked in 
this compartment, as well as containing  the internalized a–factor receptor (Davis, 
Horecka et al. 1993; Vida and Emr 1995). A mix of one to three large vacuoles and 
fragmented vacuoles was observed in vps1, class F mutant. 
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This chapter encompasses a compilation of work published in 2012 (Yibmantasiri 
et al 2012) focused around endosome-vacuolar intermediates carried out in a 
number of student projects in this laboratory. The microarray work and chemical 
genetic profiling (HOP assay) that showed a clustering of ESCRT 0, I, II, III genes 
buffering the effect of neothyonidioside was performed by S. Andreas Angermayr, 
Alice G Sorgo and Rose Heathcott. The creation and screening for neo-resistant 
mutants (neoR) was done by Ploi Yibmantasiri in her Honours project utilizing the 
SGAM technology narrowing down the neoR potential genes to five essential gene 
candidates. Bede Busby performed the ergosterol quantitation measurements in 
wild-type and mutant cells. The rest of the mutant characterisation necessary to 
complete this paper were carried out as part of this dissertation. The microscopy 
work following the fate of plasma membrane staining dye as a function of the drug 
neo and as a function of specific deletion mutations was solely part of this 
dissertation.    
Figure 3-1: Chemical genetic profile of neothyonidioside.  
Each node represents a gene deletion that sensitised cells to neothyonidioside 
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Materials and Methods 
Compound 
Neothyonidioside mixture was provided by Dr. Peter Northcote from the Natural 
Product Group, School of Chemical and Physical Sciences Victoria University of 
Wellington. The composition of the compound was determined by Jacqui Barber 
using high-field NMR spectroscopy and mass specrometry analysis as described 
in Yibmantasiri et al (2012). 
Identification of neo resistant locus using SGAM and chemical-genetic 
profiling of neo 
For details for the neo resistant strain generation, the identification resistance 
mediating mutant gene using SGAM, and the chemical-genetic profiling of neo, 
please see Appendix II. 
Vacuole staining and visualisation of live cells 
Vacuole membrane staining with the red-fluorescent dye FM 4-64FX (Invitrogen) 
was initiated on ice according to Vida and Emr 1995. The strains BY4741 (wild-
type), Δvps35, Δvps35, Δvps17, Δvps18, Δvps15, Δvps27, and  Δvps1 were grown 
in YPD liquid media at 30˚C to an OD600 of 0.4-0.8/ml. 1ml of cells were harvested 
by centrifugation at 700 g for 3 min, and resuspended in 50 µl YPD. The FM 4-
64FX dye was added to the samples so the final concentration was 40 µM. In 
treated cells, a concentration of 0.8 µM (20% MIC dose) neo was used. DMSO 
treated samples were used as controls. Samples were stained for 15 min at 22˚C 
before harvesting by centrifugation at 700g for 3 min and washed in 1ml YPD 
followed by 45 min of ―chase‖ in the absence of dye at 22˚C  in the presence of 0.8 
µM neo in the  treated cells. Redistribution of the dye after drug addition was 
observed with an Olympus FluoView FV1000 confocal laser scaning microscope 
using a 100x oil-immersion objective. 
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Results 
Neothyonidioside blocks multivesicular body/ vacuole formation. 
In control cultures, labeling of vacuoles was clearly discernible after 45 minutes of 
dye ―chase‖ (Figure 3-2). Neothyonidioside at 1µM concentration blocked labeling 
of vacuoles/multivesicular bodies (Figure 3-2). Drug-treated cells showed punctate 
staining similar to that seen in a 15° C temperature block (Vida and Emr 1995), 
and occasional incomplete vacuole labeling could be observed in some cells in the 
microscopy fields of our study. Numbers of cells with fully formed vacuoles and the 
total number of cells observed in the field were counted, and percent of the 
number of cells with wild-type vacuole morphology, 100
total
vacuole
N
N
 
was calculated. We found that control samples have nearly three-fold more fully 
formed vacuoles than neo treated samples (Figure 3-3). 
 
 
 
Cells were stained with FM 4-64FX according to Vida and Emr 1995. Cells were visualized 
using an Olympus FluoView FV1000 confocal laser scanning microscope as described in 
Materials and Methods for this Chapter. 
Figure 3-2: Plasma membranes and vacuole membranes in wild-type cells un-treated and 
treated with neo was stained with FM 4-64 FX 
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Neothyonidioside treated cells show similar morphology to class B and E 
vps Mutants. 
Vacuole morphology of wild-type cells, cells treated with neo and vacuolar protein 
sorting (vps) mutants stained with FM-4-64 FX was investigated as described in 
the Materials and Methods section of this chapter. Cells treated with a sub-lethal 
concentration of neo showed defects in vacuole formation similar to those 
observed in Δvps17 and Δvps27 (Figure 3-4).  
 
 
 
Figure 3-3: Percentage of cells with wild-type vacuole morphology in control samples and 
treated samples.  
Cells from 5 samples of control and drug treatment were counted, n= 471 and 348 
respectively 
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Figure 3-4: Vacuole morphology of neo treated cells and vps mutants. 
(a) wild-type control, (b)  wild type with sublethal concentration of neo, (c) Δvps35 , (d)  
Δvps17, (e)  Δvps18, (f) Δvps15, (g) Δvps27, (h) Δvps1  
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Neothyonidioside resistant mutant showed that wild type vacuole 
morphology 
Our published  study showed that neo resistant cells (neoR) have half the amount 
of cellular ergosterol compared to wild-type (Yibmantasiri, Leahy et al. 2012). To 
investigate if the neo resistant mutant developed in that study showed any change 
in vacuole morphology due to changes in ergosterol content we stained the wild-
type and mutant cells with FM-4-64FX. The results in Figure 3-5 showed that the 
mutant cells have the same vacuole morphology as wild-type  
 
  
Figure 3-5 : Vacuolar morphology of wild-type cells and neothyonidioside resistance mutant 
cells (neoR) 
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Discussion 
We have shown in our published study that neothyonidioside (neo) is cytotoxic, 
directly binds to ergosterol, and is not a main ABC transporter substrate (knockout 
of PDR1, PDR3, PDR5, SNQ2, and YOR1 did not increase cell sensitivity to neo 
(Yibmantasiri, Leahy et al. 2012). Deletion of genes involved in ergosterol 
biosynthesis (erg -null mutant) did not cause extra sensitivity to neo. However, a 
null mutation in ERG3 increased neo tolerance (Figure 3-6; Kristina Boeger 
summer student report). ERG3 encodes a C-5 sterol desaturase which catalyzes 
the formation of a C-5(6) double bond into episterol, a precursor in ergosterol 
biosynthesis reducing the amount ergosterol product (Arthington, Bennett et al. 
1991). It has been shown that disruption of ERG3 causes resistance to polyene 
antifungals such as nystatin and amphotericin (Woods, Bard et al. 1974; Balkis, 
Leidich et al. 2002)  both non-ABC substrates. We found that neo resistant cells 
have half the amount of cellular ergosterol compared to wild-type cells which is a 
fundamentally different response to the classic resistance mechanisms in which 
resistant cells usually increase amount of drug target(s) (Yibmantasiri, Leahy et al. 
2012). This suggests to us that neo does not simply bind and sequester ergosterol 
but has a more complicated mechanism. 
 
 Figure 3-6: Susceptibility of erg mutants to the tolerance to neothyonidioside 
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Because of the enrichment of ESCRT genes observed in the chemical-genetic 
profiling HOP-assays, we hypothesised here that neo might exert its toxic effect 
via vacuole formation similarly to the  antifungal polyene natamycin which binds to 
ergosterol but does not permeabilize the cell membrane(te Welscher, Napel et al. 
2008). This suggested that neo might exert its toxicity by blocking endocytosis and 
vacuole formation. This prediction was borne out by the microscopy experiments 
observing the fate of a vital stain for endocytosis of plasma membrane to vacuoles. 
We observed a blockage in vacuole membrane staining with a build-up of 
punctuate staining, probably prevacuolar, in the presence of neo (Figure 3-2). In 
control cultures, labeling of vacuoles was clearly discernible after 1 hour of 
treatment (Figure 3-2). Neo at this concentration blocked labeling of 
vacuoles/multivesicular bodies after 1 hour of treatment (Figure 3-2) where only 30% 
of the control level of vacuoles was observed (Figure 3-3). Labelling with FM-4-
64FX in neo treated cells was similar in the deletion mutants, Δvps17 and Δvps27 
Figure 3-4. Both of these genes were identified as hits in chemical-genetic 
homologous deletion profiling (HOP) assay. This confirmed our hypothesis that 
neo disrupts vesicular formation similar to vps mutant and formation of these 
vesicles is essential in overcoming the drug effect.  
An endosome-vacuole pathway alteration is not the only effect of neo because 
Vps17p is a subunit of the membrane-associated retromer complex and 
assembles with Vps5p to promote vesicle formation in an endosome Golgi 
retrograde transport pathway. Vsp27p is an endosomal protein and a member of 
ESCRT-0 complex, which is required for recycling Golgi proteins. These results 
strongly support that neo affects both endocytosis process as well as vesicle/ 
multivesicular body formation involving the ESCRT complex.  
Endocytosis of plasma membrane receptors has been shown to involve genes 
encoding  both endocytosis-associating proteins, including those in lipid rafts, 
clathrin, clathrin-adaptors as well as the ESCRT complex (Burston, Maldonado-
Báez et al. 2009) . Our results, which showed that neo can affect both endocytosis 
and multivesicular body formation further support the view that these two 
processes interact with one another and are essential for cell survival (prevention 
of these processes by neo results in cell death). 
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The neo morphological effects, however, are different from a polyene antifungal, 
natamycin ,which causes multiple vacuoles formation (te Welscher, Jones et al. 
2010), whereas neo appears to block prior to vacuole/MVB formation as shown 
here (Figure 3-2). We also note that, beside deletion mutants in ESCRT 
complexes, deletion mutants of the GARP complex (VPS51 and VPS52) and 
vesicle transport genes (VPS5, VPS41, VPS17), also endocytosis gene deletions 
(END3, CAP1, RVS167, RVS161) appear in our chemical-genetic profiling as 
showing hypersensitivity to neo. This is further evidence pointing to the existence 
of compensating membrane-recycling pathways in response to the neo treatment. 
It is possible that by binding to ergosterol, neo, which itself has a sterol-like core, 
imparts too much rigidity to specific parts of the membrane reducing its ability to 
bend and form multivesicular body vesicles presumably essential for membrane 
recycling and lysosomal degradation (Gruenberg and Stenmark 2004; Wollert and 
Hurley 2010). Increasing sterol concentration is known to increase membrane 
curvature rigidity and different forms of sterols have different rigidity properties 
(Gondré-Lewis, Petrache et al. 2006; Henriksen, Rowat et al. 2006). The notion 
that ergosterol rigidity is involved in neo toxicity is supported by our published work 
that showed that an ergosterol threshold level is necessary for toxicity. It follows 
that by reducing ergosterol levels below the required toxicity threshold, the cells 
become resistant to neo explaining the neoR phenotype.  We also observed that 
neoR cells can still form vesicles/ vacuoles the same way as wild-type even though 
neoR cells have half the amount of cellular ergosterol (Figure 3-5) (Yibmantasiri, 
Leahy et al. 2012). This suggested that it was the disruption of sterol distribution 
by neo, and hence prevention of bending of the membrane, and not the amount of 
sterol on plasma membrane that caused toxicity. ESCRT genes probably 
compensate neo toxicity by providing aid to membrane inward budding. Taken 
together, our results suggest a model in which the neo triterpene glycoside binds 
directly to plasma membrane sterols and at a critical sterol concentration forms a 
complex that interferes with multivesicular body vesicle formation in endosome 
intermediate steps. 
Although neo is not an ABC substrate, we cannot be sure that neo binding to 
ergosterol does not trigger a signalling pathway that activates Pdr1p/Pdr3p 
thereby activating lipid alterations (see Chapter 4). It might be that Pdr1p/Pdr3p is 
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activated but neo is not the right substrate to be pumped out by the main ABC 
pumps. What is clearly shown here however, is a link between lipid composition 
and drug resistance. Change in lipid composition allows cells to be more or less 
susceptible to drugs as well as affecting many pathways such as vacuole 
formation and endocytosis.  
It has been known that cells can transport  drugs to specific cellular compartment 
for degradation (Kuchler and Schüller 2007). This compartment-specific drug 
sequestering involves vacuoles and multivesicular formation, which require 
ESCRT complex. Genes encoding components of ESCRT complex also came up 
in chemical –genetic profiling of polyenes antifungal drugs such as amphotericin 
and nystatin but not as enriched as found with neo (Parsons, Brost et al. 2004; 
Parsons, Lopez et al. 2006). This result emphasizes the importance of ESCRT 
complex and vacuoles as ways to compensate for drug toxicity as well as 
mechanism for multidrug resistance besides the classic up-regulation of ABC-
transporters.  
Lastly, we have shown that we can determine a drug target and mechanism by 
genome-wide deletion analysis assuming a drug can act in lieu of a mutation. 
Although, the actual compound-target binding mechanism required classic 
biochemistry, chemical-genetics is a fast and powerful method in identifying what 
pathways the compounds of interest affect, and how cells can compensate for the 
toxic effects of the compound of interest.     
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Chapter 4. Developing the PDR Response Reporters  
Introduction 
Pleiotropic Drug Resistance (PDR) is a robust network achieved by interactions 
between transcriptional activators, mediator complexes and efflux pumps. The 
expression of PDR genes is rapidly induced in the presence of xenobiotics through 
the control of two transcription factors, Pdr1p and Pdr3p. Although the 
downstream efflux pumps and targets of Pdr1p and Pdr3p are well annotated, the 
events between sensing of xenobiotics and transcriptional activation by Pdr1p and 
Pdr3p are poorly understood. 
To characterize these events, reporters were developed to investigate genes that 
are involved in activating/ modulating PDR1/PDR3, hence the multidrug resistance 
phenotype in yeast. The functional rationale of the reporter(s) was to generate an 
easily measurable output at specific locations (here is plasma membrane), and 
dependent on Pdr1p/Pdr3p, as a function of the genome-wide deletion set and the 
addition of xenobiotic(s).  
To achieve this aim, an assay for activation of PDR1 and PDR3 upon treatment 
with xenobiotic(s) was required. Initially we sought to find change in expression or 
localisation of the GFP-labeled transcription factors themselves (Pdr1p-GFP and 
Pdr3p-GFP). However, there were no detectable fluorescent intensity changes 
upon xenobiotic treatment in the various strains examined. Pdr1p-GFP and Pdr3p-
GFP also were found localised in the nucleus in both control and treated cells.  
Therefore, we could not use localisation or fluorescence intensity as a way to 
measure activation of transcriptional activity of Pdr1p/Pdr3p.  
Accordingly, it was decided to use PDR target genes as reporters of Pdr1p/Pdr3p 
transcriptional activity upon xenobiotic treatment. To this end Pdr5p was chosen 
because it is the main ABC transporter in S. cerevisiae, being highly expressed in 
cells with PDR phenotype and dependent on Pdr1p/Pdr3p. It has also been 
demonstrated to increase expression upon xenobiotic treatment (Balzi and 
Goffeau 1995; DeRisi, van den Hazel et al. 2000; Gulshan and Moye-Rowley 
2007).   
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As noted Pdr5p is a naturally high abundance protein in cells, and its use as a 
reporter requires a detectable increase in fluorescence due to xenobiotic treatment. 
To cope with possible dynamic range limitations between the basal level of Pdr5p 
(non-treated cells) and activated level of Pdr5p (addition of xenobiotics) we 
generated two different reporters. 
In the first approach, PDR5-GFP (Invitrogen™), Pdr5p on the plasma membrane   
was used. The assay was designed to detect increased intensity of Pdr5p-GFP 
upon activation with xenobiotics detected by OperaTM confocal microscopy with the 
analysis software AcapellaTM identifying the plasma membrane region of the cell. 
This strain (PDR5-GFP) was mated against YCG255 (Table 2-2) the diploid was 
sporulated and tetrad dissection was conducted as in Materials and Methods 
(page 67) to yield the hybrid strain YCG285. This provided an appropriate 
genotype such that the hybrid could be mated against the deletion mutant array 
and recombinants selected for high-throughput screens in later steps. 
In the second approach, the PDR5 open reading frame (ORF) was replaced with 
GFP, but keeping the promoter intact. This reporter should result in cytoplasmic 
GFP, where entire cells should turn bright green upon treatment with xenobiotics. 
It was reasoned that this approach should help to increase the dynamic range 
between basal level and activation level detected by AcapellaTM software since 
now the whole cell would be identified instead of only the plasma membrane 
region. The appropriate PCR product (primers for replacing PDR5-ORF listed in 
strain construction section in Materials & Methods from page 67 ) was used to 
transform YCG255. The transformants were selected in YPD+ 200µg/ml 
hygromycin. This generated the reporter YCG281 (Table 2-2 page 66) 
In addition to the GFP labels, both YCG285 and YCG281 contained constitutively 
expressed cytoplasmic red fluorescent protein (RFP) under the LYP1 promoter. 
RFP was used for automated cell detection by AcapellaTM software as well as an 
internal control. All analyses involving measurement of GFP intensity were 
normalized against the RFP intensity. To exclude gene deletions which might 
affect the correct folding and localisation of general proteins (including GFP) and 
therefore appearing as false- positives, a pre-existing screen from this laboratory 
(Bircham, Maass et al. 2011) with a plasma membrane protein reporter that is not 
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involved in the PDR phenotype was used. Mrh1p is a plasma membrane protein 
and used in this laboratory to study the unfolded protein response and protein 
localisation. Gene deletions that were identified as affecting the plasma-membrane 
reporter levels in both PDR reporter screens and in Mrh1p-GFP screens were 
regarded as genes required for general plasma membrane folding/localisation and 
were therefore counted as false positives. These genes were not subjected to 
further validation.   
These reporters allow GFP fluorescence to serve as sensitive real-time indicators 
for of Pdr1p/Pdr3p activation. Each reporter was mated into the yeast gene 
deletion background, creating a ~4800 strain reporter collection as a function of 
the genome-wide non-essential gene deletions. These new strains were then 
measured for Pdr5p fluorescence by high throughput confocal microscopy after 
activation of the PDR response with 35 µM atorvastatin, a known PDR–inducer 
(LIPITOR: Materials & Methods 71)   
In addition to the Pdr5p-GFP reporter on the deletion set background, two other 
major ABC transporters in S. cerevisiae that are Pdr1p/Pdr3p targets namely 
Snq2p, and Yor1p were used as reporters. Commercial strains from the Invitrogen 
GFP collection were used to generate SNQ2 and YOR1 reporters similar to the 
PDR5 reporter, YCG285, already described. The resulting strains for Snq2p and 
Yor1p are referred to as YCG330 and YCG334 respectively (for genotypes see 
Materials and Methods Table 2-2 page 66. All three reporters were used for drug 
screening studies but owing to time limitations, only the Yor1p reporter was mated 
into the deletion set background as described here for the Pdr5p reporter.  
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Results  
To assess whether the ABC-transporters linked to GFP (targets of Pdr1p/Pdr3p) 
respond measurably to the xenobiotic challenge for use in deletion set screens, we 
tested YCG285, YCG281, YCG330 and YCG334 in the presence of atorvastatin, a 
PDR inducer, and the intensity of the GFP reporter of each strain was measured. 
We found that YCG281 (the strain with PDR5 ORF replaced with the GFP 
cassette), although the promoter region was intact, it was not used for 
upregulation upon xenobiotic treatment as anticipated (Figure 4-1). However, 
YCG285 increased upon atorvastatin treatment by 2.5 fold as measured by 
AcapellaTM software analysis and therefore this strain was used for further 
screening. 
Analysis of the other two main ABC transporters targets of Pdr1p/Pdr3p, Snq2p-
GFP (YCG 330) and Yor1p-GFP (YCG334) showed between 1.5-2 fold changes in 
intensity compared to non-treated cells determined by AcapellaTM software 
analysis (Figure 4-1). 
These results showed that the ABC-transporters labeled with GFP could be used 
to measure the response to xenobiotic challenge and therefore could be used as 
the indicator for PDR response activation. 
Susceptibility of Efflux Pump Reporters 
To assess that C-terminal GFP tagging does not change the ability of the proteins 
function normally, a susceptibility assay of the reporters against the PDR 
substrates cycloheximide (CHX) was conducted. We observed no significant 
difference in sensitivity between any reporter strain and wild-type (Figure 4-2). 
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Figure 4-1: ABC transporter GFP reporters.  
Left panels: DMSO control. Right panels: 35 µM atorvastatin treatment for 4 hours before   
images were recorded by the OPERA confocal microscope and analysed by Acapella 
software.   a-b) Δpdr5::GFP (YCG281).  c-d) PDR5-GFP (YCG285).  e-f) SNQ2-GFP (YCG330).  
g-h) YOR1-GFP (YCG334). 
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Experiments were done in triplicate. 
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Figure 4-2: Susceptibility of ABC-GFP reporters 
Dose response of reporters compared with wild-type (Y9320 + mCherry) at various 
concentrations of cycloheximide.   
 
 
 
 
 
 
Figure 4-3: Fold change GFP reporters in different xenobiotic treatments (control/treated) 
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Selection of Xenobiotics Which Activate PDR Response 
To select xenobiotics that activate the PDR response, a variety of compounds 
were tested. The compounds used, their concentration, the response to them 
measuring fold change in GFP between treated/control, in different reporters are 
shown in Figure 4-3. We found that 35 µM atorvastatin, 20 µM farnesylthiosalicylic 
acid (farnesyl), and 35 µM oligomycin caused at least a 1.5 fold increased in all 
GFP reporter expression. With the exception of farnesyl, Pdr5p-GFP reporter 
expression increased the most among three GFP reporters. Surprisingly, 
ketoconazole, which is a known Pdr5p substrate, did not cause up-regulation of 
Pdr5p-GFP. 
Reporters were also screened against a library of pharmacologically active 
compounds (LOPAC1280 TM). LOPAC is a library of 1280 high purity, small organic 
ligands with well-documented pharmacological activities including antibiotics, 
compounds involved in lipid signalling, gene regulators, phosphorylation etc. All 
LOPAC compounds were used at a concentration of 27 µM. To make sure that the 
used concentration only triggers the PDR response and not other stress 
responses such as the Unfolded Protein Response (UPR), a reporter strain with a 
promoter consisting of four tandem repeats of the unfolded protein response 
element (UPRE) driving GFP expression was screened alongside the PDR 
reporters. UPR reporter strain was generated by Peter Bircham; SBS, VUW. Only 
compounds that induced the PDR GFP reporter at least 2-fold over controls and 
did not up-regulate the UPR reporter were counted as ―hits‖. For example, 
cerevistatin upregulated the UPR reporter at the concentration used and therefore 
was not used for future screening. Compounds that induced Pdr5p, Yor1p and 
Snq2p are listed in Table 4-1. 
We found that there was a large collection of compounds that upregulated our 
PDR reporters. Some upregulated all the ABC-transporter and some were more 
specific to one or two transporters. We found that more compounds upregulated 
Pdr5p-GFP reporter than the other two reporters. 
Owing to availability and cost efficiency, atorvastatin was used as the compound 
to activate the PDR response in the primary screen. Atorvastatin has a number of 
useful attributes including that its target, HMG-CoA reductase, and its associated 
94 
 
pathway is well known in yeast and higher eukaryotes. Furthermore, the network 
of the genes sensitive to this drug is available in the lab (chemical-genetic 
interaction of atorvastatin (Bede Busy personal communication and Master Thesis 
2009).  
Table 4-1: Compounds from LOPAC Library which upregulated ABC pumps 
with C-terminal GFP tagged reporters 
 Description 
Overlap 3 pumps  
Z-L-Phe chloromethyl ketone Bovine chymotrypsin A-gamma inhibitor 
3,4-Dichloroisocoumarin Serine protease inhibitor 
Farnesylthiosalicylic acid Non-toxic Ras inhibitor 
Phenylbutazone Anti-inflammatory; substrate for 
prostaglandin peroxidase 
3-alpha,21-Dihydroxy-5-alpha-
pregnan-20-one 
Positive allosteric modulator of GABA-A 
receptors 
Meclofenamic acid sodium Cyclooxygenase and 5-Lipoxygenase 
inhibitor 
Overlap Pdr5p and Yor1p  
Lonidamine Inhibits the energy metabolism of 
neoplastic cells by interfering with 
mitochondrial hexokinase, cellular 
respiration, and glycolysis; damages cell 
and mitochondrial membranes 
5alpha-Pregnan-3alpha-ol-20-one Positive allosteric modulator of GABA-A 
chloride channels 
L-655,240 Thromboxane A2 (TXA2) receptor 
antagonist 
Overlap Pdr5p and Snq2p  
Dequalinium analog, C-14 linker Protein kinase C-alpha (PKC-alpha) 
inhibitor 
Parthenolide Inhibits serotonin release from platelets; 
inhibits production of leukotriene B4 and 
thromboxane B2 
YC-1 NO-independent guanylyl cyclase activator 
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Overlap Snq2p and Yor1p  
Amfonelic acid Increases dopamine release during 
electrical stimulation; appears to mobilize 
dopamine release from storage 
compartments 
N-Phenylanthranilic acid Cl- channel blocker 
N-p-Tosyl-L-phenylalanine 
chloromethyl ketone 
Blocks LPS- or cytokine-induced activation 
of nuclear factor kB (NFkB), which, blocks 
the induction of iNOS and COX-2 
transcription; blocks activation of pp70s6k 
by all mitogens 
Calcimycin Ca2+ ionophore used to potentiate 
responses to NMDA, but not quisqualate 
glutamate receptors 
Pdr5p alone  
N-p-Tosyl-L-phenylalanine 
chloromethyl ketone 
Blocks LPS- or cytokine-induced activation 
of nuclear factor kB (NFkB), which, blocks 
the induction of iNOS and COX-2 
transcription; blocks activation of pp70s6k 
by all mitogens 
Nifedipine L-type Ca2+ channel blocker; vasodilator 
R(+)- Butylindazone Potent [K+, Cl-]-cotransport inhibitor that 
shows no side effects on the 
bumetanimide-sensitive [Na+, K+, Cl-]-
cotransport system 
WIN 62577 NK1 tachykinin receptor antagonist 
7-cyclopentyl-5-(4-phenoxy) phenyl-
7H-pyrolo 
Potent and selective Ick (src family tyrosine 
kinase) inhibitor. 
DL-stearoylcarnitine  chloride Protein kinase C (PKC) inhibitor 
5alpha-pregnan-3alpha-ol-20-one Positive allosteric modulator of GABA-A 
chloride channels 
Diclofenac sodium Cyclooxygenase inhibitor; anti-inflammatory 
Androsterone Anabolic steroid 
Fusidic  acid sodium Inhibits protein synthesis in prokaryotes 
(Z)-Gugglesterone Bile acid receptor (FRX) antagonist. Has 
cholesterol lowering activity. 
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SU4312 Vascular endothelial growth factor (VEGF) 
receptor protein tyrosine kinase 1/2 (KDR) 
and platelet derived growth factor (PDGF) 
receptor inhibitor 
CR2945 Selective gastrin/CCK(B) receptor 
antagonist 
Yor1p alone   
SU 6656 Selective Src family kinase inhibitor. 
U0126 Specific inhibitor of MEK1 and MEK2 (MAP 
kinase kinase; MAPKK); also inhibits a 
constitutively active, mutant form of MEK 
Bupropion hydrochloride Selective dopamine reuptake inhibitor; 
antidepressant 
Actinonin Leucine aminopeptidase inhibitor 
Snq2p alone  
Bay 11-7085 Inhibits cytokine induced IkB (Inhibitor of 
NFkB) phosphorylation 
Nalidixic acid sodium Inhibits bacterial DNA polymerase (DNA 
gyrase) 
AIDA Selective mGluR1 metabotropic glutamate 
receptor antagonist 
SB-366791 Vanilloid receptor-1 (VR1) antagonist 
McN-A-343 M1 muscarinic acetylcholine receptor 
agonist. 
Salmeterol beta2 Adrenoceptor agonist 
 
Primary Screen Results  
A key question in this section of the dissertation is whether the same set of genes 
regulates the PDR response when different downstream reporters are used. Two 
reporters were used namely Pdr5p-GFP and Yor1p-GFP reporters. These two 
reporters were selected owing to their differences in Pdr1p/Pdr3p dependency. 
The genotype of these two reporters was adjusted, according to Strains 
Constructions in Materials and Methods p 67, for the appropriate selection 
markers and then each mated against the mutant deletion array to provide the 
genome-wide deletion background. Because Pdr5p is highly expressed during 
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exponential growth and Yor1p is not, both reporter strains were grown for at least 
21 hours to make sure that they were in stationary phase and basal expression of 
both proteins was achieved. 
Five screens were conducted; three with the Pdr5p reporter and two with the 
Yor1p reporter. In the primary screens, genes of interest are those showing no 
difference between the mean of the control condition and drug treated condition as 
identified with Z-scores below 5. These are the genes that when deleted result in 
an inability to upregulate PDR5 and YOR1 upon drug treatment, and therefore 
should be the common modulators of the PDR response. As stated in the 
introduction of this chapter, genes involved in protein synthesis and protein folding 
which also came up in Mrh1p control screens were considered as false positives, 
and were removed from the list. Each screen was analysed independently. Lists of 
hits from each screen were then compared and gene deletions which came up as 
hits in at least 4 out of 5 screens were counted toward the final hit list. 
From the screens, 54 gene deletions appeared as ―hits‘ (Figure 4-4) i.e. gene 
deletions that prevented the expected significant increase in Pdr5p and Yor1p 
expression upon treatment with atorvastatin. Some imaging methods of were more 
effective than others in quantifying plasma membrane GFP-reporters. We found 
that the Acapella ―texture analysis‖ (key components being ―ridges‖, ―edges‘, 
―bright‖; see Materials & Methods page 71) around the plasma membrane region 
was the most effective. A ―hit‖ is defined as gene deletions, which showed no 
significant difference in plasma membrane fluorescence between the control and 
drug-treated cells. That is to say, such deletions must be affecting PDR (see 
Figure 4-5). The systematic name, the common name and the description of these 
―hit‖ genes are listed in Appendix ITable A-1. 
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In analyzing the ―hits‖, Gene Ontology (GO) slim-analysis in the function category 
showed enrichment of 11 gene deletions in transcription activation and co-
activation (p-value 0.05 Table 4-2).  Also there was clustering of gene-deletions 
that are involved in kinase activity (PSK1, SNF4, KKQ8 and BMH1), genes that 
are involved in sphingolipid and phospholipid biosynthesis (DPL1, SKN1, PIB2), 
and genes that are involved in mitochondria integrity (PSD1, FMC1, PPE1, FIS1, 
ATP11, and YME1), but the transcription cluster was the only one showing GO 
enrichment with statistical significance.  
Transcription factors and mediators relating to RNA-polymerase-II and SAGA 
complexes associated with regulation of PDR5 were enriched although this is not 
Figure 4-4: PDR Primary screen network.  
Gene deletions that prevented normal up-regulation of Pdr5p-GFP and Yor1p-GFP upon 
atorvastatin treatment.PDR1 /PDR3 are in the middle to represent the known major control 
of PDR phenotype. Each lines of connection represent the possible regulation relationship 
between gene XXX and PDR1/PDR3. NUP42 and KAP123 are both nuclear pore complex 
which have been known to interact with other stress response transcription factors 
(www.yeastgenome.org) 
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an entirely new finding in the PDR field. Gal11p and Ngg1p have been shown to 
regulate Pdr1p but enrichment of transcription factors and activators in regulating 
PDR5 has not yet been described. Such an observation suggests a program of 
gene transcription is switched on in response to xenobiotics, maybe as part of a 
stress response. 
 
Figure 4-5: Examples of gene deletions that prevented normal upregulation of Pdr5p-GFP 
and Yor1p-GFP reporters.  
The images are of the Pdr5p-GFP reporter in the named gene deletion backgrounds. The 
images were adjusted so that fluorescence levels of DMSO control and drug treatment of 
each of the deletions (in 35µM atorvastatin) are directly comparable as to quantity. 
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Table 4-2: Eleven Genes relating to RNA transcription were GO 
enriched as revealed in the PDR primary screens. 
GO-term P-value Gene(s) annotated to the term 
sequence-specific DNA 
binding transcription 
factor activity 
0.00588 PDR3/YBL005W: 
UME6/YDR207C: 
SWI4/YER111C: 
PDR1/YGL013C: 
SKN7/YHR206W: 
RSF2/YJR127C: 
RTG1/YOL067C 
nucleic acid binding 
transcription factor 
activity 
0.00613 PDR3/YBL005W 
UME6/YDR207C: 
SWI4/YER111C: 
PDR1/YGL013C: 
SKN7/YHR206W: 
RSF2/YJR127C: 
RTG1/YOL067C 
transcription factor 
binding transcription 
factor activity 
0.04211 ROX3/YBL093C: 
SRB8/YCR081W: 
UME6/YDR207C: 
SSN2/YDR443C: 
GCN5/YGR252W 
transcription coactivator 
activity 
0.04829 SRB8/YCR081W: 
SSN2/YDR443C: 
GCN5/YGR252W 
Validation of the Primary Screen Hits 
All 54 gene deletion from the primary screens were subjected to further validation 
using spot dilution assays tested against  six known PDR substrates (oligomycin, 
cycloheximide, fluconazole, ketoconazole, atorvastatin, benomyl). If these genes 
were important to the cell‘s survival because of a role in the PDR response it 
would be expected that their deletion would show increased PDR-drug sensitivity 
in all cases. At the concentrations used, none of the drugs were lethal to wild-type 
cells. Strains with double deletion of PDR1/PDR3 were used as a positive control, 
and showed sensitivity to all the compounds. Gene deletions which showed 
increased sensitivity or resistance towards compound(s) compared to wild-type 
were subjected to further studies and were listed in Table 4-3. All experiments 
were repeated 3 times. We found that 17 gene deletions out of 54 showed an 
increase in sensitivity toward one or more compounds, 8 of these were sensitive to 
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atorvastatin. Interestingly deletion of PDR1 only caused sensitivity toward 
atorvastatin but none of the other compounds. Examples of genes conferring 
sensitivity in spot dilutions are shown in Figure 4-6. 
Table 4-3: Results from Validation of Primary Screen Result with Spot Dilution 
Assays and Western Blots 
Gene 
(ORF) 
Sensitivity in 
Δxxx  
Sensitivity in 
ΔxxxΔpdr1Δpdr3 
Reduction 
of Pdr5p 
in 
Western 
Blot 
Description 
BEM2 
(YER155C) 
Atorvastaytin 
Benomyl 
Cycloheximide 
Ketoconazole 
Atorvastaytin 
Cycloheximide 
Fluconazole 
Ketoconazole 
Oligomycin 
 
- Rho GTPase activating 
protein (RhoGAP) 
BMH1 
(YER177W) 
- Fluconazole 
Ketoconazole 
Yes 14-3-3 protein  regulation of   
exocytosis, vesicle 
transport, Ras/MAPK 
signalling, signalling  
 
CWH43 
(YCR017C) 
- Oligomycin - Putative sensor/transporter 
protein involved in cell wall 
biogenesis;   
DPL1 
(YDR294C) 
Cycloheximide - - Dihydrosphingosine 
phosphate lyase, regulates 
intracellular levels of 
sphingolipid   
 
FMC1 
(YIL098C) 
Cycloheximide 
Oligomycin 
(Atorvastatin?) 
Fluconazole 
Ketoconazole 
Oligomycin 
-  Required for assembly or 
stability at high temperature 
of the F1 sector of 
mitochondrial F1F0 ATP 
synthase 
 
GCN5 
(YGR252W) 
- Atorvastatin 
Cycloheximide 
Fluconazole 
Ketoconazole 
Oligomycin 
 
-  Catalytic subunit of the 
ADA and SAGA histone 
acetyltransferase 
complexes 
GTR2 
(YGR163W) 
- Fluconazole 
Ketoconazole 
Yes Putative GTP binding 
protein that negatively 
regulates Ran/Tc4 GTPase 
cycle; activates transcription 
 
KAP123 
(YER110C) 
- Negative genetic 
interaction 
- Karyopherin beta, mediates 
nuclear import of ribosomal 
proteins prior to assembly 
into ribosomes and import 
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of histones H3 and H4 
MDM39 
(GET1) 
(YGL020C) 
- Fluconazole 
Ketoconazole 
- Subunit of the GET 
complex; involved in 
insertion of proteins into the 
ER membrane 
 
OPI3 
(YJR073C) 
- Oligomycin - Phospholipid 
methyltransferase  
catalyzes the last two steps 
in phosphatidylcholine 
biosynthesis 
 
PDR1 
(YGL013C) 
Atorvastatin N/A 
(Negative genetic 
interaction) 
Yes  Master regulator involved in 
recruiting other zinc cluster 
proteins to pleiotropic drug 
response elements 
(PDREs)   
 
PIB2 
(YGL023C) 
Cycloheximide 
Ketoconazole 
Fluconazole 
Ketoconazole 
Yes Protein binding 
phosphatidylinositol 3-
phosphate 
 
PIN4 
(YBL051C) 
Atorvastatin 
Benomyl 
Cycloheximide 
- -  G2/M phase progression   
contains an RNA 
recognition motif, NLS 
 
PSD1 
(YNL169C) 
Benomyl 
Ketoconazole 
- -  Mitochondrial inner 
membrane, converts 
phosphatidylserine to 
phosphatidylethanolamine 
 
RCY1 
(YJL204C) 
Atorvastatin 
Ketoconazole 
Negative genetic 
interaction 
- F-box protein involved in 
recycling plasma membrane 
proteins 
 
RHO4 
(YKR055W) 
Benomyl 
Cycloheximide 
Fluconazole 
Ketoconazole 
Oligomycin 
 
- - Small GTPase of the 
Rho/Rac subfamily of Ras-
like proteins 
ROX3 
(YBL093C) 
Atorvastatin 
Cycloheximide 
Fluconazole 
Ketoconazole 
Oligomycin 
 
Negative genetic 
interaction 
Yes Subunit of the RNA 
polymerase II mediator 
complex 
RPN10 
(YHR200W) 
Cycloheximide 
Ketoconazole 
Cycloheximide 
(Oligomycin?) 
- Non-ATPase base subunit 
of the 19S regulatory 
particle (RP) of the 26S 
proteasome 
 
SNF4 
(YGL155W) 
Atorvastatin 
Oligomycin 
Oligomycin - Activating gamma subunit of 
the AMP-activated Snf1p 
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kinase complex 
SPT7 
(YBR081C) 
Cycloheximide 
Fluconazole 
Ketoconazole 
Oligomycin 
 
Cycloheximide 
Fluconazole 
Ketoconazole 
Oligomycin 
Yes Subunit of the SAGA 
transcriptional regulatory 
complex,   
SRB8 
(YCR018W) 
Atorvastatin 
Cycloheximide 
Fluconazole 
Oligomycin 
 
Atorvastatin 
Cycloheximide 
Yes Subunit of the RNA 
polymerase II mediator 
complex for Pol-II? 
 
SSZ1 
(YHR064C) 
Cycloheximide 
Oligomycin 
Cycloheximide 
Fluconazole 
Ketoconazole 
Oligomycin 
 
- Hsp70 protein; also involved 
in pleiotropic drug 
resistance via   activation of 
PDR1 and PDR5  
SWI4 
(YER111C) 
Cycloheximide Cycloheximide 
Fluconazole 
Ketoconazole 
- DNA binding component of 
the SBF complex (Swi4p-
Swi6p), a transcriptional 
activator 
UME6 
(YDR207C) 
Atorvastatin 
Benomyl 
Cycloheximide 
Atorvastatin 
Cycloheximide 
Fluconazole 
Ketoconazole 
Oligomycin 
 
- Key transcriptional regulator 
of early meiotic genes,   
YME1 
(YPR024W) 
- Atorvastatin 
Cycloheximide 
Fluconazole 
Ketoconazole 
Oligomycin 
- Mitochondrial inner 
membrane i-AAA protease 
complex,   responsible for 
degradation of unfolded or 
misfolded proteins   
Foot note: Sensitivity of Δxxx was compared to wild-type cells. Sensitivity of 
ΔxxxΔpdr1Δpdr3 was compared to Δpdr1Δpdr3. Different compound concentrations were 
used in Δxxx and ΔxxxΔpdr1Δpdr3 , as stated in Materials and Methods Table 2-1.  The 
concentrations used in  the ΔxxxΔpdr1Δpdr3 strains were adjusted so that the Δpdr1Δpdr3 
strain grows normally. Genes listed above cause increase in sensitivity to drug(s) in the 
Δpdr1Δpdr3 background. The symbol ―-‖ means Δxxx caused no sensitivity towards 
compounds tested in wild-type or extra sensitivity in Δpdr1Δpdr3 background, or no 
reduction in Pdr5p abundance observed in Western blot. 
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Genes which Increase Sensitivity in the double mutant Δpdr1Δpdr3 
background 
To investigate if any of the genes identified in the primary screens caused extra 
sensitivity in double knockout of transcription factors PDR1 and PDR3, we mated 
the 54 hit strains with strains lacking both PDR1 and PDR3 (genotype: pdr1Δ:: 
NAT pdr3Δ::URA3 can1Δ::STE2pr_Sphis5  lyp1Δ his3Δ1 leu2Δ0 ura3Δ0 met15Δ0 
LYS2+). The PDR deletion strains were a gift from Namal Coorey; SBS, VUW. The 
rationale behind this was that gene deletions that conferred extra sensitivity in 
(already sensitive) the Δpdr1Δpdr3 background strain should in theory, be the 
genes that are upstream of Pdr1p/Pdr3p and control other compensatory 
pathways. 
We found that most genes that caused sensitivity when deleted by themselves 
also caused extra sensitivity to one or more drugs when tested in the Δpdr1Δpdr3 
background. Furthermore, we found that deletion of CWH43, YDR532C, BMH1, 
GET1, OPI3, GTR2, YME1, and GCN5 only caused sensitivity in the Δpdr1Δpdr3 
background. Deletion of RCY1, KAP123, and ROX3 were synthetic lethal with 
Δpdr1Δpdr3, while single deletions of these genes individually were viable (Table 
4-3). Interestingly, while single Δrcy1, and Δrox3 increased sensitivity to 
compounds tested above (Table 4-3), Δkap123 did not cause increased sensitivity 
in the first spot dilution assays. Examples of gene deletions which conferred 
sensitivity in this background are shown in Figure 4-7 (gene deletions which 
conferred sensitivity in both Δxxx and Δxxx Δpdr1Δpdr3), and Figure 4-8 (gene 
deletions which conferred sensitivity in Δpdr1Δpdr3 background alone). The 
network of gene deletions that conferred sensitivity in spot dilution assays grouped 
by GO function is shown in Figure 4-9. 
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Figure 4-6: Examples of gene deletions from primary screens that conferred sensitivity to 
compound(s) tested.  
Concentrations used in spot dilution assays were listed in Materials and Methods Table 2-1. 
YPD was used as a control condition. CHX: Cycloheximide 
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Figure 4-7: Examples of gene deletions which result in an increase in sensitivity toward 
compound(s) tested as both single deletions (Δxxx) and in the Δpdr1Δpdr3 background 
(Δxxx Δpdr1Δpdr3).  
The spot dilutions above were carried out with gene deletions in Δpdr1Δpdr3 background. 
Concentrations used in spot dilution assays were listed in Materials and Methods Table 2-1. 
YPD was used as a control condition for cycloheximide and ketoconazole. YPGE was used 
as a control condition for oligomycin.  
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Figure 4-8: Example of gene deletions which result in increase in sensitivity toward 
compound(s) tested only when in Δpdr1Δpdr3 background.  
Figure 4-9: Network of genes from PDR secondary screen.  
Gene deletions from the primary screens were subjected to spot dilution assay as Δxxx , 
and Δxxx Δpdr1 Δpdr3. Deletions which confer sensitivity toward at least one the six test 
compounds tested on the genome-wide deletion background are shown here. PDR1/PDR3 
are shown as the hub connecting known regulators of the PDR. Each connection line  
represents a possible regulatory relationship between gene XXX and PDR1/PDR3. 
  Δkre28 Δkre28 
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Gene deletions and effect on Pdr5p abundance 
Twenty-six gene deletions that increased xenobiotics sensitivity were subjected to 
Western analysis for Pdr5p. This is to investigate if increase in xenobiotic 
sensitivity in these gene deletion backgrounds was due to changes in Pdr5p 
abundance (Figure 4-10 and Table 4-3). We found that in addition to Δpdr1 and 
Δpdr3, several other genes reduced Pdr5p relative to the Pma1p control, which 
showed no alteration in abundance on Western blots. These genes were Δrox3, 
Δspt7, Δgtr2, and Δbmh1.  Table 4-3 also lists other gene deletions that did not 
result in reduction of Pdr5p abundance measured by Western blot. 
Since the expression of another plasma membrane, Pma1p, internal control, did 
not change upon deletions of the above genes, this suggested that the effect of 
these various gene deletions was to be specific and not a pleiotropic effect. Of 
particular interest are those that also group significantly by GO analysis as 
transcription factors and RNA-polymerase-II mediators, namely ROX3 and SPT7. 
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Figure 4-10: Gene deletions that reduce Pdr5p abundance 
Images from the primary screen (top panels) and Western blots (middle panels) showing 
gene deletions which reduced Pdr5p abundance. Top panels a) wild-type;  b) Δpdr1;  c) 
Δpdr3;  d) Δbmh1;  e) Δgtr2;  f) Δlge1;  g) Δspt7;  h) Δrox3. The cell images were adjusted so 
that fluorescent intensities can be directly compared. Bottom panel showed Pdr5p-GFP 
expression in Δpdr1Δpdr3 background with cytoplasmic RFP mCherry internal control. 
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Network analysis predicts gene deletions contribute to PDR phenotype.  
From the results reported here, the network of genes that affect the PDR response 
in S. cerevisiae can be seen to include PDR1 PDR3, as well as gene deletions 
that showed GO enrichment such as mediators, the SAGA complex, and the 
genes involved in signalling. 
To make this network more comprehensible, and give better idea of how these 26 
genes from the secondary validation work together, we literature searched for both 
physical and genetic interactions among these 26 genes (http://thebiogrid.org/). 
We then identified the most highly connected genes (―hubs‖) among these 26 
genes (Figure 4-11and Figure 4-12).  
We then extended this network of genes affecting the PDR phenotypes by re-
interrogating the primary screen in a specific way as follows: we made a list of 
gene deletions in the published genetic and physical interaction data that interact 
with PDR1 and PDR3 and with the highly connected ―hubs‖ (http://thebiogrid.org/).  
This curated list of genes was then used to ―screen" the genes that registered in 
our primary screen but missed the cutoff used in this study for declaring them as 
―hits‖. A list of a further 18 gene deletions was obtained that were then tested to 
see if they showed sensitivity in spot dilution assays or reduced Pdr5p abundance 
by Western blot. We found that 10 out of 18 gene deletions tested were either 
showed sensitivity toward compounds tested or decreased Pdr5p abundance in 
Western blot, or both. The results are shown in Table 4-4.These results suggested 
that these genes contribute to the PDR network. 
Again, we found that most of the genes that displayed sensitivity in the spot 
dilution assay or reductions of Pdr5p in Western blots were enriched in 
transcription factors, the SAGA/transcriptional activator and chromatin remodelling 
(DEP1, NGG1, SPT8, ADA2) by GO analysis. 
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Table 4-4 : Genes which interact with secondary hits nodes and /or PDR1 PDR3 and 
might have effect on PDR phenotype  (N/T =not tested) 
Gene Sensitivity in single 
deletion 
Sensitivity in 
Δ pdr1 
Δpdr3 
background 
Description 
ADA2 
(YDR448W) 
Cycloheximide Not 
conclusive 
Transcription coactivator, 
component of the ADA and 
SAGA transcriptional 
adaptor/HAT (histone 
acetyltransferase) complexes 
 
DEP1 
(YAL013W) 
Cycloheximide Fluconazole 
Oligomycin 
 
Transcriptional modulator 
involved in regulation of 
structural phospholipid 
biosynthesis 
ERG3 
(YLR056W) 
Atorvastatin 
Cycloheximide 
Oligomycin 
no C-5 sterol desaturase, 
catalyzes the introduction of a 
C-5(6) double bond into 
episterol, a precursor in 
ergosterol biosynthesis 
HEK2  
(YBL032W) 
no Ketoconazole 
Oligomycin 
RNA binding protein 
HEX3 (SLX5) 
(YDL013W) 
Atorvastatin 
Oligomycin? 
Fluconazole 
Ketoconazole 
Subunit of the Slx5-Slx8 
SUMO-targeted ubiquitin ligase 
(STUbL) complex, 
 
HSP82 
(YPL240C) 
N/T N/T Hsp90 chaperone required for 
pheromone signalling 
 
LGE1 
(YPL055C) 
no no Protein of unknown function 
 
 
MNN10 
(YDR245W) 
Atorvastatin 
Benomyl 
Atorvastatin 
Cycloheximide 
Fluconazole 
Ketoconazole 
Subunit of a Golgi 
mannosyltransferase complex. 
NGG1 
(YDR176W) 
Atorvastatin 
Cycloheximide 
Ketoconazole 
Oligomycin 
N/T Transcriptional regulator; 
component of transcriptional 
adaptor and histone 
acetyltransferase complexes, 
the ADA complex, the SAGA 
complex, and the SLIK complex 
 
SPT8 
(YLR055C) 
Atorvastatin 
Fluconazole 
Ketoconazole 
 
Fluconazole 
Ketoconazole 
 
Subunit of the SAGA 
transcriptional regulatory 
complex but not present in 
SAGA-like complex  
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Figure 4-11: Published genetic (http://thebiogrid.org/) networks among our screen results 
and some of the known PDR-contributing genes. 
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Figure 4-12: Published physical interaction (http://thebiogrid.org/) networks among our 
screen results and some of the known PDR-contributing genes. 
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Discussion 
Section I: Methodologies, validation and limitations of the reporter screens 
 (a). Reporters for Investigating Possible PDR Modulators:  Primary Screen 
with Pdr5p and Yor1p Reporters 
We developed a Green Fluorescent Protein (GFP)-based reporter system utilizing 
Pdr5p, and Yor1p in order to identify other possible modulators of the PDR 
response in addition to the known regulators Pdr1p/Pdr3p. 
When we screened the LOPAC library with our GFP reporters (Pdr5p, Snq2p, and 
Yor1p), we found that some compounds with different analogues of some 
compounds activate different sets of pumps. For example, phenylalanine 
chloromethyl ketone, the Z-L analogue activated all three pumps, while the N-p-
Tosyl-L analogue activated only Snq2p, and Yor1p. There are two explanations for 
this. First is that, different analogues interact differently with different pumps. The 
second explanation is that the N-p-Tosyl-L analogue activates Yrm1p, whose 
recognition sites are found only in SNQ2 and YOR1 promoter region and not in 
PDR5, whilst the Z-L analogue activates TFs for all three pumps. This result is the 
first evidence that the PDR phenotype has back up pathways which are 
independent of Pdr1p/Pdr3p.  
The results reported as ―hits‖ in this chapter are gene deletions that resulted in a 
constant ABC-GFP reporter fluorescence level in the presence of xenobiotic 
compounds that otherwise would result in increased expression of ABC-GFP-
reporter. Gene deletions that scored this way but that also caused the UPRE-GFP 
assay to switch on were eliminated as false positive. Hits were recorded when a 
particular gene deletion scored in 4 out of the 5 screens of which 3 repeats were 
for Pdr5p-GFP and 2 repeats for Yor1p-GFP. Although Pdr5p and Yor1p are 
Pdr1p/Pdr3p targets, their expression and degree of dependency on these two 
transcription factors are different. PDR5 is more dependent on Pdr1p/Pdr3p  than 
YOR1 (Kolaczkowska and Goffeau 1999). PDR5 also contains recognition 
sequences belonging to other transcription factors such as Yap1p and Cad1p. 
These latter both contribute to the oxidative stress response (Miyahara, Hirata et 
al. 1996). Expression of YOR1 can also be controlled by Yrr1p another 
transcription factor known to contribute to the PDR phenotype. Because we do not 
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know the extent of the PDR network and therefore the extent of commonality of 
modulators, using these two pumps as reporters increased the chances of 
identifying common genes that affect both ABC transporters.   
 (b). Does the primary screen specifically identify genes needed for 
increased expression of ABC transporters in the plasma membrane? 
Some positive controls of expected hits are built into the reporter screens, namely 
that deletions of PDR1 and PDR3 were expected hits and indeed were obtained 
from all the screens. Some of the genes have also been shown to effect drug 
resistance such as PSD1, and SSZ1 also were identified as hits (Hallstrom, 
Katzmann et al. 1998). This was proof-of-principle that using ABC transporter 
levels in the plasma membrane is a valid screening methodology. 
 (c). Lack of appearance of putative positive controls 
It is noteworthy that some positively controlled genes did not come up as hits in 
our screen. These were GAL11, YRR1, and ELM1. Gal11p is a subunit of the RNA 
polymerase II mediator complex and is known to be a mediator required for Pdr1p 
and Pdr3p function in the PDR response (Thakur, Arthanari et al. 2008; Shahi, 
Gulshan et al. 2010) and to have physical interactions with both transcription 
factors. In the current studies, some mediators such as ROX3 and SRB8 scored 
as hits as expected. The reason why GAL11 did not appear as a hit neither in the 
primary screen nor in the spot dilution assays might be due to alternative 
pathways and/or replacement of Gal11p by other mediators. The possible 
alternative pathways will be discussed below.  
YRR1 is Zn2Cys6 zinc-finger transcription factor and was shown to contribute to 
multidrug resistance via binding to the promoter of Snq2p and Yor1p. A mutant in 
YRR1 was shown to confer resistance to a variety of compounds such as 
revoromycin A, 4-NQO, and oligomycin (Cui, Shiraki et al. 1998). The YRR1 
deletion was expected to record as a hit in the Yor1p reporter screen but not in the 
Pdr5p reporter screen. However, we did not get YRR1 as a hit in the Yor1p 
reporter screen against atorvastatin. One explanation for this might be that Yrr1p 
is not needed in the atorvastatin response or it could be that Yrr1p acts 
downstream of Pdr1p/Pdr3p and the requirement of Yrr1p can be bypassed as 
long as Pdr1p/Pdr3p are present. YRR1 is autoregulated and contains the PDRE 
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in its promoter. It has been suggested that Pdr1p controls the expression of YRR1 
and might use Yrr1p as a way to amplify its signal to the overlap targets between 
Pdr1p/Pdr3p and Yrr1p (Zhang, Cui et al. 2001; Gavin, Aloy et al. 2006).  
The lack of appearance of some genes expected as positive controls means that 
the set of genes recorded as hits will be a minimal list only, suggesting some other 
condition may also necessary in our screens to pick up all the genes involved.  
Another explanation is that these gene functions can be bypassed by alternative 
parallel pathways. 
 (d). Validation of primary screen hits using spot dilution growth assays 
All the 54 primary screen hits were subjected to spot dilution assays with various 
compounds to make sure that the 54 deletion genes (Table 4-3, Figure 4-6,Figure 
4-7, and Figure 4-8) we obtained as hits were not specific to the atorvastatin 
response alone. It must be emphasised that spot dilution assays measure growth 
sensitivity rather than Pdr5p abundance as is measured with the PDR5-GFP and 
Western blot analyses. Growth analysis therefore measures the overall ability of 
cells to deal with xenobiotics, which may be affected by factors other than Pdr5p 
abundance, and the ability to pump out the xenobiotics. Additional factors might 
include other ABC pumps such that gene deletions in the spot dilution assays 
might not be affecting Pdr5p but might be increasing sensitivity towards 
compounds because of decrease in abundance of other pumps such as Snq2p, 
Yor1p. Relating to Pdr5p, however, Δbmh1, Δgtr2, Δpdr1, Δrox3, Δspt7 all showed 
reduction in Pdr5p abundance in Western blots (Table 4-3) these genes will be 
further discussed below in the Western blot results. With these reservations, we 
conclude that the spot dilution assays did in general validate the primary screen. 
In the spot dilution assays 26 gene deletions out of the 54 identified in the primary 
screens showed some form of xenobiotic sensitivity. Of these, 5 genes displayed 
sensitivity when deleted as single genes (Δxxx), 10 displayed sensitivity as both 
single deletion and extra sensitivity in Δpdr1Δpdr3 background (Δxxx Δpdr1Δpdr3). 
Eight genes showed sensitivity only in the absence of PDR1 and PDR3 (Δxxx 
Δpdr1Δpdr3) and 3 genes displayed negative genetic interactions when deleted in 
Δpdr1Δpdr3 background (Δxxx Δpdr1Δpdr3, did not grow in rich media) (Table 
4-3).  It can be concluded that some gene deletions caused extra sensitivity in the 
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Δpdr1Δpdr3 background, which by definition must be a PDR response that is 
different to that controlled, by PDR1 and PDR3.  
When spot dilution assays were carried out to test for xenobiotic sensitivity in 
these single deletion backgrounds, we were surprised to see that Δpdr1, a deletion 
in a main PDR transcription factor, only caused sensitivity to atorvastatin. By 
contrast, Δume6 was sensitive to nearly all xenobiotics including atorvastatin, 
similarly for Δsrb8, and Δspt7. Some genes such as Δrho4, and Δbem2 which 
have no known function on transcriptional activity themselves conferred sensitivity 
to a greater variety of compounds than did Δpdr1. Deletion of PDR3 alone did not 
show sensitivity toward any compounds in the concentrations used. Perhaps, this 
is because Pdr1p and Pdr3p functions overlap and compensate for each other‘s 
activity. Our results clearly suggest that PDR1 and PDR3 are not the sole 
contributors to the PDR phenotype and there are upstream modulators required 
for a PDR phenotype to be fully developed.  
Other noteworthy points are, first, that genes that are involved in a pathway that is 
affected by the xenobiotics will show sensitivity toward those xenobiotics when 
deleted (Table 4-3). For example, gene deletions that conferred sensitivity toward 
oligomycin by inhibiting ATPsynthase in the electron transport chain tend to 
involve in mitochondrial function, and metabolism (SNF4, YME1, and OPI3). Again, 
this result reinforces the importance of chemical-genetic interactions as a powerful 
tool to identify the drug-target pathway and drug mode-of-action as previously 
mentioned in Chapter 3. In that chapter, we concluded that neo affected vacuole 
formation and the endocytosis pathway as indicated by enrichment of ESCRT 
complex in the neo chemical-genetic profile. Secondly, gene deletions, which 
displayed sensitivity toward multiple xenobiotics, tend to involve signal 
transduction and transcriptional control (Table 4-3) (e.g. BEM2, RHO4, GCN5, 
SPT7, SRB8, and UME6). This result strongly suggests an involvement of 
upstream signalling pathway in PDR response. 
 (e). Western blot analysis of reporter protein abundance. 
Gene deletions that reduced the abundance of Pdr5p were Δpdr1 and Δpdr3, 
Δrox3, Δspt7, Δgtr2, Δbmh1, Δlge1, Δspt8, Δdep1, Δhsp82. These reductions 
were specific to the particular gene deletions and not a pleiotropic effect as Pma1p, 
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another plasma membrane protein, displayed no alteration as a function of these 
gene deletions. With the exception of Δhsp82, all of these gene deletions 
appeared in the list of hits in the primary screen (Pdr5p-GFP/Yor1p-GFP) albeit 
Δlge1 and Δspt8 at a slightly lower confidence level in only 2 screens out of 3 and 
Δdep1 appearing only in the Pdr5p-GFP screen. All of these genes, except LGE1, 
are transcription factors, have role in transcriptional activators or as chromatin 
remodelling complexes affecting transcription. Such observations lead to the 
suggestion that the PDR phenotype involves a specialised transcriptional 
regulatory unit. The fact that LGE1, whose function is unknown and HSP82 also 
appear in this list of gene deletions suggest they must have an allied function.  The 
notion that the PDR response involves a specialised  transcription unit as distinct 
from say simple interaction of xenobiotics with Pdr1p/Pdr3p transcription factors is 
discussed further below when evidence of signalling gene involvement is also 
taken into account.     
It is of note that Δpdr1 or Δpdr3 alone reduced but did not abolish the amount of 
Pdr5p as seen by the Pdr5p/Yor1-GFP intensity screen and from Western blots 
(Figure 4-10). Deletion of PDR1 had a stronger effect on the reduction of 
expression of PDR5 than did the deletion of PDR3. This effect is due to the fact 
that PDR5 expression is known to be more Pdr1p-dependent than Pdr3p (see 
Introduction) and that Pdr1p also has transcriptional control over the expression of 
PDR3. However, the combined deletion of both PDR1 and PDR3 reduced cellular 
abundance of Pdr5p to non-detectable levels by Western Blot but still could be 
detected using PDR5-GFP in the Δpdr1Δpdr3 background (Figure 4-10). The 
difference might be because Western Blots are not as sensitive as the GFP 
intensity quantitation in the microscopy screen.   
Section II: Gene deletions that show negative genetic interaction with 
Δpdr1Δpdr3 
A number of gene deletions appeared as negative genetic interactions with 
Δpdr1Δpdr3 suggesting that the deletions are components of a different pathway 
to that controlled by PDR1/PDR3. As an example, supporting this interpretation 
Δrox3 resulted in negative genetic interaction with Δpdr1Δpdr3 as well as reducing 
Pdr5p in the Western blot analysis while deletion of genes in the general SAGA 
complex such as SPT7 and GCN5 did not. However, deletion of other mediators 
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such as SRB8 and GAL11 which directly interact with Pdr1p/Pdr3p (Thakur, 
Arthanari et al. 2008; Shahi, Gulshan et al. 2010) did not result in negative genetic 
interaction with Δpdr1Δpdr3 implying that ROX3 mediates a compensatory 
pathway for PDR1/PDR3 different to the Gal11p involvement.  
We also found that deletion of RCY1 resulted in a negative genetic interaction in 
the Δpdr1Δpdr3 background suggesting that Rcy1p compensate for the loss  of 
function of Pdr1p/Pdr3p. Rcy1p is an F-box protein involved in recycling plasma 
membrane proteins  and  signal transduction (Craig and Tyers 1999). Since Rcy1p 
is involved in recycling plasma membrane protein involving SNAREs and 
endocytosis, deletion of RCY1 would have an effect on the localisation of any 
signal receptors on plasma membrane as well as the ABC transporters. 
Preventing internalisation of receptors and recycling of transporters might ablate a 
putative signal from toxic compounds to Pdr1p/Pdr3p use.  This would result in a 
build-up of lethal toxic metabolites inside the cells (Wolfger, Mahe' et al. 1997; 
Rogers , Decottignies et al. 2001; Jungwirth and Kuchler 2006; Sipo and Kuchler 
2006; Kuchler and Schüller 2007; Paumi, Chuk et al. 2009). Rcy1p function in 
endocytosis mi 
Negative genetic interactions observed between Δkap123 and Δpdr1Δpdr3 was by 
comparison unexpected because while deletion of both ROX3 and RCY1 alone 
result in increased sensitivity towards many compounds tested, deletion of 
KAP123 alone did not result in increase of sensitivity toward any compounds 
tested. KAP123 encodes for karyopherin beta, which mediates nuclear import of 
ribosomal proteins prior to assembly into ribosomes and is involved in import of 
histones H3 and H4 (Mosammaparast, Guo et al. 2002; Sydorskyy, Dilworth et al. 
2003).  
 The negative genetic interaction might be due to the fact that Kap123p is required 
for mediating nuclear import of many proteins. KAP123 shows genetic interaction 
with the essential gene PSE1, where a double mutant Δkap123 Δpse1 blocks 
mRNA export from the nucleus. PSE1 encodes another karyopherin/importin that 
interacts with the nuclear pore complex and acts as a nuclear import receptor for 
specific proteins, including Pdr1p, Yap1p, Ste12p, and Aft1p (Seedorf and Silver 
1997; Delahodde, Pandjaitan et al. 2001; Isoyama, Murayama et al. 2001; Ueta, 
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Fukunaka et al. 2003). All of these proteins are transcription factors. Pdr1p and 
Yap1p as discussed previously are involved in multidrug resistance, Ste12p is 
transcription factor activating the kinase-signalling cascade controlling growth and 
mating and Aft1p is an iron-responsive transcription factor.   
Though the negative genetic interactions reported here resulted in a no-growth 
phenotype, tetrad dissections need to be conducted to confirm the synthetic 
lethality of these genes with Δpdr1Δpdr3. 
Section III. Signalling pathway related genes that were identified by the 
screens 
 
Genes involved in signalling pathways, such as Rho-GTPase, Ras, and  MAPK 
were also noticeably enriched in our screens (Figure 4-13). This finding 
complements our LOPAC screen result in which many of the compounds that 
upregulated our ABC-reporters are also known signalling and kinase inhibitors 
(listed below). Similar complementary results have been observed in C. albicans. 
LaFayette et al. (2010) showed that protein kinase inhibitors in a LOPAC screen 
which have little toxicity on their own, enhanced the toxicity of fluconazole in C. 
albicans, leading them to propose that kinase signalling regulates multidrug 
resistance in this pathogenic yeast species (LaFayette, Collins et al. 2010). These 
Figure 4-13: Signalling genes in the network of genes for PDR secondary validation  
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data combined with the screening results reported here strongly suggest that 
kinase-signalling pathways are involved in controlling the PDR phenotype. 
The observations from both LOPAC and PDR screens further support the notion 
that there are alternative pathways contributing to the PDR phenotype beside 
PDR1 and PDR3. These compounds (Table 4-5) might either amplify the ―signal‖ 
of Pdr1p/Pdr3p or relay the signal in the presence of xenobiotics, or may be 
involved as general stress responders when PDR1 and PDR3 are absent.   
 
All genes that are involved in the signalling category except RHO4 upregulated the 
Pdr5p (and Yor1p) pumps independent of Pdr1p/Pdr3p function.  
Most of the genes in this category seen in the primary screen are involved in Rho-
GTPase activating kinases (BEM2, RHO4, SNF4), PKA, Ras-MAPK (BMH1). GO   
analysis performed on the gene deletions that caused sensitivity in the spot 
dilution assay showed significant enrichment in genes involved in enzyme 
activation and protein binding. These genes are BEM2, BMH1, and SNF4 (p-value 
0.03599). This adds to the suggestion that a signalling pathway, probably kinase 
proteins (RAS/ MAPK), are required to relay the xenobiotic information sensed at 
the plasma membrane to the Pdr1p/Pdr3p in the nucleus. 
Table 4-5: LOPAC compounds that activate PDR reporters and inhibit 
signalling-related pathways or molecules 
Compounds Mode-of-action 
Farnesylthiosalicylic acid  Non-toxic Ras inhibitor  
3-alpha,21-dihydroxy-5-alpha- 
pregnan-20-one 
Positive allosteric modulator of GABA-A 
receptors 
Dequalinium analog, C-14 linker Protein kinase C-alpha (PKC-alpha) 
inhibitor 
N-phenylanthranilic acid Cl- channel blocker 
7-cyclopentyl-5-(4-phenoxy) phenyl-
7H-pyrolo 
Potent and selective Ick (src family tyrosine 
kinase) inhibitor. 
DL-stearoylcarnitine  chloride Protein kinase C (PKC) inhibitor 
SU 6656 Selective Src family kinase inhibitor 
U0126 Specific inhibitor of MEK1 and MEK2 (MAP 
kinase kinase; MAPKK) 
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PKC and MAPK kinases are involved in the regulation of many stress responses  
and  transcription factors such as Msn2p, Skn7p are involved in osmolarity, 
general stress, salt stress and oxidative stress (Ikner and Shiozaki 2005). 
However, Ras and PKC have not yet been shown to regulate the PDR response. It 
is likely that PKC and MAPK can also activate Pdr1p/Pdr3p directly or via other 
stress transcription factors. For example, Ssz1p is shown to positively regulate the 
function of Pdr1p but not Pdr3p. It also regulates PDR1-dependent PDR5 and 
YOR1 expression (Hallstrom 1998). However, the exact mechanism by which 
cytoplasmic Ssz1p could control Pdr1p in the nucleus is not clear. Hallstrom and 
Moye-Rowley 1998 suggested that there might be a signalling pathway between 
Ssz1p and Pdr1p.  Gavin et al 2006 showed that Ssz1p physically interacts with 
Bem2p, a Rho GTPase activating protein (Gavin, Aloy et al. 2006). It is likely that 
Bem2p relays the regulatory signal from Ssz1p to the subunit of chromatin 
modification complexes, Gcn5p with which it physically interacts (Lee, Sardiu et al. 
2011).   
Another mechanism by which signalling could contribute to PDR is by providing 
backup mechanisms to detoxify xenobiotics. It is possible that Cwh1p and Bmh1p 
will play this role. Our reasoning is as follows: Cwh1p is a putative 
sensor/transporter, and deletion of this gene is synthetic lethal with ∆pkc1, 
suggesting that Cwh1p is involved in PKC1 signalling. Protein Bmh1p is a 14-3-3 
protein that in yeast is thought to function in signal transduction, via Ras/MAPK 
signalling (Burbelo and Hall 1995; Bruckmann, Hensbergen et al. 2007). We 
propose that Cwh1p might sense the signal and relay it to Bmh1p. This Bmh1p 
could be a signal switcher acting to distinguish the signalling response in cells 
encountering ABC-transporter substrates from those that do not. Bmh1p also 
plays a role in vesicle transport activating the process of compartmental 
detoxification where toxins are sequestered into the vacuole. In the presence of 
xenobiotics, Bmh1p may relay signals via Ras/MAPK which autophosphorylates 
the transcription factors or chromatin modification network and activates the 
classic PDR response upregulating pumps or other stress response transcription 
factors such as Msn2p. and Skn7p. Both of these transcription factors have 
recognition sequences in the promoter regions of both PDR5 and SNQ2 as well as 
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other major facilitators (Harbison, Gordon et al. 2004; Venters and Pugh 2009; 
Biggin 2011).   
Section IV: Genes involved in RNA-transcription activation (transcription 
factors, mediator subunits, chromatin modification complexes) 
 
 
Additional genes that work independently of PDR1 and PDR3 but that also 
contribute to the PDR phenotypes were revealed quite unexpectedly. These genes 
mainly involve transcriptional regulation, either as transcription factors, mediators, 
via SAGA transcriptional regulatory complex, or in chromatin modification, and 
seemed to be activated in response to stress.  GO function analysis of the genes 
shown in Table 4-2 using the SGD GO analysis tool (www.yeastgenome.org) 
showed significant enrichment in transcriptional activity and co-activation which 
were PDR1, PDR3, UME6, SWI4, SKN7, RSF2, RTG1, ROX3, SRB8, SSN2, and 
GCN5 .  
Out of these genes, 3 of them (ROX3, SRB8 and SSN2) function as subunits of 
the RNA polymerase II mediator complex. Srb8p physically interacts with Pdr3p 
and deletion of SRB8 (Δsrb8) renders cells that have lost the mitochondrial 
genome (ρ0 cells) to become sensitive to cycloheximide (Shahi, Gulshan et al. 
2010). We found that deletion of SRB8 also resulted in hypersensitivity in strains 
Figure 4-14: transcriptional controlling genes in the network of genes for PDR secondary 
validation 
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with intact mitochondrial genome (ρ+ ) and not just in ρ0 cells as reported 
previously (Shahi, Gulshan et al. 2010), suggesting that Srb8p might have more 
roles in the PDR phenotype than anticipated. 
In the primary screen of deletions that prevented up-regulation of ABC-pumps,   
there were 7 regulatory transcription factors (PDR1, UME6, SKN7, PDR3, HMS2, 
RTG1 and RSF2 see Figure 4-4) all of which have potential in controlling the PDR 
response. However, only deletion of PDR1 and UME6 resulted in an increase in 
growth sensitivity towards one or more of the 6 compounds at the concentration 
we tested. Deletion of PDR1 caused a reduction of Pdr5p in the Western blot 
assay while Δume6 did not. The presence wild-type copy of PDR1 PDR3 might 
mask the effect of these transcription factor gene deletions, and /or they might be 
regulated by Pdr1p/Pdr3p which would explain why no additional sensitivity to the 
compounds was seen. 
Ume6p is key transcriptional regulator of early meiotic genes. Deletion of UME6 
causes a decrease in resistance toward many compounds such as rapamycin, 
ethanol, cycloheximide, sulfometuron methyl, lovastatin (www.yeastgenome.org) 
but the link between UME6 and drug resistance has not been shown previously. 
Deletion of UME6 (Δume6) resulted in a more severe growth defect toward many 
more compounds than did deletion of PDR1. In fact Δume6 Δpdr1 Δpdr3 was 
more sensitive towards all the compounds tested than Δpdr1 Δpdr3. However, 
Δume6 did not cause a reduction in Pdr5p as detected by Western blot analysis 
probably because Ume6p controls other ABC pumps than Pdr5p. Indeed Ume6p 
has a recognition sequence in front of the YOR1 promoter (Harbison, Gordon et al. 
2004).    
Already discussed above are other major components of this group namely 
chromatin modification complexes SAGA/ADA subunits as well as  subunits of the 
RNA polymerase II mediator complex and a transcriptional activator cimplex 
(SPT7, GCN5, ROX3, SRB8, and SWI4)  where we discussed compelling 
evidence that their involvement is PDR-specific and not a global response. 
The recognition site of Swi4p has been found in the promoters of SNQ2 and PDR5, 
and some of the major facilitators. Skn7p which is controlled by the SWI complex 
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and MAPK also has recognition sites on SNQ2, PDR5 and YOR1 (Harbison, 
Gordon et al. 2004; Workman, Mak et al. 2006; Venters and Pugh 2009). Although, 
we cannot exclusively said that Swi4p control these pumps based on the 
recognition sites on the promoters alone, it give us a good hint of what might 
actually happen. The SAGA, SWI/SNF chromatin modification complex though 
often global in function may provide cells with a specific minor backup pathway for 
Pdr1p/PDr3p. We propose that in the absence of the major regulator Pdr1p/Pdr3p 
these minor regulator components become essential.  Both SPT8 and SWI4 show 
negative genetic interactions with GAL11, strongly supporting our proposal that the 
SAGA and SWI complexes provide cells with an independent alternative pathway 
to achieve the PDR phenotype, maybe by bypassing the requirement of Gal11p or 
Pdr1p/PDr3p altogether. This could explain why GAL11 does not appear as a hit in 
our primary screen or spot dilution as expected. This hypothesis also explains the 
observed results that most of the strains containing deletion of genes in this 
category were sensitive to xenobiotics and become hypersensitive in Δpdr1Δpdr3 
background.  
Venters and Pugh 2009 found that spatial assembly of the transcription machinery 
and chromatin regulators at promoters can result in altered gene expression 
dependant on the signal received (Venters and Pugh 2009) (Figure 4-15).   It 
seems likely to us that interactions of such major and minor contributors with 
spatial variation could be the basis of transcription factors selectivity in responses 
to different xenobiotics. 
 
Figure 4-15: Spatial assembly of the transcription machinery 
Spatial assembly of the transcription machinery and chromatin regulators has major effect 
on gene expression and transcriptional activity. Figure from (Venters and Pugh 2009) 
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Section V: Lipid pathway genes 
In describing the GO category groups emerging from the screens described here, 
it became apparent that the genes most dependent on Pdr1p/Pdr3p are involved 
in sphingolipid and phospholipid homeostasis. Besides structural functions 
sphingolipids and phospholipids are known to be involved in signalling (Sun, 
Taniguchi et al. 2000; Friant, Lombardi et al. 2001; Hannun and Obeid 2008). 
Another category is mitochondrial status which can be linked to stress response 
signalling (Manoli, Alesci et al. 2007). Mammalian cell lines which display a 
multidrug resistant phenotype show an increase in sphingolipid in the cell 
membrane and these cell lines show a change in ceremide regulation, a pro-
apoptotic signal (Sietsma, Veldman et al. 2001). However, the link between 
sphingolipid/phospholipid signalling and PDR is less well understood in yeast.  Liu 
and Sharom 1998 also showed that there is energy transfer between the ATP-
binding domain of the ABC-transporter and phosphatidylethanolamine derivatives 
which is sphingolipid ceremide-based using fluorescence resonance (Liu and 
Sharom 1998). Our results suggest that the link between sphingolipid and PDR , 
and genes like DPL1 which encode dihydrosphingosine phosphate lyase should 
be further investigated. 
Section VI: Genes predicted to be involved in the mediation/ modulation of 
the PDR response via network interaction 
It has been shown that genes which interact with one another in the network tend 
to work in the similar pathway or have similar function and can buffering each 
other mutation effects (Tong, Evangelista et al. 2001; Tong, Lesage et al. 2004). 
To investigate if genes that interact (physically and genetically) with our ―hit‖ genes 
might be involved in modulating PDR phenotype, we performed xenobiotics spot 
dilutions and Western Blots. To maximise the chance of identifying genes that 
have major effect on the PDR phenotype, and not just downstream transporters, 
we only tested deletion of genes that interact with our enrichment genes (e.g. 
Chromatin remodelling complex, signalling genes), and with PDR1 PDR3. Most of 
these genes also have just missed the ―cut off‖ of being identify as hits in the 
primary screen. 
Out of the 18 gene deletions we tested 10 displayed either increases in xenobiotic 
sensitivity when deleted or reduced Pdr5p abundance in Western blot or both. 
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These genes are ADA2, DEP1, ERG3, HEK2, HEX3, HSP82, LGE1, MNN10, 
NGG1, and SPT8. Six of these 10 genes showed xenobiotic hypersensitivity when 
deleted, and 4 of the 10 (with all but one overlap) caused a reduction in Pdr5p 
abundance when deleted (Table 4-4).  Ngg1p has been shown to interact with the 
transcriptional activation domains of Pdr1p and Prd3p (Martens, Genereaux et al. 
1996) and partially requires Ada2p. Nevertheless, this result comes from a 
prediction of PDR-functionality and strongly supports the role of transcription 
factors other than PDR1 and PDR3, regulators, mediators in providing 
mechanisms for PDR response. These results also highlight chromatin 
modification as a specific response being not just a global pleiotropic 
transcriptional effect. 
One gene that we found to be the odd one out was LGE1. Deletion of this gene in 
any background did not increase sensitivity towards any of the compounds tested 
but reduced Pdr5p abundance (Figure 4-10). LGE1 is an uncharacterised gene but 
may have a role in conveying a message between damaged mitochondrial and the 
nucleus in ρ0 cells (Gulshan, Schmidt et al. 2008) and in histone H2B 
ubiquitination. Deletion of LGE1 also causes a decrease in PDR3 expression in ρ0 
cells. Importantly, LGE1 displays phenotypic suppression with PDR3. 
Overexpression of PDR3 can bypass the requirement of LGE1 for PDR5 activation 
in ρ0 cells (Zhang, Kolaczkowska et al. 2005). More importantly, LGE1 displays 
negative genetic interaction with GAL11, suggesting that Lge1p can compensate 
for the loss of GAL11, or provide an alternative pathway to achieve PDR 
phenotype. This might be the reason why GAL11 did not come up as positive hit in 
the primary screen. Together this evidence points towards an important role of 
Lge1p in the PDR response that might include the link between mitochondrial 
stress and activation of PDR by upregulation of PDR5 in a Pdr3p-dependent 
manner. We also show here the power of our genome-wide screen and interaction 
network in helping to ascertain the function of novel genes.   
 
Conclusion 
In conclusion, we used ABC-transporter proteins labelled with GFP as real-time 
reporters of the activation of Pdr1p and Pdr3p. The reporters were expressed in 
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the S. cerevisiae genome deletion array genetic background (about 4500 strains), 
then treated with atorvastatin as a quintessential xenobiotic activator of PDR. We 
assayed for gene deletions that prevented normal up-regulation of Pdr5p-GFP and 
Yor1p-GFP in the presence of the drug by high-throughput quantitative confocal 
microscopy. From this primary screen, we observed that 54 genes deletions 
caused failure to upregulate our reporters. When we further tested these mutants 
in spot dilution assays 26 showed sensitivity towards the panel of 6 compounds 
tested. When we assessed the known functions of these 26 genes we found four 
different groups into which these genes fell. These are kinase/ Rho-GTPase 
signalling (BMH1, SNF4, SSZ1, BEM2, RHO4, GTR2, RPN10), 
mitochondria/phospholipid/sphingolipid and membrane integrity (RCY1, CWH43, 
MDM39, PIB2, OPI3, PSD1, FMC1, YME1, DPL1), mediators (SRB8, ROX3), and 
chromatin modification/transcriptional activators/regulators (UME6, PDR1, PDR3, 
SWI4, KAP123, SPT7, GCN5, PIN4). Our results show that there must be other 
pathways, which can compensate for the loss of PDR1 and PDR3 and contribute 
to the PDR phenotype. For one, a signalling pathway and a context-specific 
chromatin remodelling must be involved, demonstrating an underappreciated role 
of signalling pathways in the PDR response (Figure 4-16). Presence of xenobiotics 
could possibly activate the kinase/GTPase MAPK stress response signalling. This 
signalling is then received by the SAGA/ chromatin remodelling complex as well as 
RNA polymerase II mediator complex. These complexes then recruit onto the 
PDR1 PDR3 promoters and switch on their expression. Pdr1p/Pdr3p can then 
activate many ABC-transporters and major facilitator genes. Xenobiotics are then 
pumped out of the cell. At the same time that this happens or when PDR1 and 
PDR3 are absent, the alternative pathways can be switched on as backups. 
Different stress-response transcription factors can be switched on in the presence 
of xenobiotics depending on the modifications to the SAGA complex or what 
subunits of RNA Pol II are recruited (represented by different colours in Figure 
4-16). These TFs can then switch on the same target genes as Pdr1p/Pdr3p or the 
new sets of genes such as lipid , sterol, phospholipid/sphingolipid which can then 
change the membrane integrity and affect the xenobiotics uptake. Loss of 
mitochondrial genome (ρ0) can also activate the PDR response probably involving 
Lge1p (retrograde response). Other modulators in the PDR response also include 
members of the Hsp70 and Hsp90 protein families as well as ubiquitination 
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proteins. Here, we have shown that it is very likely that there are upstream 
signalling pathway(s) to Pdr1p/Pdr3p, and that PDR responses can be achieved 
via compensatory pathway that are independent of Pdr1p/Pdr3p. 
Many other open questions still remain about what may regulate Pdr1p/Pdr3p and 
contribute to PDR response. We found many proteins with unknown molecular 
function such as Cwh43p, a putative sensor/transporter containing several 
glycosylation and phosphorylation sites, which potentially can be used as 
regulatory sites during signal transduction. In the future we would like to generate 
hyperactive mutant form of PDR1 (pdr1-3) that increase Pdr5p expression, and 
see if any of the hit genes reported will reduce Pdr5p expression in this mutant 
background. In theory those genes should be up-stream of Pdr1p. 
Our method can be adapted to many other cellular pathway systems to identify 
potential regulators, both activators and suppressors. This assay, done in live cells, 
can be used to investigate morphological changes due to mutations or chemicals 
per cells and quantify them. 
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Figure 4-16: Possible alternative pathways to activate the PDR response in S. cerevisiae.  
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Chapter 5. Use of a Yap1p-GFP reporter to investigate 
relationships between oxidative stress and PDR 
Introduction 
As described in the Introduction (Chapter 1), there is good reason to search for 
overlap of regulatory and other genes between stress pathways-such as the PDR 
pathways and the oxidative stress pathways. We investigated whether different 
stress inducing agents activated the same ―sensors‖, or whether  ―sensors‖ are 
specific to different agents. As outlined, YAP1 is a key oxidative response gene to 
study from this standpoint. 
Normally, oxidative stress response is assessed in three major ways.  First, by 
directly measure cellular ROS such as nitric oxide. Second, by measure the 
resulting damage of oxidative stress to biomolecules, such as DNA damage or 
mitochondrial dysfunction (Halliwell and Whiteman 2004). Third, by detect the level 
of antioxidants such as Glutathione (GSH), the most abundant antioxidant in 
aerobic cells.  However, ROS are hard to detect as they are highly reactive and 
short lived, thus making these methods problematic. Although mitochondrial 
dysfunction and DNA damage phenotypes provide a good oxidative stress 
indicator, they can be caused by many other stresses. Finally, acidification often 
used during protein purification, may also contribute to oxidation of GSH and other 
antioxidant enzymes, resulting in overestimation of the oxidized form of GSH. 
None of these methods, however will directly implicate genes involved in sensing, 
and regulating an oxidative stress response. 
The aim of this chapter was to identify genes involved in Yap1p activation during 
oxidative stress induced by different oxidants using genome-wide, high content 
imaging. To do this, gene deletions were sought that prevent the normal (wild-type) 
nuclear re-localisation of a Yap1p-GFP reporter upon treatment with oxidants. 
Gene deletions that prevented the re-localisation of Yap1p-GFP from the 
cytoplasm to the nucleus in the presence of oxidative stress-inducing agents H2O2 
and/or diethyl maleate were sought, as these are potentially involved in Yap1p 
regulation. The approach in this chapter, therefore, was  to compare the results 
from the Yap1p-GFP screens with the results from the PDR screen to assess 
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commonalities and overlaps between these two screens. It should be noted that 
we also initially tested Yap1p-GFP induction with diamide, but due to greater 
availability and a better phenotype that was obtained with diethyl maleate; we 
chose to use diethyl maleate for the further studies. 
As with the PDR studies, searching for these genes using a genome-wide 
approach means we can explore all the non-essential genes which might buffer 
pathways related to Yap1p. In addition, using Yap1p-GFP as reporter meant we 
can directly observe the real-time transcriptional activation of the oxidative stress 
response, and explore upstream signalling genes that are regulating the process. 
This chapter describes the first genome-wide, high-content microscopy study of   
possible regulators of the oxidative stress response in S. cerevisiae, and how they 
might link Yap1p and the PDR response. 
Materials and Methods 
Compounds and Concentration used 
Hydrogen peroxide, diamide and diethyl maleate were all purchased from Sigma 
Aldrich.  
Hydrogen peroxide was diluted to 10 mM stock in sterile distilled water on the day 
of use. The final concentration in the media was 1 mM. Diamide and diethyl 
maleate stock was made on the day of use in sterile distilled water, with the final 
concentration in the media of 1.5 mM and 2 mM respectively. Cells were incubated 
in 384 well PekinElmer Cell carrier plates with and without drugs at 30˚C for 90 
min.  
Yap1p GFP Reporter Strain/ Screens 
Commercial YAP1 with the C-terminal GFP fluorescent tag from Invitrongen was 
used. This strain was mated against YCG253 (Table 2-2 page 66) and sporulated 
for 7 days at 20˚C. Tetrad dissection and haploid selection was conducted 
according to General Materials and Methods (page 67). The resultant strain was 
YCG379 (Table 2-2 page 66). Cytoplasmic RFP mCherry and RFP with NLS were 
used as internal controls. 
To investigate the modulators controlling Yap1p transcriptional activity, YCG379 
was mated against the deletion mutant array as described in the PDR screen 
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according to the General Materials and Methods page 67. After final haploid 
selection, the cells carrying the deletion and the Yap1p-GFP reporter were then 
subjected to 1 mM hydrogen peroxide, or 2 mM diethyl maleate and incubated for 
90 min at 30˚C before imaging in the PekinElmer OperaR High content microscope 
with the settings as described (General Material and Methods page 71) 
Data analysis 
As with the PDR screen, images were analysed using Acapella software (script 
modified by Peter Bircham). For the peroxide screen (in which nuclear localisation 
was very clearly observed in the treated experiments), the ratio between 
 was calculated. A ratio of 1 means that there was no difference 
between the H2O2 treated cells and the control. Deletion of HIS3 (Δhis3) is a 
control commonly used in gene deletion screens as it has no effect on the process 
of interest. The deletion set contains a border of Δhis3 colonies on each plate as a 
control.  The ratios of nuclear GFP between control and treated cells (equation 
above) of all Δhis3 colonies were averaged and the standard deviation was 
calculated. Gene deletions were considered ―hits‖ if the nuclear GFP ratio was less 
than 2 standard deviations from the mean ratio of the average control Δhis3 (That 
is, deletion of the gene prevented normal ―wild-type‖ nuclear localisation of Yap1p 
following H2O2-induced-oxidative stress response). If there was no nuclear 
localisation of Yap1p-GFP in treated cells, it is suggested that the deletion these 
cells are carrying is a modulator of the transcriptional activity of Yap1p.  
For the diethyl maleate screen, Texture Analysis using the Acapella Software was 
used for analysis, as treatments resulted in the nuclear localisation of Yap1p-GFP 
as well as punctate staining in the cytoplasm (Texture analysis page 71). The ratio 
of  f the treated and control samples for each gene deletion was 
calculated. The Z-score of the difference between the ratio of treated and control 
was then calculated (Z-score formula was given in the General Material and 
Methods page 71). A Z-score of zero mean there is no difference between cells 
treated with diethyl maleate and the untreated control cells. Gene deletions 
resulting in Z-scores below 4.5 were considered as ―hits‖ and correspond to genes 
control
Treated
NuclearGFP
NuclearGFP
FPCytoplasmG
NuclearGFP
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which modulate the transcriptional activity of Yap1p in the diethyl maleate-induced 
oxidative stress response. 
Yap1p-GFP pulse chase experiment 
Cells containing  the Yap1p-GFP reporter were subjected to 1mM H2O2 for 10 
minutes then 100 µg/ml cycloheximide was added to stop protein synthesis of new 
Yap1p-GFP i.e. the protein synthesis effects of the oxidation were ―chased‖.  
Under chase conditions, cell images were taken every 15 min for 6 h using the 
automated PerkinElmer Opera® High Content confocal microscope. These images 
were analysed using Acapella software to measure GFP intensity in the cytoplasm 
and the nucleus. 
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Results 
Yap1p-GFP reporter behaviour in the presence of oxidants 
 We found that Yap1p with C-terminal GFP reporter localised to the cytoplasm in 
non-treated cells and localised to the nucleus upon H2O2 treatment (Figure 5-1). 
Therefore, it may be concluded that the GFP-tag at the Yap1p C-terminus does 
not interfere with the normal localisation of the transcription factor. The nuclear 
localisation was specific to the oxidative stress response since Yap1p-GFP treated 
with atorvastatin (PDR-stress) did not result in nuclear localisation. 
In diamide and diethyl maleate treatments, (both of which are free thiol oxidizing 
agents) the Yap1p-GFP reporter localised to the nucleus with some punctate spots 
in the cytoplasm. Diethyl maleate resulted in more complete Yap1p nuclear 
localisation than diamide (Figure 5-2). Due to both the availability and diethyl 
maleate resulted in more complete nuclear localisation of the Yap1p-GFP reporter, 
diethyl maleate, and not diamide, was used for screening in this dissertation. 
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Figure 5-1: Yap1p-GFP reporter treated with different oxidants.  
Yap1p-GFP with no oxidant treatment localised to cytoplasm. With oxidants, Yap1p-GFP 
localised to nucleus. The reporter contains cytoplasmic mCherry and a RedStar2-nuclear 
localisation signal (NLS) as an internal control. Atorvastatin (35 µM) was used asnegative 
control. 
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Yap1p -GFP reporter peroxide (H2O2) and diethyl maleate screens 
In order to identify possible regulators/modulators of Yap1p in the oxidative stress 
response, we screened the S. cerevisiae deletion set for deletions that prevent the 
normal Yap1p-GFP nuclear localisation upon treatment with oxidants.  
Example of gene deletions which resulted in cytoplasmic retention of Yap1p upon 
peroxide treatment i.e. ―hits‖ are shown in Figure 5-3 and Table A-2 (Appendix I), 
and for diethylmaleate in Figure 5-4 and Table A-3 (Appendix I). The quantitative 
changes caused by the deletions shown in these figures are seen by comparing 
the gene deletion images with the wild-type control (Panel (a) in each figure). 
Corresponding panels show nuclear localisation distinguished by the red 
fH2Ouorescent dye mCherry attached to the nuclear localisation signal (NLS). 
Each oxidant screen was repeated twice and the results were reproducible. There 
were 56 genes recorded as ―hits‖ in the H2O2 treatment and 51 in the diethyl 
maleate treatment.  There was no significant overlap between genes identified in 
the two oxidants screens.  Hits from both screens were enriched in genes involved 
Figure 5-2: The punctate pattern of Yap1p-GFP observed when cells were treated with 
diamide or diethyl maleate. 
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in chromosome/DNA integrity, transcriptional activator/modulation, and genes that 
respond to environmental stresses as showed in Figure 4-5, Figure 4-6, Table 4-1, 
and Table 4-2. 
 
 
 
Figure 5-3 : Examples of gene deletions that prevented normal nuclear localisation of 
Yap1p-GFP upon treatment with 1 mM H2O2.  
a) wt Yap1p-GFP, b) Δada2 , c) Δgpx3 d) Δkap123 , e) Δmms1, f) Δpde2. The reporter 
contains cycloplasmic mCherry and NLS as internal controls. 
Figure 5-4 : Examples of gene deletions that prevented normal nuclear localisation of 
Yap1p-GFP upon treatment with 2 mM diethyl maleate. 
a) wt Yap1p-GFP, b) Δgpx2 , c) Δmms1 d) Δrad54 , e) Δtsa1, f) Δybp1. The reporter contains 
cycloplasmic mCherry and NLS as internal controls. 
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Figure 5-5 : Gene deletions that prevent normal nuclear localisation of Yap1p-GFP upon 
H2O2 treatment.  
Each connection represents a possible regulatory relationship between YAP1 and the 
associated gene. Darker green node represents known regulator of Yap1p.  
 
Figure 5-6 : Gene deletions that prevent normal nuclear localisation of Yap1p-GFP upon 
diethyl maleate treatment. 
Annotations are as described in Figure 4-5.  
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Table 5-1 :GO function enrichment of gene deletions preventing normal nuclear 
localisation of Yap1p-GFP reporter upon H2O2 treatment 
GO term p-values Genes/ORF 
histone acetyltransferase activity 
 
 
0.01693 ADA2/YDR448W 
SAS2/YMR127C 
N-acetyltransferase activity 
 
 
0.04278 ADA2/YDR448W 
SAS2/YMR127C 
ubiquitin-protein ligase activity 
 
 
 
 
 
0.02439 BRE1/YDL074C 
UBR1/YGR184C 
CST9/YLR394W 
UBC7/YMR022W 
 
DNA replication 0.0381 DCC1/YCL016C 
DPB4/YDR121W 
MMS1/YPR164W 
SIR2/YDL042C 
 
phosphoric diester hydrolase activity 0.04813 TDP1/YBR223C 
PDE2/YOR360C 
 
Table 5-2 :GO function enrichment of gene deletions preventing normal nuclear 
localisation of Yap1p-GFP reporter upon diethyl maleate treatment 
GO term p-values Genes/ORF 
RNA polymerase II transcription factor 
binding transcription factor activity involved 
in positive regulation of transcription 
 
0.0026 THI2/YBR240C 
SRB8/YCR081W 
SSN2/YDR443C 
 
response to DNA damage stimulus/DNA 
repair  
 
0.0069 MMS1/YPR164W 
RAD54/YGL163C 
RAD55/YDR076W 
RTT109/YLL002W 
SLX1/YBR228W 
SLX5/YDL013W 
SRS2/YJL092W 
TSA1/YML028W 
 
cellular response to oxidative stress 0.0511 GPX2/YBR244W 
MXR2/YCL033C 
TSA1/YML028W 
YBP1/YBR216C 
 
Note: Some of the gene deletions show GO enrichment in stress response but with p-value 
more than 0.1 (for example GPX3 from H2O2 screen) 
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Pulse chase experiments of Yap1p-GFP Reporter 
From the H2O2 screen, we identified GO enrichment of genes involved in 
ubiquitination and proteolysis. To further test if the ubiqutination process is 
involved in Yap1p regulation, we conducted pulse chase experiments as described.   
Cells labeled with Yap1p-GFP in the cytoplasm were ―pulsed‖ with H2O2 for 10 
minutes and then ―chased‖ in the presence of cycloheximide - inhibiting further 
protein synthesis under these conditions. Thus, all the changes in GFP localisation 
should be correspond to re-localisation of pre-existing Yap1p-GFP. 
If Yap1p transcriptional activity is only controlled by subcellular localisation 
(cytoplasm and nucleus), we should see a decline of Yap1p-GFP intensity inside 
the nucleus and increase of Yap1p-GFP intensity in the cytoplasm over time as 
cells adapt to the oxidative stress. However, if proteolysis is involved either in the 
nucleus or in cytoplasm, we should see Yap1p-GFP intensity decline in these 
subcellular locations over time.  
We found that cytoplasmic Yap1p-GFP stayed constant throughout the experiment 
except in SC (media) controls where cycloheximide was not added. Nuclear 
Yap1p-GFP intensity started to decline 105 minutes after cycloheximide was 
added. The overall Yap1p-GFP (Nucleus+cytoplasm) in the experiment with 
cycloheximide treatment decreased slightly but not significantly over time (Figure 
5-7) 
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Figure 5-7 : Pulse chase experiment of Yap1p-GFP treated with H2O2 
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 Discussion 
Section I: The validity of the reporter 
The Yap1p-GFP localised to the nucleus in an oxidative stress specific fashion. In 
screens for both oxidants, some of the known regulators of Yap1p nuclear 
localisation appeared as ―hits‖, indicating that the screen is functioning correctly. 
The genes were GPX3 in the H2O2 screen and YBP1 in diethyl maleate screen, 
proving that our reporter was valid. 
An interesting result we found was the punctate pattern and partial nuclear 
localisation of Yap1p-GFP in diethyl maleate and diamide-treated cells (Figure 5-1) 
not previously described in the literature. An explanation for this might be that the 
commercial Yap1p reporter in this study has GFP linked to the C-terminus of the 
proteins, whilst in most published studies GFP was linked to the N-terminus. The 
C-terminal of Yap1p is known to contain a cysteine-rich domain and NLS, which 
controls nuclear localisation of the protein upon encountering oxidative stress. 
Disulfide bonds  between cysteine residues in the C-terminus are required for a 
normal response to diamide (Kuge, Arita et al. 2001). Thus, GFP linked to the C-
terminus might have influenced the formation of disulfide bonds in the C-terminus 
during diamide and diethyl maleate response, resulting in partial nuclear 
localisation and the punctate pattern of Yap1p. 
It is noteworthy that H2O2 causes oxidative stress by generating ROS while both 
diamide and diethyl maleate are weaker oxidizers and cause oxidative stress by 
depleting the antioxidant GSH, (Bauman, McKim Jr et al. 1992). Nevertheless, the 
mechanisms of actions for these two thiol-oxidant compounds are different. 
Diamide causes disulfide formation between itself and GSH, resulting in GS-SH, 
which then can modify other proteins (C-GS-SH). On the other hand diethyl 
maleate chemically modifies GSH. This might be another explanation for why 
different phenotypes, with regard to Yap1p nuclear localisation, were observed 
when cells were treated with different oxidants. 
The C-terminal disruption might also be the reason why we did not observe the 
expected lack of nuclear localisation of Yap1p-GFP in Δybp1 cells in the H2O2 
treatment. It may be that the C-terminus GFP has an effect on the minor 
conformational change during the interaction between Ybp1p and Yap1p in the 
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presence of H2O2. This effect seemed to be more specific to H2O2, where disulfide 
bond formation between N- and C- terminus are needed for Yap1p nuclear 
localisation(Delaunay, Pflieger et al. 2002). While in diethyl maleate, no disulfide 
bridge between these two terminals is needed and minor disruption causing by C-
terminal GFP tagged is more forgiving. We think C-terminal GFP-Yap1p can still 
be used as a valid oxidative stress reporter because Yap1p-GFP can still respond 
to oxidants as Δybp1 still prevented Yap1p-GFP nuclear localisation in diethyl 
maleate, and Δgpx3 still came up as hit in H2O2 screen as expected.  As 
mentioned in the introduction, the position of Yap1p disulfide bonds formed during 
oxidative stress is oxidant dependent. Furthermore, the correct conformation is 
essential for nuclear localisation of Yap1p (Coleman, Epping et al. 1999; Kuge, 
Arita et al. 2001; Gulshan, Rovinsky et al. 2005). However, the role of the C-
terminus and N-terminus cysteine rich in Yap1p regulation are still not entirely 
clear. 
We found no significant overlap in hits from these two oxidants screens (Δmms1 
was the only overlap), leading us to believe that cells use different sets of genes to 
regulate Yap1p transcriptional activity in the presence of different oxidants. 
Nevertheless, the general functions of the genes involved in Yap1p regulation are 
similar between the two oxidants screens, with genes functioning mainly in DNA 
repair and genome integrity (mitochrondrial), and mediator and stress responses 
(Table 5-1and Table 5-2). These will be discussed below. 
Section II. Yap1p regulation is part of the DNA repair and DNA integrity 
network. 
Many of the hit genes from both oxidant screens were involved in chromosome 
integrity or DNA repair and showed GO enrichment for these processes (Table 5-1 
and Table 5-2). This might be due to the fact that ROS, which cause oxidative 
stress are a major cause of DNA damage. Pan et al. (2006) showed that the DNA 
integrity network consists of several principal modules involved in DNA replication, 
DNA-replication checkpoints, and the oxidative stress response. All three major 
modules act as guardians against lethal spontaneous DNA damage (Pan, Ye et al. 
2006). The hits identified in this study- CAC2, DCC1, DPB4, TDP1, SIR2, MMS1, 
RTT109, SLX1, SLX5, SRS2, RAD54, RAD55,and TSA1 all have been shown to 
involved in such DNA damage pathways and DNA integrity networks (Pan, Ye et 
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al. 2006; Workman, Mak et al. 2006). Therefore, regulation of Yap1p is linked with 
the chromosome integrity network.  
In addition, Kuge et al. (1997) showed that Yap1p DNA binding capacity was 
moderately increased in the response to DNA damage. They suggested that this 
might involve post-translational modification within the DNA-binding domain in the 
N-terminus of Yap1p (Kuge, Jones et al. 1997). Rowe et al. (2012)  also 
suggested that DNA damage might activate  transcriptional activity of Yap1p 
(Rowe, Degtyareva et al. 2012). The importance of the DNA integrity network as 
part of Yap1p regulation was also emphasized by the fact that our only overlap in 
the two different oxidants screens was MMS1. Mms1p is a subunit of an E3 
ubiquitin ligase complex involved in replication repair (Hryciw, Tang et al. 2002). 
Additionally, Tsa1p which is a known Yap1p target and oxidative stress modulator 
(Inoue, Matsuda et al. 1999), has been shown to involved in the DNA damage 
stress response and DNA repair and might be involved in a negative feedback 
loop controlling ROS, cellular redox state and Yap1p  (Pan, Ye et al. 2006). 
Section III: A different transcriptional activation complex and different 
subunits of RNA polymerase II mediator complex are used for Yap1p 
regulation when exposed to different oxidants  
GO term analysis showed significant enrichment in genes involved in chromatin 
remodelling and the RNA polymerase II mediator complex in both H2O2 and diethyl 
maleate screens. Though the genes mostly differ, this is a similar functional 
enrichment seen with the PDR response. Two genes that overlap in both sets of 
responses are SRB8 and KAP123. In the H2O2 screen, most of the genes 
identified as hits are involved in  transcriptional activation and chromatin 
remodelling such as ADA2 and SWI3, and SAS2  and one subunit of RNA 
polymerase II mediator, SIN4. On the other hand, more RNA polymerase II 
mediator subunits were identified in the diethyl maleate screen, (SSN2, SRB8, and 
MED1) along with the chromatin remodelling complexes (SNF5, ISW1, ASF1) and 
transcription factors (TOS8, MIT1, THI2, and FRA1).  
The SWI/SNF nucleosome-remodelling complex is known to activate genes in the 
stress response and might be controlling the oxidative stress response in the MAP 
kinase pathway (Ikner and Shiozaki 2005). As mentioned in the introduction, ADA/ 
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SAGA complexes have been shown to control transcription of many stress 
response genes, including PDR1 in the multidrug resistance response. 
Interestingly, ROX3, which had been shown to result in H2O2 sensitivity when 
deleted (Gulshan, Rovinsky et al. 2005), was not identified  as a hit in our screens, 
but SIN4 which is another mediator in the same complex was. Our explanation is  
that other mediator subunits like Sin4p and Ssn2p might be more specific to the 
oxidative stress response as Sin4p has been shown to physically interact with 
Yap1p (Gavin, Aloy et al. 2006). Another explanation is that other transcription 
factors or chromatin remodelling complexes can provide the compensatory 
pathway which can bypass the requirement of Rox3p. 
The fact that we identified a different set of genes with similar functions when cells 
were challenged with different oxidants suggested to us that different subsets of 
chromatin remodeling and mediator complexes are used for different oxidants, and 
hence result in a different subset of Yap1p targets being expressed. 
Section IV: Genes involved in ubiquitination might regulate Yap1p and are 
more H2O2 specific 
We also observed that our screens identified many of the genes involved in the 
ubiquitination process. This observation was more pronounced in the H2O2 screen 
than in the diethyl maleate screen. These genes were BRE1 (E3 ubiquitin ligase) , 
UBR1 (E3 ubiquitin ligase), and UBC7 (ubiquitin conjugating enzyme). The 
enrichment of ubiquitination genes was also confirmed by GO enrichment analysis 
(5% level of significance).  
Ubiquitination is used for protein regulation by either tagging them for degradation, 
or modifying them to perform certain functions, such as removing the suppressor 
proteins from active protein complexes (Ciechanover 1994; Ciechanover and Iwai 
2004). One of the hits identified in the H2O2 screen, Ubr1p has been shown to 
control the oxidative stress response via degradation of active Pap1p, a 
homologue of Yap1p in S. pombe (Kitamura, Taki et al. 2011). Constitutively active 
Pap1p in the nucleus can result in growth inhibition in a  ubr1 mutant (Kitamura, 
Taki et al. 2011). Ubr1p has also been found to regulate nitric oxide sensing in 
mammalian cells (Hu, Sheng et al. 2005). In mammals, b-ZIP transcription factors 
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functioning in oxidative stress are regulated via ubiquitination proteolysis in the 
cytoplasm (Kitamura, Taki et al. 2011).  
Our results are consistent with the literature and strongly suggest that Yap1p is 
regulated by Ubr1p, and possibly by other ubiquitination-related proteins. This 
result was also supported by the pulse chase experiment, where we observed the 
decline in Yap1p-GFP intensity over time in the nucleus, but no change in 
cytoplasm. Since cytoplasmic Yap1p-GFP did not significantly change over time, 
we speculated that Yap1p-GFP in the nucleus might be degraded, presumably 
after all the oxidative stress response genes had already been activated. This 
degradation process might involve Yap1p being ubiquitinated before entering the 
nucleus. Nonetheless, ubiquitination seems to give cells another way to regulate 
Yap1p in addition to nuclear transport.  
Our results suggest ubiquitination (involved in protein degradation) plays a role in 
Yap1p regulation and is consistent with Gulshan et al. 2012, whose group recently 
showed that Yap1 degradation is accelerated in response to oxidative stress 
induced by both H2O2 and diethyl maleate (Gulshan, Thommandru et al. 2012).  
Not consistent with their results however, we could see  no GO enrichment for 
ubiquitination genes in the diethyl maleate screen. Gulshan et al 2012 looked at 
degradation after Yap1p had localised to the nucleus and it could be that nuclear 
degradation of Yap1p is a common response toward all oxidants. On the other 
hand, ubiquitination and controlling of Yap1p nuclear localisation is more specific 
to Yap1p regulation in the presence of H2O2. In the future, to test this hypothesis, a 
pulse chase and Yap1p-GFP microscopy experiments using other oxidants or 
conducted in different proteolysis–related mutation backgrounds would be useful. 
Section V: Stress response genes which are targets of Yap1p might provide 
a feedback loop for Yap1p regulation 
 Some genes appearing as hits i.e. causing localisation of Yap1p-GFP in the 
nucleus from the diethyl maleate screen were also genes that are regulated by 
Yap1p, namely TSA1 (thioredoxin peroxidase) and GPX2 (glutathione peroxidase). 
Tsa1p is a thioredoxin peroxidise. It may catalyze the conversion of ROS to H2O 
and the corresponding alcohol, and thioredoxin facilitates the reduction of other 
proteins by cysteine thiol-disulfide exchange (Inoue, Matsuda et al. 1999). Tsa1p 
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was shown to play an important role in the DNA integrity network (Pan, Ye et al. 
2006). It is also essential for the transcriptional induction of other components of 
the thioredoxin system, TRX2 and TRR1, in response to H2O2 in a Yap1p/Skn7p-
dependent manner (Ross, Findlay et al. 2000). In fact, Fomenko et al. (2011) 
showed that thiol peroxidases play a role in regulating global gene expression in 
response to H2O2 by stimulating signalling through a MAP kinase pathway. They 
proposed that thiol peroxidases, including Tsa1p, act as redox sensors and 
oxidative stress signalling-transfer proteins. Therefore, Tsa1p contributes to the 
oxidative stress response by acting as a sensor and relaying the stress signal, as 
well as acting as a ROS scavenger (Fomenko, Koc et al. 2011). 
Another Yap1p target gene that prevented Yap1p-GFP nuclear localisation in the 
presence of diethyl maleate when deleted is GPX2. GPX2 encodes phospholipid 
hydroperoxide glutathione peroxidase, which is a peroxide-scavenging enzyme 
induced by Yap1p and Skn7p (Ikner and Shiozaki 2005). GPX3 which is another 
glutathione peroxidase is involved in regulation of Yap1p in response to H2O2-
induced oxidative stress but does not respond to either diamide or diethyl maleate. 
Gpx2p might act very similarly to Gpx3p in Yap1p regulation because 
overexpression of GPX2 can compensate for the loss of GPX3 to a certain extent 
and thioredoxin (TRX) is an endogenous electron donor for Gpx2p, similar to 
Gpx3p (Tanaka, Izawa et al. 2005). If this is true, then Gpx2p is possibly used by 
cells to distinguish between different oxidants by acting as a thiol-specific 
peroxidase in regulating Yap1p, probably via specific disulfide bonding in the C-
terminus of Yap1p. 
Besides being involved in diamide, and diethyl maleate, GPX2 expression is 
greatly induced by calcineurin-mediated Ca2+ signalling (Tanaka, Izawa et al. 
2005). A rise in intracellular Ca2+ and the presence of the oxidative stress-inducing  
H2O2, leads to leakage of mitochondrial content which in mammals results in 
induction of apoptosis (Valle, Fagian et al. 1993). In S. cerevisiae, it has been 
reported that Tsa1p (mentioned above as having a role in Yap1p regulation), and 
catalase help protect leakage of mitochondria induced by Ca2+ and H2O2 
(Kowaltowski, Vercesi et al. 2000). In addition, Inoue et al., (1999) had shown that 
GPX2 and other glutathione gene expressions are increased in cells lacking Tsa1p. 
They proposed that increased glutathione was used as a backup system in the 
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Δtsa1 mutant, as well maintaining the catalytic cycle of glutathione peroxidase 
reaction (Inoue, Matsuda et al. 1999).  It is therefore likely that Gpx2p, which can 
be used as a thioredoxin peroxidase backup system contributes to Yap1p 
regulation, especially in the presence of thiol oxidizing agents and Ca2+.  
Section VI: Yap1p-GFP screens and PDR screens 
Much literature has been devoted to showing crosstalk between the YAP1 
oxidative stress response transcription factors and PDR ABC transporter genes 
(Wu, Wemmie et al. 1993; Miyahara, Hirata et al. 1996; Wendler, Bergler et al. 
1997; Moye-Rowley 2003). However, it is still not clear how Yap1p is linked to 
PDR and if there is cross talk in regulation between these two stress responses. 
From this point of view, we assessed the screen results from the primary PDR 
screen and Yap1p-GFP screens. We found that both PDR and Yap1p screens are 
enriched in genes functioning in transcriptional activation. However, the actual 
genes were different. PDR screens also contained more ―hits‖ involved in kinase-
mediated signalling than the Yap1p screen. There was little overlap between redox 
sensitive screens and PDR screens, and none of the gene deletions identified 
from the PDR screen conferred any sensitivity toward 1, 1.5, 2 or 2.5 mM of H2O2.  
One exception is deletion of KAP123, which showed slight sensitivity toward 
2.5mM H2O2. This observation suggested that different stress might utilise different 
―sensor‖ or regulators.   
Three gene deletions were found in common for the PDR screens (i.e. preventing 
normal up-regulation of ABC-transporter Pdr5p and Yor1p) and the Yap1p diethyl 
maleate screen (i.e. preventing normal nuclear localisation of Yap1p). These were 
SSN2, SRB8 and KAP123. These genes function in gene regulation and nuclear 
transport. Both Ssn2p and Srb8p are mediator subunits which physically interact 
with Yap1p and with one another (Collins, Miller et al. 2007). However, the SSN2 
deletion did not confer any sensitivity towards any compounds tested in the spot 
dilution assay (probably due to high redundancy in the PDR network).  Srb8p, on 
the other hand, acts as a mediator for Pdr3p (Shahi, Gulshan et al. 2010), and 
causes an increase in xenobiotic sensitivity when deleted. The fact that SRB8 
affects Yap1p nuclear localisation suggests that Srb8p might be a link between the 
PDR response and Yap1p mediated oxidative stress response. This point is 
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possibly strengthened by the known negative genetic interaction with BMH1 - one 
of the regulatory genes shown in the current work to be at the heart of the PDR 
response. Recent  literature is now explicit that the post-translational modification 
of histones are part of specific signalling pathways triggered by specific stimuli, 
resulting in ―context-dependent and specific‖ transcriptional activation of genes 
(Henry, Wyce et al. 2003; Smith and Shilatifard 2010; Bhaumik 2011). Therefore, 
we proposed that the chromatin remodelling complex and mediator complexes 
identified in the PDR and Yap1p screens have specific functions and are induced 
in PDR or oxidative stress-specific manner.  
Based on the function of overlapped gene result, we propose that Yap1p may 
contribute to the PDR phenotype via the activation of other transcription factors, or 
through chromatin remodeling acting as a signal amplifier of an alternative 
pathway to PDR.   
Another interesting point was that all the hits in common between the PDR and 
Yap1p screens were observed in the diethyl maleate screen. One explanation for 
this observation might be that diethyl maleate is a xenobiotic compared to H2O2, 
which is also produced internally.  At the same time diethyl maleate also activates 
the oxidative stress response due to its ability to disrupt the cellular redox state 
resulting in oxidative stress response (Castillo, Ayté et al. 2002; Fomenko, Koc et 
al. 2011). We have not tried to use diethyl maleate to upregulate a PDR reporter, 
but it would be interesting to test this to see if the PDR response also is 
upregulated by this oxidant. 
Another gene, PDE2, appeared in the GO enrichments of the H2O2 screens and 
might play role in both oxidative stress and the PDR response. PDE2 encodes a 
high-affinity cyclic AMP (cAMP) phosphodiesterase which inhibits protein kinase A 
(PKA) (Sass, Field et al. 1986). The Ras-cAMP pathway regulates cAMP-
dependent PKA activity, which in turn regulates many cellular responses such as   
Skn7-mediated oxidative stress and hyperosmotic stress (Park, Grant et al. 2005).  
Overexpression of PDE2 can restore oxidative stress tolerance to Δyap1 in the 
presence of H2O2 as well as stress tolerance in Δmsn2 Δmsn4 (Park, Grant et al. 
2005).  It seems likely that Pde2p might be involved in regulation of Yap1p and its 
alternative pathway involving Skn7p. The deletion of PDE2 also increases  the 
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Pdr5p-GFP reporter intensity in the PDR screens in non-stress conditions, nearly 
as much as RDR1 deletion which is a known suppressor of PDR5 (Hellauer, 
Akache et al. 2002) ( the data and discussion of deletions which upregulated 
Pdr5p is beyond the scope of this dissertation).  
Taken together we suggest that Pde2p controls Yap1p via the PKA signalling 
pathway, perhaps assisting stress tolerance in the stationary phase (Pdr5p is 
found to be used for toxin elimination during exponential phase and is not highly 
expressed in the stationary phase). Since PDE2 only appeared as a hit under 
H2O2 exposure, PDE2 might specifically regulate/modulate Yap1p in a H2O2 
specific manner.  
Conclusion 
The fact that we found different sets of genes in the screens performed with H2O2 
and with diethyl maleate, and no significant overlapped with the PDR screens, 
suggested that different regulators and/or modulators are required for Yap1p 
regulation in response to different oxidants or different type of stresses. These 
genes might also help cells to distinguish different oxidants depending on their 
mechanism of actions (Figure 5-8). Ross et al. (2000) showed that TRX2 seems to 
respond differently between low and high concentration of H2O2. The C-terminal 
region of Yap1p is the major nuclear localisation control but other regions of the 
protein have also been suggested to play role in the regulation of Yap1p in 
oxidative stress responses (Wemmie, Steggerda et al. 1997). The C-terminal, with 
the combination with different subunits of RNA polymerase II mediator complex, 
chromatin modification complex, and redox target genes (Tsa1p, Gpx2p, Gpx3p) 
might serve as sensors for different oxidants. The role of the Yap1p N-terminus 
and C-terminus and their interaction with any regulatory proteins as a way to 
regulate Yap1p still needed further study. In addition, we identified PDE2 as a 
potential regulator of Yap1p in the presence of H2O2, and deletion of this gene also 
increased Pdr5-GFP reporter intensity. Pde2p might play role as a negative 
regulator for the PDR response and positive regulator in the Yap1p response to 
H2O2. 
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Depending on how oxidative stress is generated, different sets of regulators are activated.  
H2O2 directly generates ROS and seems to be regulated via ubiquitination. Diamide and 
diethyl maleate cause oxidative stress by depleting GSH pool and seem to be regulated by 
Gpx2p and Yap1p target gene products (Tsa1p) i.e. negative feedback. 
  
Figure 5-8: The diagram shows that different sets of genes may be used to regulate the 
Yap1p response to different oxidative stress-inducing agents.  
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Chapter 6. Final Discussion and Conclusion 
Section I: New Methodologies 
We have generated genomic tools which allowed us to investigate a set of 
biological processes (and complex traits) relating to environmental bioctives, 
namely, multidrug resistance mechanisms, oxidative stress response and drug 
mode-of –action. 
(a) Modification of SGAM and application of chemical-genetic profile to 
identify drug target and mode-of-action 
The first two processes we explored to do with xenobiotics , namely, PDR and 
oxidative stress, overlap in function and are used to export xenobiotics by ABC-
transporters conferring  multi drug resistance (Balzi and Goffeau 1995; Gulshan 
and Moye-Rowley 2007; Kuchler and Schüller 2007). This approach leaves open 
questions about xenobiotics/drugs that are not ABC-transporter substrates. How 
do cells detoxify these compounds? Many well-known antifungal drugs such as 
amphotericin and nystatin, are not ABC-transporter substrates and yet resistance 
against these two drugs also has been observed whose targets are complex and 
resistance not easy to explain. In Chapter 3, we identified a drug target 
mechanism in part by modifying the SGAM method (Jorgensen, Nelson et al. 2002) 
in combination with the information obtained from the genome-wide chemical-
genetic profiling to identify the target and study the mode-of action of a non-efflux 
pump substrate with antifungal property, neothyonidioside (neo). 
In our use of SGAM methodology (described in Yibmantasiri et al 2012), we 
treated a drug resistance locus as an antibiotic marker and used the deletion 
mutant array as a high density genetic map. Although SGAM has been used to 
identify a genetic mutation (Jorgensen, Nelson et al. 2002), it has not been applied 
to identify a drug resistant locus as we have done. We narrowed down the 
potential neo resistant genes to five essential genes which appeared in the centre 
of the linkage group of gene deletions that surrounded the neo (drug) resistant 
locus. Based on the enrichment of ESCRT and sterol genes from the neo chemical 
genetic profile, we applied a candidate gene approach and sequenced NCP1, an 
NADP-cytochrome P450 reductase involved in ergosterol biosynthesis which 
showed a key mutation blocking ergosterol synthesis at lanosterol (Yibmantasiri et 
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al 2012). In that paper, we presented good evidence that neo must disruptively 
bind to egosterol but only above certain threshold concentrations of ergosterol. 
Because of the ESCRT gene involvement we hypothesized that neo disrupts 
vesicle formation, which is an essential process of cells. We used confocal 
microscopy to investigate the mode-of-action of neo in more detail. We found that 
a sublethal concentration of neo (0.8 µM) prevents normal vacuole formation 
(Figure 3-2). Given the fact the neo resistant strain has less cellular ergosterol 
(Yibmantasiri, Leahy et al. 2012) and that there is a threshold effect of egosterol at 
which neo is toxic we proposed that neo disrupts vacuole formation by disrupting 
membrane fluidity when it binds to ergosterol in plasma membrane. Identifying the 
neo resistance mutation was a central part of the logic leading to this conclusion 
and central to the mutation identification was the modified use of the genomic tool, 
SGAM. It is unlikely the conclusion on the target of neo, i.e. membrane fluidity via 
egosterol binding, could have been reached without the use of genomic tools as 
described here. 
(b) Development of genome-wide high content microscopy screen with 
fluorescent reporters 
 The first genomic tool we generated was the reporter gene system linked with 
green fluorescent protein (GFP) which was then introduced into the S. cerevisiae 
non-essential gene deletion set. This genome-wide deletion-reporter system was 
then used to systematically explore biological processes of interest by measuring 
fluorescence intensity and object texture at subcellular locations from images 
captured by an automatic high-content fluorescent microscope (Opera). 
In the first reporter system, Pdr5p and Yor1p, ABC transporters found in many 
cells showing the multidrug resistant phenotype (Kuchler and Schüller 2007), were 
expressed as fusion proteins linked to GFP and served as real-time indicators of 
transcriptional activity of Pdr1p and Pdr3p. Both Pdr1p and Pdr3p are the main 
transcription factors controlling the multidrug resistant response to xenobiotics, 
known as pleiotropic drug resistance (PDR) in yeast. We used this reporter to 
search for ―upstream‖ genes involved in sensing xenobiotics thence delivering 
signals to the Pdr1p/Pdr3p transcription factors. It became clear during this search 
that modulators and/or genes, which provide alternative pathway for the PDR 
phenotype, also were identified. An assumption behind this reporter-based search 
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was that deletions that failed to up-regulate both reporters at the cell surface in the 
presence of atorvastatin could be identified as potential modulators of 
Pdr1p/Pdr3p. 
The second genome-wide high-content microscopy reporter system we developed 
was the Yap1p-GFP reporter, a basic leucine zipper (bZIP) transcription factor 
required for oxidative stress tolerance (Moye-Rowley, Harshman et al. 1989). In 
order to identify genes involved in Yap1p regulation in response to different 
oxidants, we screened for gene deletions that prevented the normal nuclear 
localization of the reporters upon oxidative stress encounter. 
These two reporter systems are, to our knowledge, the first reporters which 
combine high-content microscopy with genome wide screening such that far more 
resolution of the cell reactions during stress, beside growth, can be studied. These 
screens thus allowed us to identify deletions that only give subtle changes that 
probably would not be detected by a growth assay alone. Both reporter systems 
provided reproducible results over numerous screen repeats. The screens 
received independent validation when deletion mutants from the PDR primary 
screens were subjected to spot dilution and Western blot assays. 
 
Section II: New gene functions identified in these studies by 
genomic approaches 
(a) Enrichment of ESCRT genes in the non-efflux-pump substrate 
neothyonidioside 
In our published study, we performed a chemical-genetic homozygous deletion 
profiling (HOP) assay (Yibmantasiri, Leahy et al. 2012). Analysis of GO term 
enrichment of the neo profile, pinpointed the ESCRT complexes as essential 
components for neo resistance. All of the members of ESCRT-II (VPS25, VPS36, 
SNF8), some components of ESCRT-0 (VPS27), ESCRT-I (STP22, VPS28), and 
ESCRT-III (SNF7, VPS20) and VPS4, an ATP-ase that drives the activity of the 
ESCRT-III complex as well as deletion mutants of the GARP complex (VPS51 and 
VPS52) and vesicle transport genes (VPS5, VPS41, VPS17), also endocytosis 
gene deletions (END3, CAP1, RVS167, RVS161)  become essential in the 
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presence of neo (Figure 3-1). We proposed that Neo blocks multivesicular body 
and vacuole formation via disruption of membrane fluidity.ESCRT genes 
compensate Neo toxicity by providing aid to membrane inward budding 
The enrichment of vesicle-related genes and ESCRT complex genes from the 
chemical genetic profile was also observed with polyenes, nystatin and 
amphotericin (Parsons, Brost et al. 2004; Parsons, Lopez et al. 2006) but not as 
strongly as with neo. It has been shown that cells use lysosomes to detoxify drugs 
that can lead to PDR phenotypes (Kuchler and Schüller 2007). We propose that 
disruption of   plasma membrane sterol distribution by these compounds leads to 
initiation of signal transduction, which in turn activates the PDR response. The 
suggestion here is that this response might also involve ESCRT complex and 
vacuole formation, especially when cells encounter drugs that are not ABC-
transporter substrates. 
(b) Enrichment of genes involved in chromatin modification, RNA 
polymerase II mediator complexes, and transcription factors in PDR screens 
Chromatin remodelling complexes and co-activators such as RNA polymerase II 
mediator subunits, affect transcriptional activity of gene expression globally (Hahn 
and Young 2011; Niederacher, Klopf et al. 2011). However, these functions also 
occur for specific gene expression (―chromatin signalling pathway‖)   (Smith and 
Shilatifard 2010; Hnisz, Tscherner et al. 2011). Chromatin modification/remodelling 
complexes have been associated with the drug resistant phenotype in S. 
cerevisiae, C. albicans, and mammalian breast cancer cell lines (Gao, Wang et al. 
2004; Morschhäuser, Barker et al. 2007; Toth, Boros et al. 2012). In the current 
studies we identified such genes encoding components of SAGA complexes and 
transcriptional activators relating to the PDR response. Since none of the deletions 
conferred sensitivity toward H2O2, we suggest that these genes are likely to be 
PDR specific modulators and different mediators and chromatin modifications are 
used to differentiate different stress responses. These gene activities are likely to 
be specific and not global. Deletions of SPT7, ROX3, SPT8, and DEP1 for 
example decrease Pdr5p abundance in Western blots without affecting another 
plasma membrane protein Pma1p.   
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Such ―chromatin signalling pathways‖ discussed above can regulate gene 
expression in host-pathogen interactions as well as modulate drug resistance trait 
by changing histone modification status (Lopez-Rubio, Riviere et al. 2007; Hnisz, 
Tscherner et al. 2011). It has been shown that the histone acetylase complex can 
alter cAMP/PKA signalling which then affect the virulence of C. albicans  (Hnisz, 
Tscherner et al. 2011). Recent studies show that novel histone acetylase 
/decetylase inhibitors reduce virulence of many pathogenic fungi (Simonetti, 
Passariello et al. 2007; Agbor-Enoh, Seudieu et al. 2009; Wurtele, Tsao et al. 
2010). These pathways may provide new targets for overcoming drug resistance, 
especially if the drug resistant phenotype is achieved from mechanisms other than 
hyperactive Pdr1p/Pdr3p. Compound library screening using these deletion 
backgrounds and looking for compound sensitivity should provide more insight of 
how these genes might work together to influence PDR phenotype. 
(c) Different genes involved in regulating Yap1p nuclear localization in 
different oxidants 
Our results show that different sets of genes control Yap1p upon application of 
different oxidants. Nevertheless, the broad functions of these genes were very 
similar. Genes that are involved in Yap1p regulation in both H2O2 and diethyl 
maleate treatments were enriched in DNA integrity, and stress response. We 
suggest that Yap1p might be regulated by ubiquitination in an H2O2-specific 
manner since ubiquitination genes were enriched in this oxidant screen. We also 
showed that the known Yap1p targets such as TSA1 (encodes thiol peroxidase), 
and GPX2 (encodes glutathione peroxidise) were also involved in Yap1p 
regulation, probably via their ability to sense and regulate the redox state of the 
cells which in turn change the redox state of Yap1p (Yap1p in the reduced state is 
localized to the nucleus). We propose that Gpx2p assists oxidation and activation 
of Yap1p in a thiol-oxidant specific manner. In a similar way, Gpx3p activates 
Yap1p when exposed to H2O2.   
Section III: Predicting and verifying genes from network 
information 
As is implicit in much of the above discussion, genomic approaches to defining 
gene function are hypothesis forming. A testable one is that known negative 
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genetic and physical interactions of specific genes arising from our PDR screen 
―hits‖ that fall into similar GO categories will affect down-stream reporters in a 
similar way. If in fact this can be shown, the prediction and its verification serves to 
validate the supposed function of the original hits and better defines the 
interaction-associated genes. To this end we curated interacting genes from SGD 
that interact with PDR1 and PDR3 (both physically and genetically) and with 
highly-interacted GO nodes from our results (SAGA, kinase, lipids). We tested 
these genes by spot dilution of specific deletions both as Δxxx and in the Δpdr1 
Δpdr3 background in our xenobiotic compound panel and by abundance of Pdr5p 
in Western blots. We found that 10/18 mutants appeared as additional hits by one 
or other of these assays. These genes, listed in Table 4-4, are enriched in 
chromatin remodelling. The ―hits‘ were gene specific i.e. likely to be non-global as 
their deletion did not affect the abundance of Pma1p in plasma membrane in 
Western blots; neither did they cause sensitivity toward H2O2. Unexamined in the 
foregoing discussion is the question of the function of genetic networks. Indeed 
this comment may apply to the now growing literature on genetic interaction 
networks, starting with yeast but increasingly seen in other species as key genetic 
tools such as genome-scale deletion sets of genes become available. The results 
reported here do, in fact, begin to answer that question by experimentally showing 
that gene deletions additional to primary hubs of networked genes can also affect 
the phenotypes controlled by the hubs. One example from our results that utilised 
network function is LGE1, a gene that encodes a protein of unknown function. 
LGE1 fell short of the ―cut off‖ to be identified as a ―hit‖ in the primary screen. We 
supposed that deletion of LGE1 might affect the PDR phenotype because LGE1 
displayed phenotypic suppression PDR3 and is synthetic lethal with SWI4, and 
Ume6p. As shown in Chapter 4, deletion of LGE1 did not increase xenobiotic 
sensitivity in any deletion backgrounds. However, it did reduce Pdr5p abundance. 
This effect might due to an LGE1 function being associated with the network hub 
PDR3, SWI4 and UME6, engaged in transcriptional regulation. By assessing the 
network, we can ascertain the pathway in which Lge1p might work. This adds a 
dimension to understanding complex phenotypes, which usually have been 
couched in classical genetic terms of the ―additive‖ and ―epistatic‖ contributions of 
multiple genes measured by the tools of quantitative genetics.   
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 Section IV: New pathways contribute to PDR network 
(a) Kinase signalling pathway relay xenobiotics information and activate 
PDR response 
We identified 26 gene deletions that prevented normal up-regulation of Pdr5p and 
Yor1p and conferred sensitivity to several xenobiotic compounds. Many of these 
genes are involved in signalling (Rho-GTPase, MAPK). Since the gene deletions 
appeared not to be involved in transporter location we propose that there is 
signalling ―upstream‖ of Pdr1p/Pdr3p which might also be involved in other stress 
responses and work in combination with chromatin remodelling complexes and 
transcriptional activators.   
(b) Lipids, mitochondria and PDR   
The screening results reported in this thesis also highlighted the importance of the 
lipid homeostasis and mitochondria in PDR responses. Deletion of mitochondria 
matrix proteins such as FMC1 or genes encoding phospholipid or sphingolipid 
DEP1, YME1, PIB2 resulted in hypersensitivity to many of the xenobiotic 
compounds greater than that displayed by the Δpdr1Δpdr3 strain showing these 
were additional effects to those regulated by Pdr1p/Pdr3.  This result is seemingly 
at odds with the known upregulation of Pdr5p in ρ0 (mitochondria genome-
deleted/defected) cells that is Pdr3p-dependent (Hallstrom and Moye-Rowley 2000; 
Moye-Rowley 2005; Shahi, Gulshan et al. 2010).  Were they involved in the same 
pathway deletion of these mitochondrial genes should not cause extra sensitivity in 
the Δpdr1Δpdr3 strain. An explanation may lie  with sphingolipid precursors that 
play a  role in signalling and link with mitochondrial status and stress tolerance 
(Sietsma, Veldman et al. 2001), suggesting that some of the genes involved in 
sphingo/phospholipid  synthesis might also play roles in different (to Pdr1p/Pdr3) 
stress responses that can also upregulate ABC-transporter gene expression. 
The importance of lipid composition and structure also emerged from our study of 
neo dose response in different erg mutants (Kristina Boeger‘s summer research 
report). We showed in chapter 5 that neo, a sterol binder, can have ―preferable‖ 
substrate(s). Ergosterol and some precursors bind to neo whilst episterol 
(substrate for Erg3p) does not. This conclusion can be deduced from the fact that 
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only the deletion of ERG3 amongst erg mutants caused increase in resistance 
toward neo. It could be useful to use this information in the design of compounds 
that target more specific sterols. Then, used in combination with known clinical 
drugs to increase cell susceptibility to combat drug resistance in both pathogenic 
fungi as well as in cancer cells. 
(c) Possible pathways to achieve PDR phenotypes. Lessons from our 
genomic studies 
From our combined results, we propose that cells encountering xenobiotics or 
other drug-like compounds (Figure 6-1) initiate a signalling pathway. The initiation 
might arise from compounds directly binding to sterol in the  plasma membrane as 
in the case of neo and polyenes, or maybe via interaction with phospholipid or 
other protein (e.g. Chw43p, our hit) in lipid rafts (Hallstrom, Lambert et al. 2001). 
From our results, signalling pathways might involve PKC and/or Ras/MAPK which 
have been shown to play a role in stress responses by activation of Skn7p 
(another TF for oxidative stress) and Msn2p/Msn4p in translocating these 
transcription factors to the nucleus on encountering stress (Krems, Charizanis et al. 
1996; Görner, Durchschlag et al. 1998; Hanlon, Rizzo et al. 2011). This signalling 
cascade might also activate other proteins involved in post translational 
modification such as Bmh1p, an important hit and one of the main network hubs 
from our PDR screens. Bmh1p (14-3-3 protein) controls many processes including 
exocytosis, vesicle transport, and Ras/MAPK signalling (van Heusden, Wenzel et 
al. 1992; Bruckmann, Hensbergen et al. 2007). Bmh1p is found in both the nucleus 
and plasma membrane and can bind both proteins and DNA 
(www.yeastgenome.org). We suggest it is a ―decision junction‖ distinguishing 
xenobiotics as pump and non- pump substrates. In this view, compounds can 
either be pumped out of the cell using ABC-transporters and major facilitators 
(MFS), or, alternatively, transported to vacuoles and lysosome. Especially,  when 
the compounds are not PDR substrates (e.g polyenes, neo). It has been shown 
that 14-3-3 proteins are required as a scaffold for the enhancer proteins to bind at 
the promoter (Kellner, Ramos et al. 2012). This activation process involves the 
mediator complex and chromatin modification complexes which might act as 
sensors for signalling (kinases) and responses of chromatin-signalling pathways  
(Smith and Shilatifard 2010).    
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It is possible different subunits of the mediator complex as well as chromatin 
modification complex and transcription activators are used to activate transcription 
factors other than PDR1/PDR3 depends on compounds mechanism of actions. It 
is also possible that other such transcription factors function as amplifiers for 
Pdr1p/Pdr3p signal. Zheng et al. 2010 showed that genes can contain many 
recognition sequences belonging to different transcription factors. Some of these 
are acting as major regulators and some as minor regulators. In the absence of 
major regulators, the minor regulators could become more important and deletion 
of minor regulators could then cause more severe phenotypic effects (Zheng, 
Benschop et al. 2010). The same authors also showed that there is a strong 
preference for negative genetic interaction between genes encoding specific DNA-
binding transcription factors (STFs), especially between STFs which show 
overlapping targets (Zheng, Benschop et al. 2010). These findings and 
interpretations are consistent with our PDR screen results. Many gene deletions 
that showed more severe sensitivity towards many xenobiotics in the absence of 
PDR1 PDR3 clearly implicate that they are involved drug response processes that 
are not the classical PDR response (or Pdr1p/Pdr3p-dependent). To be 
considered also is that activation of transcription factors can also lead to activation 
of other transcription factors, for example, Pdr1p activates Pdr3p, and Yrr1p; 
PDR3 and YRR1 also are autoregulated.  
The targets of the transcription factors can also act as regulators of transcription 
factors as can be seen from the diethyl maleate screen result. Tsa1p and Gpx2, 
both Yap1p targets, can also act as sensors for the change of cellular redox state 
and relay information to Yap1p, which leads to nuclear localization of Yap1p. 
Chromatin modification, SAGA, and members of mediator complexes provide cells 
with another way to sense and relay stress signals besides post-translational 
modification of proteins.  
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Section V: Comparison of our results to relevant key papers 
If our hits act in the same pathway as Pdr1p/Pdr3p, then our gene deletions 
should also appeared in the MDR list of Hillenmeyer chemical-genetic screens of 
178 drugs (Hillenmeyer, Fung et al. 2008). We found that out of 54 gene deletions 
we identified as causing hypersensitivity to drugs, 9 of them overlapped with the 
Hillenmeyer MDR list (deletions of BMH1, PDR, SKN7, RCY1, PIN4, CWH43, 
ERV14, FIS1, and OPI3). If pathways we proposed above are correct, Bmh1p 
Figure 6-1 : Diagram representing possible pathways in S.cerevisiae activated by 
xenobiotics  
 It is very likely that kinase signalling cascade, ubiquitination and change in context-specific 
chromatin modification are involved in distinguishing between different substrates.  
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plays a major role as a sensor and signalling, and therefore acts upstream of 
Pdr1p/Pdr3p and should contribute to the PDR phenotype; BMH1 was a hit in the 
Hillenmyer screen. However, none of our chromatin remodelling complex 
candidates, RNA polymerase II mediator candidate genes, and kinase genes 
overlapped with the Hillenmeyer et al. MDR list. This discrepancy suggests that, 
either we have characterised alternative pathways that have not yet been 
identified or that different screening systems inherently produce different results. 
The latter is a possibility because Hillenmeyer et al. used diploid cells which could 
lead to epistatic effects between genes masking gene deletions.  Furthermore, the 
Hillenmeyer et al. screens were growth screens, whilst ours are reporter systems 
which probably can screen for more subtle changes. Another difference is that our 
reporter systems are set up so that Pdr1p/Pdr3p and their targets remain intact 
and that the effect of each gene deletion is individually assessed, whilst the 
Hillenmeyer et al. screen is based on competitive fitness of all the deletion mutants 
assayed together.  
Another paper key paper for discussion is Barreto et al 2011, who used genome 
wide screens for  changed tolerance to cationic drugs that affect  potassium 
homeostasis (Barreto, Canadell et al. 2011). They found nearly the same set of 
SAGA complex genes as described here (SPT7 GCN5, NGG1), however they 
thought the genes were part of a pleiotropic ―global‖ effect and did not discussed 
this result further. We, however, think that the effects of these SAGA gene 
deletions are not merely a global effect since they affected one plasma membrane 
protein (Pdr5p) and not another (Pma1p).   
Section VI: Power of Genomics 
We showed here that unbiased genome-wide approaches can identify previously 
unsuspected regulators of complex traits of interest, namely drug mode-of-action  
and development of drug resistance and stress response.  
The techniques of SGAM and chemical-genetic profiling generate results allowing 
specific hypotheses to test for the mode-of-action of a drug (neo in this study) 
could be. Without these hypothesis-generating methodologies we would have no 
clue where to start and it would take much longer to come up with the significant 
results – if at all. 
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By using the genome-wide reporter system that we developed we could explore all 
the non-essential gene contributions to most biological processes of interest. In 
the case of PDR and Yap1p, the reporters provide reproducible results validated 
by other tests and can be used to develop networks of gene functionality around 
the biological process in question. We found that there are signalling pathways 
upstream of Pdr1p/Pdr3p and Yap1p. Additionally, we found that different ―sensors‖ 
and regulators are induced upon exposure to different xenobiotic stresses. To our 
To our knowledge, it is the first genome-wide reporter system that allows us to 
measure intra-cellular phenotypes as well as the localization of the reporters in 
large numbers of individual cells in a genome-wide manner for the PDR response 
and the oxidative stress response. In a methodological advance, texture analysis 
from Acapella software allowed us to look at texture around the cellular organelle 
of interest (here plasma membrane in PDR reporter, cytoplasm and nucleus in 
Yap1p) providing greater quantitative accuracy than just measuring GFP intensity. 
By observing intracellular morphology of the cells in the deletion screens,  we were 
able to distinguish between gene deletions that have ―upstream‖ effects on   
Pdr1pPdr3p TF activity (and hence Pdr5p expression), and gene deletions that 
affect PDR GFP reporter location internally. Examples of the latter are gene 
deletions that disrupt protein folding or that Pdr5p/Yor1p reporters are localized in 
cytoplasm or in the ER instead of plasma membrane. Without microscopy, these 
deletions would present as false positives in our screen. This is another advantage 
of high-content microscopy over FACS.   
Future Direction 
 A useful line of enquiry would be to study genes involved in a pre-PDR1/PDR3 
signalling pathway, as well as some SAGA complex genes. Subunits of SAGA- 
SWI complexes have been shown to have negative genetic interactions with many 
of the RNA polymerase II mediator complex genes, suggesting that they can 
compensate one another. For example, GAL11 genetically interacts with SPT8 
and SWI4 (Collins, Miller et al. 2007), hence, to a certain extent, the requirement 
of Gal11p for PDR can be bypassed. In vitro biochemical assays could be 
conducted to test this hypothesis in which all the components of transcriptional 
activation are added except Gal11p. In theory, this should reduce the expression 
of Pdr5p. This defect should be able to be rescued by adding Swi4p and/or Spt8p 
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back unless Swi4p and Spt8p compensate the loss of Gal11p by alternative 
pathways involving other ABC-transporters all together, or independent of 
Pdr1p/Pdr3p. 
We would also like to look at ubiquination as a regulator for Yap1p and stress 
response both oxidative stress and possible crosstalk with PDR. 
We would like to look at the gene deletions which in normal growth conditions 
upregulate Pdr5p and Yor1p relative to wild-type level such as PDE2, which has 
been mentioned briefly in Chapter 5. These genes should, in theory, be the 
negative regulator of the PDR pathway. We obtained these data, however due to 
the time limitation we did not validate these data. From the GO analysis at 5% 
level of significance, we found enrichment in processes of oxidation-reduction, 
chemical homeostasis, response to stimuli and xenobiotic stimulus and regulation 
of protein kinase activity. We would like to validate these data with spot dilution 
assay and western blot and if any genes show particular interest, to investigate 
them in more detail. A major question arising out of this work is, do Pdr1p/Pdr3p 
act at the same time or sequentially because Pdr1p can form both homodimers 
and heterodimers? Will mediators determine the sequence and/or what subsets of 
target genes are turned on? 
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Appendix I  
Table A-1:List of gene deletions which cause insignificant change in PDR 
reporters upon atorvastatin treatment 
Systematic 
Name 
Standard 
Name 
 Description 
YDR374C 
 
 Putative protein of unknown function 
YFR018C 
 
 Putative protein of unknown function 
YIL152W 
 
 Putative protein of unknown function 
YNL315C ATP11 Molecular chaperone, required for the assembly of 
alpha and beta subunits into the F1 sector of 
mitochondrial F1F0 ATP synthase 
 
YER155C BEM2 Rho GTPase activating protein (RhoGAP) involved in 
the control of cytoskeleton organization and cellular 
morphogenesis; required for bud emergence 
 
YER177W BMH1 14-3-3 protein, major isoform; controls proteome at 
post-transcriptional level, binds proteins and DNA, 
involved in regulation of many processes including 
exocytosis, vesicle transport, Ras/MAPK signaling, 
and rapamycin-sensitive signalling 
 
YOR061W CKA2 Alpha' catalytic subunit of casein kinase 2 (CK2), a 
Ser/Thr protein kinase with roles in cell growth and 
proliferation; CK2, comprised of CKA1, CKA2, CKB1 
and CKB2, has many substrates including 
transcription factors and all RNA polymerase 
 
YDL155W CLB3 B-type cyclin involved in cell cycle progression; 
activates Cdc28p to promote the G2/M transition; may 
be involved in DNA replication and spindle assembly; 
accumulates during S phase and G2, then targeted for 
ubiquitin-mediated degradation 
YCR017C CWH43 Putative sensor/transporter protein involved in cell wall 
biogenesis; contains 14-16 transmembrane segments 
and several putative glycosylation and 
phosphorylation sites; null mutation is synthetically 
lethal with pkc1 deletion 
YGL078C DBP3 Putative ATP-dependent RNA helicase of the DEAD-
box family involved in ribosomal biogenesis 
YDR294C DPL1 Dihydrosphingosine phosphate lyase, regulates 
intracellular levels of sphingolipid long-chain base 
phosphates (LCBPs), degrades phosphorylated long 
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chain bases, prefers C16 dihydrosphingosine-l-
phosphate as a substrate 
YGR071C ENV11 Protein proposed to be involved in vacuolar functions; 
mutant shows defect in CPY processing and 
fragmented vacuoles; deletion mutant has increased 
glycogen accumulation and displays elongated buds; 
green fluorescent protein (GFP)-fusion protein 
localizes to the nucleus 
YGL054C ERV14 Protein localized to COPII-coated vesicles, involved in 
vesicle formation and incorporation of specific 
secretory cargo; required for the delivery of bud-site 
selection protein Axl2p to cell surface; related to 
Drosophila cornichon 
 
YIL065C FIS1 Protein involved in mitochondrial membrane fission 
and peroxisome abundance; required for localization 
of Dnm1p and Mdv1p during mitochondrial division; 
mediates ethanol-induced apoptosis and ethanol-
induced mitochondrial fragmentation 
 
YIL098C FMC1 Mitochondrial matrix protein, required for assembly or 
stability at high temperature of the F1 sector of 
mitochondrial F1F0 ATP synthase; null mutant 
temperature sensitive growth on glycerol is 
suppressed by multicopy expression of Odc1p 
 
YHR176W FMO1 Flavin-containing monooxygenase, localized to the 
cytoplasmic face of the ER membrane; catalyzes 
oxidation of biological thiols to maintain the ER redox 
buffer ratio for correct folding of disulfide-bonded 
proteins 
 
YGR252W GCN5 Acetyltransferase, modifies N-terminal lysines on 
histones H2B and H3; acetylates Rsc4p, a subunit of 
the RSC chromatin-remodeling complex, altering 
replication stress tolerance; catalytic subunit of the 
ADA and SAGA histone acetyltransferase complexes; 
founding member of the Gcn5p-related N-
acetyltransferase superfamily; mutant displays 
reduced transcription elongation in the G-less-based 
run-on (GLRO) assay 
YGL020C 
GET1 
(MDM39) 
Subunit of the GET complex; involved in insertion of 
proteins into the ER membrane; required for the 
retrieval of HDEL proteins from the Golgi to the ER in 
an ERD2 dependent fashion and for normal 
mitochondrial morphology and inheritance 
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YGR163W GTR2 Putative GTP binding protein that negatively regulates 
Ran/Tc4 GTPase cycle; activates transcription; 
subunit of EGO and GSE complexes; required for 
sorting of Gap1p; localizes to cytoplasm and to 
chromatin; homolog of human RagC and RagD 
 
YJR147W HMS2 Protein with similarity to heat shock transcription 
factors; overexpression suppresses the pseudohyphal 
filamentation defect of a diploid mep1 mep2 
homozygous null mutant 
 
YFR038W IRC5 Putative ATPase containing the DEAD/H helicase-
related sequence motif; null mutant displays increased 
levels of spontaneous Rad52p foci 
 
YER110C KAP123 Karyopherin beta, mediates nuclear import of 
ribosomal proteins prior to assembly into ribosomes 
and import of histones H3 and H4; localizes to the 
nuclear pore, nucleus, and cytoplasm; exhibits genetic 
interactions with RAI1 
 
YKL168C KKQ8 Putative serine/threonine protein kinase with unknown 
cellular role 
 
YDR532C KRE28 Subunit of a kinetochore-microtubule binding complex 
with Spc105p that bridges centromeric 
heterochromatin and kinetochore MAPs and motors, 
and is also required for sister chromatid bi-orientation 
and kinetochore binding of SAC components 
 
YCL061C MRC1 S-phase checkpoint protein required for DNA 
replication; interacts with and stabilizes Pol2p at 
stalled replication forks during stress, where it forms a 
pausing complex with Tof1p and is phosphorylated by 
Mec1p; protects uncapped telomeres 
 
YDR192C NUP42 Subunit of the nuclear pore complex (NPC) that 
localizes exclusively to the cytoplasmic side; involved 
in RNA export, most likely at a terminal step; interacts 
with Gle1p 
 
YJR073C OPI3 Phospholipid methyltransferase (methylene-fatty-acyl-
phospholipid synthase), catalyzes the last two steps in 
phosphatidylcholine biosynthesis 
 
YGL013C PDR1 Zinc cluster protein that is a master regulator involved 
in recruiting other zinc cluster proteins to pleiotropic 
drug response elements (PDREs) to fine tune the 
regulation of multidrug resistance genes 
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YBL005W 
 
PDR3 Transcriptional activator of the pleiotropic drug 
resistance network, regulates expression of ATP-
binding cassette (ABC) transporters through binding to 
cis-acting sites known as PDREs (PDR responsive 
elements); post-translationally upregulated in cells 
lacking a functional mitochondrial genome 
 
YGL023C PIB2 Protein binding phosphatidylinositol 3-phosphate, 
involved in telomere-proximal repression of gene 
expression; similar to Fab1 and Vps27 
 
YBL051C PIN4 Protein involved in G2/M phase progression and 
response to DNA damage, interacts with Rad53p; 
contains an RNA recognition motif, a nuclear 
localization signal, and several SQ/TQ cluster 
domains; hyperphosphorylated in response to DNA 
damage 
 
YHR075C PPE1 Protein with carboxyl methyl esterase activity that may 
have a role in demethylation of the phosphoprotein 
phosphatase catalytic subunit; also identified as a 
small subunit mitochondrial ribosomal protein 
 
YNL169C PSD1 Phosphatidylserine decarboxylase of the mitochondrial 
inner membrane, converts phosphatidylserine to 
phosphatidylethanolamine 
 
YAL017W PSK1 One of two (see also PSK2) PAS domain containing 
S/T protein kinases; coordinately regulates protein 
synthesis and carbohydrate metabolism and storage 
in response to a unknown metabolite that reflects 
nutritional status 
 
YJL204C RCY1 F-box protein involved in recycling plasma membrane 
proteins internalized by endocytosis; localized to sites 
of polarized growth 
 
YKR055W RHO4 Non-essential small GTPase of the Rho/Rac subfamily 
of Ras-like proteins, likely to be involved in the 
establishment of cell polarity 
 
YDR279W RNH202 Ribonuclease H2 subunit, required for RNase H2 
activity; related to human AGS2 that causes Aicardi-
Goutieres syndrome 
 
YBL093C ROX3 Subunit of the RNA polymerase II mediator complex; 
associates with core polymerase subunits to form the 
RNA polymerase II holoenzyme 
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YHR200W RPN10 Non-ATPase base subunit of the 19S regulatory 
particle (RP) of the 26S proteasome; N-terminus plays 
a role in maintaining the structural integrity of the RP; 
binds selectively to polyubiquitin chains; homolog of 
the mammalian S5a protein 
 
YJR127C RSF2 Zinc-finger protein involved in transcriptional control of 
both nuclear and mitochondrial genes, many of which 
specify products required for glycerol-based growth, 
respiration, and other functions 
 
YOL067C RTG1 Transcription factor (bHLH) involved in interorganelle 
communication between mitochondria, peroxisomes, 
and nucleus 
 
YGR143W SKN1 Protein involved in sphingolipid biosynthesis; type II 
membrane protein with similarity to Kre6p 
 
YHR206W SKN7 Nuclear response regulator and transcription factor; 
physically interacts with the Tup1-Cyc8 complex and 
recruits Tup1p to its targets; part of a branched two-
component signaling system; required for optimal 
induction of heat-shock genes in response to oxidative 
stress; involved in osmoregulation 
 
YGL115W SNF4 Activating gamma subunit of the AMP-activated Snf1p 
kinase complex (contains Snf1p and a 
Sip1p/Sip2p/Gal83p family member); activates 
glucose-repressed genes, represses glucose-induced 
genes; role in sporulation, and peroxisome biogenesis 
YER161C SPT2 Protein involved in negative regulation of transcription; 
required for RNA polyadenylation; exhibits regulated 
interactions with both histones and SWI-SNF 
components, has similarity to mammalian HMG1 
proteins 
 
YBR081C SPT7 Subunit of the SAGA transcriptional regulatory 
complex, involved in proper assembly of the complex; 
also present as a C-terminally truncated form in the 
SLIK/SALSA transcriptional regulatory complex 
 
YCR081W SRB8 Subunit of the RNA polymerase II mediator complex; 
associates with core polymerase subunits to form the 
RNA polymerase II holoenzyme; essential for 
transcriptional  
regulation; involved in glucose repression 
 
YDR443C SSN2 Subunit of the RNA polymerase II mediator complex; 
associates with core polymerase subunits to form the 
RNA polymerase II holoenzyme; required for stable 
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association of Srb10p-Srb11p kinase; essential for 
transcriptional regulation 
 
YHR064C SSZ1 Hsp70 protein that interacts with Zuo1p (a DnaJ 
homolog) to form a ribosome-associated complex that 
binds the ribosome via the Zuo1p subunit; also 
involved in pleiotropic drug resistance via sequential 
activation of PDR1 and PDR5; binds ATP 
 
YOR027W STI1 Hsp90 cochaperone, interacts with the Ssa group of 
the cytosolic Hsp70 chaperones and activates Ssa1p 
ATPase activity; interacts with Hsp90 chaperones and 
inhibits their ATPase activity; homolog of mammalian 
Hop 
 
YER111C SWI4 DNA binding component of the SBF complex (Swi4p-
Swi6p), a transcriptional activator that in concert with 
MBF (Mbp1-Swi6p) regulates late G1-specific 
transcription of targets including cyclins and genes 
required for DNA synthesis and repair 
 
YBR165W UBS1 Ubiquitin-conjugating enzyme suppressor that 
functions as a general positive regulator of Cdc34p 
activity; nuclear protein that may represent a link 
between nucleocytoplasmic transport and ubiquitin 
ligase activity 
YDR207C UME6 Key transcriptional regulator of early meiotic genes, 
binds URS1 upstream regulatory sequence, couples 
metabolic responses to nutritional cues with initiation 
and progression of meiosis, forms complex with 
Ime1p, and also with Sin3p-Rpd3p 
 
YPR024W YME1 Catalytic subunit of the mitochondrial inner membrane 
i-AAA protease complex, which is responsible for 
degradation of unfolded or misfolded mitochondrial 
gene products; mutation causes an elevated rate of 
mitochondrial turnover 
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Table A-2:Hit genes from Yap1p-GFP screen with H2O2 treatment 
Systematic 
name 
Standard 
Name 
Description 
YHR210C  Putative protein of unknown function; non-
essential gene; highly expressed under 
anaeorbic conditions; sequence similarity to 
aldose 1-epimerases such as GAL10 
 
YLR345W  Similar to 6-phosphofructo-2-kinase/fructose-
2,6-bisphosphatase enzymes responsible for the 
metabolism of fructoso-2,6-bisphosphate; mRNA 
expression is repressed by the Rfx1p-Tup1p-
Ssn6p repressor complex; YLR345W is not an 
essential gene 
 
YDR448W* ADA2 Transcription coactivator, component of the ADA 
and SAGA transcriptional adaptor/HAT (histone 
acetyltransferase) complexes 
 
YHR018C ARG4 Argininosuccinate lyase, catalyzes the final step 
in the arginine biosynthesis pathway 
 
YGR124W ASN2 Asparagine synthetase, isozyme of Asn1p; 
catalyzes the synthesis of L-asparagine from L-
aspartate in the asparagine biosynthetic 
pathway 
 
YLR412W BER1 Protein involved in microtubule-related 
processes, N-acetylation; GFP-fusion protein 
localizes to the cytoplasm and is induced in 
response to the DNA-damaging agent MMS; 
YLR412W is not an essential gene; similar to 
Arabidopsis SRR1 gene 
 
YDL074C* BRE1 E3 ubiquitin ligase, forms heterodimer with 
Rad6p to monoubiquinate histone H2B-K123, 
which is required for the subsequent methylation 
of histone H3-K4 and H3-K79; required for 
DSBR, transcription, silencing, and checkpoint 
control 
 
YCR063W* BUD31 Component of the SF3b subcomplex of the U2 
snRNP; diploid mutants display a random 
budding pattern instead of the wild-type bipolar 
pattern 
 
YML102W* CAC2 Subunit of chromatin assembly factor I (CAF-1), 
with Rlf2p and Msi1p; chromatin assembly by 
CAF-1 is important for multiple processes 
including silencing at telomeres, mating type 
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loci, and rDNA; maintenance of kinetochore 
structure; deactivation of the DNA damage 
checkpoint after DNA repair; and chromatin 
dynamics during transcription 
 
YML042W CAT2 Carnitine acetyl-CoA transferase present in both 
mitochondria and peroxisomes, transfers 
activated acetyl groups to carnitine to form 
acetylcarnitine which can be shuttled across 
membranes 
 
YLR418C* CDC73 Component of the Paf1p complex; binds to and 
modulates the activity of RNA polymerases I and 
II; required for expression of certain genes, 
modification of some histones, and telomere 
maintenance; involved in transcription elongation 
as demonstrated by the G-less-based run-on 
(GLRO) assay 
 
YGL029W* CGR1 Protein involved in nucleolar integrity and 
processing of the pre-rRNA for the 60S 
ribosome subunit; transcript is induced in 
response to cytotoxic stress but not genotoxic 
stress 
 
YKL137W CMC1 Evolutionarily conserved copper-binding protein 
of the mitochondrial intermembrane space, may 
be involved in delivering copper from the matrix 
to the cytochrome c oxidase complex; contains a 
twin CX9C motif 
 
YIL036W* CST6 Basic leucine zipper (bZIP) transcription factor, 
in ATF/CREB family; mediates transcriptional 
activation of NCE103 (encoding carbonic 
anhydrase) in response to low CO2 levels such 
as in the ambient air; proposed to be a regulator 
of oleate responsive genes; involved in 
utilization of non-optimal carbon sources and 
chromosome stability 
 
YLR394W CST9 SUMO E3 ligase; required for synaptonemal 
complex formation; localizes to synapsis 
initiation sites on meiotic chromosomes; 
potential Cdc28p substrate 
 
YLR286C CTS1 Endochitinase, required for cell separation after 
mitosis; transcriptional activation during the G1 
phase of the cell cycle is mediated by 
transcription factor Ace2p 
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YDL117W* CYK3 SH3-domain protein located in the mother-bud 
neck and the cytokinetic actin ring; mutant 
phenotype and genetic interactions suggest a 
role in cytokinesis 
 
YCL016C DCC1 Subunit of a complex with Ctf8p and Ctf18p that 
shares some components with Replication 
Factor C, required for sister chromatid cohesion 
and telomere length maintenance 
 
YDR121W* DPB4 Shared subunit of DNA polymerase (II) epsilon 
and of ISW2/yCHRAC chromatin accessibility 
complex; involved in both chromosomal DNA 
replication and in inheritance of telomeric 
silencing 
 
YMR246W FAA4 Long chain fatty acyl-CoA synthetase, activates 
imported fatty acids with a preference for C12:0-
C16:0 chain lengths; functions in long chain fatty 
acid import; important for survival during 
stationary phase; localized to lipid particles 
 
YAR050W FLO1 Lectin-like protein involved in flocculation, cell 
wall protein that binds to mannose chains on the 
surface of other cells, confers floc-forming ability 
that is chymotrypsin sensitive and heat resistant; 
similar to Flo5p 
 
YDR070C FMP16 Putative protein of unknown function; proposed 
to be involved in responding to conditions of 
stress; the authentic, non-tagged protein is 
detected in highly purified mitochondria in high-
throughput studies 
 
YKR039W GAP1 General amino acid permease; Gap1p senses 
the presence of amino acid substrates to 
regulate localization to the plasma membrane 
when needed 
 
YER083C GET2 Subunit of the GET complex; involved in 
insertion of proteins into the ER membrane; 
required for the retrieval of HDEL proteins from 
the Golgi to the ER in an ERD2 dependent 
fashion and for meiotic nuclear division 
 
YIR037W* HYR1 
(GPX3) 
Thiol peroxidase that functions as a 
hydroperoxide receptor to sense intracellular 
hydroperoxide levels and transduce a redox 
signal to the Yap1p transcription factor 
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YKL161C KDX1 Protein kinase implicated in the Slt2p mitogen-
activated (MAP) kinase signaling pathway; 
interacts with numerous components in the 
mating pheromone and CWI MAPK pathways; 
associates with Rlm1p 
 
YIR034C LYS1 Saccharopine dehydrogenase (NAD+, L-lysine-
forming), catalyzes the conversion of 
saccharopine to L-lysine, which is the final step 
in the lysine biosynthesis pathway; also has 
mRNA binding activity 
 
YDR144C MKC7 GPI-anchored aspartyl protease, member of the 
yapsin family of proteases involved in cell wall 
growth and maintenance; shares functions with 
Yap3p and Kex2p 
 
YPR164W MMS1 Subunit of an E3 ubiquitin ligase complex 
involved in resolving replication intermediates or 
preventing the damage caused by blocked 
replication forks; regulates Ty1 transposition; 
involved with Rtt101p in nonfunctional rRNA 
decay 
 
YJL066C MPM1 Mitochondrial membrane protein of unknown 
function, contains no hydrophobic stretches 
 
YGL136C* MRM2 Mitochondrial 2' O-ribose methyltransferase, 
required for methylation of U(2791) in 21S rRNA; 
MRM2 deletion confers thermosensitive 
respiration and loss of mitochondrial DNA; has 
similarity to Spb1p and Trm7p, and to E. coli 
FtsJ/RrmJ 
 
YPL184C* MRN1 RNA-binding protein proposed to be involved in 
translational regulation; binds specific categories 
of mRNAs, including those that contain 
upstream open reading frames (uORFs) and 
internal ribosome entry sites (IRES) 
 
YOR360W PDE2 High-affinity cyclic AMP phosphodiesterase, 
component of the cAMP-dependent protein 
kinase signaling system, protects the cell from 
extracellular cAMP, contains readthrough motif 
surrounding termination codon 
 
YPL198W RPL7B Protein component of the large (60S) ribosomal 
subunit, nearly identical to Rpl7Ap and has 
similarity to E. coli L30 and rat L7 ribosomal 
proteins; contains a conserved C-terminal 
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Nucleic acid Binding Domain (NDB2) 
 
YFL036W RPO41 Mitochondrial RNA polymerase; single subunit 
enzyme similar to those of T3 and T7 
bacteriophages; requires a specificity subunit 
encoded by MTF1 for promoter recognition; 
binding of Mtf1p to the Rpo41p-promoter 
complex stabilizes the binding and induces DNA 
bending 
 
YLR287C-
A 
RPS30A Protein component of the small (40S) ribosomal 
subunit; nearly identical to Rps30Bp and has 
similarity to rat S30 ribosomal protein 
 
YLR221C* RSA3 Protein with a likely role in ribosomal maturation, 
required for accumulation of wild-type levels of 
large (60S) ribosomal subunits; binds to the 
helicase Dbp6p in pre-60S ribosomal particles in 
the nucleolus 
 
YCR009C RVS161 Amphiphysin-like lipid raft protein; interacts with 
Rvs167p and regulates polarization of the actin 
cytoskeleton, endocytosis, cell polarity, cell 
fusion and viability following starvation or 
osmotic stress 
 
YDR159W SAC3 Nuclear pore-associated protein; required for 
biogenesis of the small ribosomal subunit; 
component of TREX-2 complex (Sac3p-Thp1p-
Sus1p-Cdc31p) involved in transcription 
elongation and mRNA export from the nucleus; 
involved in post-transcriptional tethering of active 
genes to the nuclear periphery and to non-
nascent mRNP; mutant displays reduced 
transcription elongation in the G-less-based run-
on (GLRO) assay 
 
YMR127C* SAS2 Histone acetyltransferase (HAT) catalytic subunit 
of the SAS complex (Sas2p-Sas4p-Sas5p), 
which acetylates free histones and nucleosomes 
and regulates transcriptional silencing; member 
of the MYSTacetyltransferase family 
 
YKL130C SHE2 RNA-binding protein that binds specific mRNAs 
and interacts with She3p; part of the mRNA 
localization machinery that restricts 
accumulation of certain proteins to the bud 
 
YNL236W SIN4 Subunit of the RNA polymerase II mediator 
complex; associates with core polymerase 
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subunits to form the RNA polymerase II 
holoenzyme; contributes to both postive and 
negative transcriptional regulation; dispensible 
for basal transcription 
 
YDL042C SIR2 Conserved NAD+ dependent histone 
deacetylase of the Sirtuin family involved in 
regulation of lifespan; plays roles in silencing at 
HML, HMR, telomeres, and the rDNA locus; 
negatively regulates initiation of DNA replication 
 
YDR425W SNX41 Sorting nexin, involved in the retrieval of late-
Golgi SNAREs from the post-Golgi endosome to 
the trans-Golgi network; interacts with Snx4p 
 
YLL021W SPA2 Component of the polarisome, which functions in 
actin cytoskeletal organization during polarized 
growth; acts as a scaffold for Mkk1p and Mpk1p 
cell wall integrity signaling components; potential 
Cdc28p substrate 
 
YDL159W STE7 Signal transducing MAP kinase kinase involved 
in pheromone response, where it phosphorylates 
Fus3p, and in the pseudohyphal/invasive growth 
pathway, through phosphorylation of Kss1p; 
phosphorylated by Ste11p, degraded by 
ubiquitin pathway 
 
YPR009W SUT2 Putative transcription factor; multicopy 
suppressor of mutations that cause low activity 
of the cAMP/protein kinase A pathway; highly 
similar to Sut1p 
 
YAR042W SWH1 Protein similar to mammalian oxysterol-binding 
protein; contains ankyrin repeats; localizes to the 
Golgi and the nucleus-vacuole junction 
 
YJL176C SWI3 Subunit of the SWI/SNF chromatin remodeling 
complex, which regulates transcription by 
remodeling chromosomes; required for 
transcription of many genes, including ADH1, 
ADH2, GAL1, HO, INO1 and SUC2 
 
YBR223C TDP1 Tyrosyl-DNA Phosphodiesterase I, hydrolyzes 3' 
and 5'-phosphotyrosyl bonds, involved in the 
repair of DNA lesions created by topoisomerase 
I and topoisomerase II; mutations in human 
homolog result in the neurodegenerative disease 
SCANI 
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YGL026C TRP5 Tryptophan synthase, catalyzes the last step of 
tryptophan biosynthesis; regulated by the 
general control system of amino acid 
biosynthesis 
 
YOR115C TRS33 One of 10 subunits of the transport protein 
particle (TRAPP) complex of the cis-Golgi which 
mediates vesicle docking and fusion; involved in 
endoplasmic reticulum (ER) to Golgi membrane 
traffic 
 
YMR022W UBC7 Ubiquitin conjugating enzyme, involved in the 
ER-associated protein degradation pathway; 
requires Cue1p for recruitment to the ER 
membrane; proposed to be involved in 
chromatin assembly 
 
YGR184C UBR1 E3 ubiquitin ligase (N-recognin), forms 
heterodimer with Rad6p to ubiquitinate 
substrates in the N-end rule pathway; regulates 
peptide transport via Cup9p ubiquitination; 
mutation in human UBR1 causes Johansson-
Blizzard Syndrome (JBS) 
 
YPL139W YAR1 Cytoplasmic ankyrin-repeat containing protein of 
unknown function, proposed to link the 
processes of 40S ribosomal subunit biogenesis 
and adaptation to osmotic and oxidative stress; 
expression repressed by heat shock 
  
*gene deletions that prevent Yap1p_GFP to localise to nucleus upon H2O2 treatment. The 
rest of the list were genes which 50% of cells population Yap1p_GFP localized to nucleus 
upon H2O2 treatment and 50% of the population did not.  
195 
 
Table A-3 :Hit genes from Yap1p-GFP screen with diethyl maleate 
treatment  
Systematic 
Name 
Standard 
Name 
Description 
YBR184W  Putative protein of unknown function; YBR184W is 
not an essential gene 
 
YBR238C  Mitochondrial membrane protein with similarity to 
Rmd9p; not required for respiratory growth but 
causes a synthetic respiratory defect in 
combination with rmd9 mutations; transcriptionally 
upregulated by TOR; deletion increases life span 
 
YBR285W  Putative protein of unknown function; YBR285W is 
not an essential gene 
 
YDL012C  Tail-anchored plasma membrane protein 
containing a conserved CYSTM module, possibly 
involved in response to stress; may contribute to 
non-homologous end-joining (NHEJ) based on 
ydl012c htz1 double null phenotype 
 
YCR011C ADP1 Putative ATP-dependent permease of the ABC 
transporter family of proteins 
 
YCR010C ADY2 Acetate transporter required for normal 
sporulation; phosphorylated in mitochondria 
 
YBR262C AIM5 Mitochondrial inner membrane protein; subunit of 
the mitochondrial inner membrane organizing 
system (MitOS, MICOS, or MINOS), a scaffold-like 
structure on the intermembrane space side of the 
inner membrane which has a role in the 
maintenance of crista junctions and inner 
membrane architecture 
 
YJL115W ASF1 Nucleosome assembly factor, involved in 
chromatin assembly and disassembly, anti-
silencing protein that causes derepression of silent 
loci when overexpressed; plays a role in regulating 
Ty1 transposition 
 
YBR270C BIT2 Subunit of TORC2, a membrane-associated 
complex that regulates actin cytoskeletal 
dynamics during polarized growth and cell wall 
integrity; interacts with Slm1p and Slm2p, 
homologous PH domain-containing TORC2 
substrates; similar to Bit61p 
 
YCR034W FEN1 Fatty acid elongase, involved in sphingolipid 
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biosynthesis; acts on fatty acids of up to 24 
carbons in length; mutations have regulatory 
effects on 1,3-beta-glucan synthase, vacuolar 
ATPase, and the secretory pathway 
 
YLL029W FRA1 Protein involved in negative regulation of 
transcription of iron regulon; forms an iron 
independent complex with Fra2p, Grx3p, and 
Grx4p; cytosolic; mutant fails to repress 
transcription of iron regulon and is defective in 
spore formation 
 
YCL036W GFD2 Protein of unknown function, identified as a high-
copy suppressor of a dbp5 mutation 
 
YDR358W GGA1 Golgi-localized protein with homology to gamma-
adaptin, interacts with and regulates Arf1p and 
Arf2p in a GTP-dependent manner in order to 
facilitate traffic through the late Golgi 
 
YDL035C GPR1 Plasma membrane G protein coupled receptor 
(GPCR) that interacts with the heterotrimeric G 
protein alpha subunit, Gpa2p, and with Plc1p; 
sensor that integrates nutritional signals with the 
modulation of cell fate via PKA and cAMP 
synthesis 
 
YBR244W GPX2 Phospholipid hydroperoxide glutathione 
peroxidase induced by glucose starvation that 
protects cells from phospholipid hydroperoxides 
and nonphospholipid peroxides during oxidative 
stress 
 
YGL084C GUP1 Plasma membrane protein involved in remodeling 
GPI anchors; member of the MBOAT family of 
putative membrane-bound O-acyltransferases; 
proposed to be involved in glycerol transport 
 
YDL223C HBT1 Substrate of the Hub1p ubiquitin-like protein that 
localizes to the shmoo tip (mating projection); 
mutants are defective for mating projection 
formation, thereby implicating Hbt1p in polarized 
cell morphogenesis 
 
YBR245C ISW1 Member of the imitation-switch (ISWI) class of 
ATP-dependent chromatin remodeling complexes; 
ATPase that forms a complex with Ioc2p and 
Ioc4p to regulate transcription elongation, and a 
complex with Ioc3p to repress transcription 
initiation 
197 
 
YER110C KAP123 Karyopherin beta, mediates nuclear import of 
ribosomal proteins prior to assembly into 
ribosomes and import of histones H3 and H4; 
localizes to the nuclear pore, nucleus, and 
cytoplasm; exhibits genetic interactions with RAI1 
 
YPR070W MED1 Subunit of the RNA polymerase II mediator 
complex; associates with core polymerase 
subunits to form the RNA polymerase II 
holoenzyme; essential for transcriptional 
regulation 
 
YCL044C MGR1 Subunit of the mitochondrial (mt) i-AAA protease 
supercomplex, which degrades misfolded 
mitochondrial proteins; forms a subcomplex with 
Mgr3p that binds to substrates to facilitate 
proteolysis; required for growth of cells lacking 
mtDNA 
 
YEL007W MIT1 Transcriptional regulator of pseudohyphal growth; 
protein with sequence similarity to S. pombe gti1+ 
(gluconate transport inducer 1) and C. albicans 
Wor1 
 
YPR164W MMS1 Subunit of an E3 ubiquitin ligase complex involved 
in resolving replication intermediates or preventing 
the damage caused by blocked replication forks; 
regulates Ty1 transposition; involved with Rtt101p 
in nonfunctional rRNA decay 
 
YCL033C MXR2 Methionine-R-sulfoxide reductase, involved in the 
response to oxidative stress; protects iron-sulfur 
clusters from oxidative inactivation along with 
MXR1; involved in the regulation of lifespan 
 
YDL096C OPI6 Dubious open reading frame unlikely to encode a 
protein, based on available experimental and 
comparative sequence data; partially overlaps 
verified gene PMT1/YDL095W; YDL096C is not 
essential 
 
YDL127W PCL2 Cyclin, interacts with cyclin-dependent kinase 
Pho85p; member of the Pcl1,2-like subfamily, 
involved in the regulation of polarized growth and 
morphogenesis and progression through the cell 
cycle; localizes to sites of polarized cell growth 
 
YCL056C PEX34 Peroxisomal integral membrane protein that 
regulates peroxisome populations; interacts with 
Pex11p, Pex25p, and Pex27p to control both 
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constitutive peroxisome division and peroxisome 
morphology and abundance during peroxisome 
proliferation 
 
YDR276C PMP3 Small plasma membrane protein related to a 
family of plant polypeptides that are 
overexpressed under high salt concentration or 
low temperature, not essential for viability, deletion 
causes hyperpolarization of the plasma membrane 
potential 
 
YDL104C QRI7 
(petite) 
Highly conserved mitochondrial protein, essential 
for t6A modification of mitochondrial tRNAs that 
decode ANN codons; similar to Kae1p and E. coli 
YgjD, both of which are also required for tRNA t6A 
modification 
 
YGL163C RAD54 DNA-dependent ATPase, stimulates strand 
exchange by modifying the topology of double-
stranded DNA; involved in the recombinational 
repair of double-strand breaks in DNA during 
vegetative growth and meiosis; member of the 
SWI/SNF family 
 
YDR076W RAD55 Protein that stimulates strand exchange by 
stabilizing the binding of Rad51p to single-
stranded DNA; involved in the recombinational 
repair of double-strand breaks in DNA during 
vegetative growth and meiosis; forms heterodimer 
with Rad57p 
 
YAL036C RBG1 Member of the DRG family of GTP-binding 
proteins; associates with translating ribosomes; 
interacts with Tma46p, Ygr250cp, Gir2p and 
Yap1p via two-hybrid 
 
YCR028C-
A 
RIM1 
(petite) 
Single-stranded DNA-binding protein essential for 
mitochondrial genome maintenance; involved in 
mitochondrial DNA replication 
 
YBR229C ROT2 Glucosidase II catalytic subunit required for 
normal cell wall synthesis; mutations in rot2 
suppress tor2 mutations, and are synthetically 
lethal with rot1 mutations 
 
YLL002W RTT109 Histone acetyltransferase critical for cell survival in 
the presence of DNA damage during S phase; 
acetylates H3-K56 and H3-K9; involved in non-
homologous end joining and in regulation of Ty1 
transposition; interacts physically with Vps75p 
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YBR280C SAF1 F-Box protein involved in proteasome-dependent 
degradation of Aah1p during entry of cells into 
quiescence; interacts with Skp1 
 
YBR228W SLX1 Subunit of a complex, with Slx4p, that hydrolyzes 
5' branches from duplex DNA in response to 
stalled or converging replication forks; function 
overlaps with that of Sgs1p-Top3p 
 
YDL013W SLX5 Subunit of the Slx5-Slx8 SUMO-targeted ubiquitin 
ligase (STUbL) complex, stimulated by SUMO-
modified substrates; contains a RING domain and 
two SIMs (SUMO-interacting motifs); forms 
SUMO-dependent nuclear foci, including DNA 
repair centers 
 
YBR289W SNF5 Subunit of the SWI/SNF chromatin remodeling 
complex involved in transcriptional regulation; 
functions interdependently in transcriptional 
activation with Snf2p and Snf6p 
 
YCR081W SRB8 Subunit of the RNA polymerase II mediator 
complex; associates with core polymerase 
subunits to form the RNA polymerase II 
holoenzyme; essential for transcriptional 
regulation; involved in glucose repression 
 
YDL133W SRF1 Regulator of phospholipase D (Spo14p); interacts 
with Spo14p and regulates its catalytic activity; 
capable of buffering the toxicity of C16:0 platelet 
activating factor, a lipid that accumulates 
intraneuronally in Alzheimer's patients 
 
YJL092W SRS2 DNA helicase and DNA-dependent ATPase 
involved in DNA repair, needed for proper timing 
of commitment to meiotic recombination and 
transition from Meiosis I to II; blocks trinucleotide 
repeat expansion; affects genome stability 
 
YDR293C SSD1 Translational repressor with a role in polar growth 
and wall integrity; regulated by Cbk1p 
phosphorylation to effect bud-specific translational 
control and localization of specific mRNAs; 
interacts with TOR pathway components; contains 
a functional N-terminal nuclear localization 
sequence and nucleocytoplasmic shuttling 
appears to be critical to Ssd1p function 
 
YDR443C SSN2 Subunit of the RNA polymerase II mediator 
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complex; associates with core polymerase 
subunits to form the RNA polymerase II 
holoenzyme; required for stable association of 
Srb10p-Srb11p kinase; essential for transcriptional 
regulation 
 
YCR030C SYP1 Protein of unknown function that is involved in 
endocytic site formation; may regulate assembly 
and disassembly of the septin ring; colocalizes 
and interacts with septin subunits; potential role in 
actin cytoskeletal organization 
 
YBR240C THI2 Transcriptional activator of thiamine biosynthetic 
genes; interacts with regulatory factor Thi3p to 
control expression of thiamine biosynthetic genes 
with respect to thiamine availability; acts together 
with Pdc2p to respond to thiaminediphosphate 
demand, possibly as related to carbon source 
availability; zinc finger protein of the Zn(II)2Cys6 
type 
 
YGL096W TOS8 Homeodomain-containing protein and putative 
transcription factor found associated with 
chromatin; target of SBF transcription factor; 
induced during meiosis and under cell-damaging 
conditions; similar to Cup9p transcription factor 
 
YML028W TSA1 Thioredoxin peroxidase, acts as both a ribosome-
associated and free cytoplasmic antioxidant; self-
associates to form a high-molecular weight 
chaperone complex under oxidative stress; 
deletion results in mutator phenotype 
 
YBR216C YBP1 Protein required for oxidation of specific cysteine 
residues of the transcription factor Yap1p, 
resulting in the nuclear localization of Yap1p in 
response to stress 
 
YBR264C YPT10 Rab family GTP-binding protein that contains the 
PEST signal sequence specific for proteolytic 
enzymes; may be involved in vesicular transport; 
overexpression leads to accumulation of Golgi-like 
cisternae with budding vesicles 
 
YML001W YPT7 Rab family GTPase; GTP-binding protein of the 
rab family; required for homotypic fusion event in 
vacuole inheritance, for endosome-endosome 
fusion, similar to mammalian Rab7 
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